<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Risperidone versus placebo for schizophrenia - Rattehalli, RD - 2016 | Cochrane Library</title> <meta content="Risperidone versus placebo for schizophrenia - Rattehalli, RD - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006918.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Risperidone versus placebo for schizophrenia - Rattehalli, RD - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006918.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006918.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Risperidone versus placebo for schizophrenia" name="citation_title"/> <meta content="Ranganath D Rattehalli" name="citation_author"/> <meta content="Logan Hospital" name="citation_author_institution"/> <meta content="rdrattehalli@hotmail.com" name="citation_author_email"/> <meta content="Sai Zhao" name="citation_author"/> <meta content="Systematic Review Solutions Ltd" name="citation_author_institution"/> <meta content="Bao Guo Li" name="citation_author"/> <meta content="Tianjin Medical University Cancer Institute and Hospital" name="citation_author_institution"/> <meta content="Mahesh B Jayaram" name="citation_author"/> <meta content="Melbourne Neuropsychiatry Centre" name="citation_author_institution"/> <meta content="Jun Xia" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Stephanie Sampson" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD006918.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/12/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006918.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006918.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006918.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Antipsychotic Agents [*administration &amp; dosage, adverse effects]; Placebos [therapeutic use]; Publication Bias; Randomized Controlled Trials as Topic; Risperidone [*administration &amp; dosage, adverse effects]; Schizophrenia [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006918.pub3&amp;doi=10.1002/14651858.CD006918.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="IYhCEbRn";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006918\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006918\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006918\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006918\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","pt","ms","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006918.pub3",title:"Risperidone versus placebo for schizophrenia",firstPublishedDate:"Dec 15, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006918.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006918.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006918.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006918.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006918.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006918.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006918.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006918.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006918.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006918.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4125 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006918.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-sec-0308"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-sec-0079"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-sec-0298"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/appendices#CD006918-sec-0318"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/table_n/CD006918StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/table_n/CD006918StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Risperidone versus placebo for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/information#CD006918-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Ranganath D Rattehalli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/information#CD006918-cr-0003">Sai Zhao</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/information#CD006918-cr-0004">Bao Guo Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/information#CD006918-cr-0005">Mahesh B Jayaram</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/information#CD006918-cr-0006">Jun Xia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006918.pub3/information#CD006918-cr-0007">Stephanie Sampson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/information/en#CD006918-sec-0357">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 December 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006918.pub3">https://doi.org/10.1002/14651858.CD006918.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006918-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006918-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006918-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006918-abs-0009">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006918-abs-0001" lang="en"> <section id="CD006918-sec-0001"> <h3 class="title" id="CD006918-sec-0001">Background</h3> <p>Risperidone is the first new‐generation antipsychotic drug made available in the market in its generic form. </p> </section> <section id="CD006918-sec-0002"> <h3 class="title" id="CD006918-sec-0002">Objectives</h3> <p>To determine the clinical effects, safety and cost‐effectiveness of risperidone compared with placebo for treating schizophrenia. </p> </section> <section id="CD006918-sec-0003"> <h3 class="title" id="CD006918-sec-0003">Search methods</h3> <p>On 19th October 2015, we searched the Cochrane Schizophrenia Group Trials Register, which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. We checked the references of all included studies and contacted industry and authors of included studies for relevant studies and data. </p> </section> <section id="CD006918-sec-0004"> <h3 class="title" id="CD006918-sec-0004">Selection criteria</h3> <p>Randomised clinical trials (RCTs) comparing oral risperidone with placebo treatments for people with schizophrenia and/or schizophrenia‐like psychoses. </p> </section> <section id="CD006918-sec-0005"> <h3 class="title" id="CD006918-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened studies, assessed the risk of bias of included studies and extracted data. For dichotomous data, we calculated the risk ratio (RR), and the 95% confidence interval (CI) on an intention‐to‐treat basis. For continuous data, we calculated mean differences (MD) and the 95% CI. We created a 'Summary of findings table' using <a href="http://ims.cochrane.org/gradepro" target="_blank">GRADE</a> (Grading of Recommendations Assessment, Development and Evaluation). </p> </section> <section id="CD006918-sec-0006"> <h3 class="title" id="CD006918-sec-0006">Main results</h3> <p>The review includes 15 studies (N = 2428). Risk of selection bias is unclear in most of the studies, especially concerning allocation concealment. Other areas of risk such as missing data and selective reporting also caused some concern, although not affected on the direction of effect of our primary outcome, as demonstrated by sensitivity analysis. Many of the included trials have industry sponsorship of involvement. Nonetheless, generally people in the risperidone group are more likely to achieve a significant clinical improvement in mental state (6 RCTs, N = 864, RR 0.64, CI 0.52 to 0.78, <i>very low‐quality evidence</i> ). The effect withstood, even when three studies with &gt;50% attrition rate were removed from the analysis (3 RCTs, N = 589, RR 0.77, CI 0.67 to 0.88). Participants receiving placebo were less likely to have a clinically significant improvement on Clinical Global Impression scale (CGI) than those receiving risperidone (4 RCTs, N = 594, RR 0.69, CI 0.57 to 0.83, <i>very low‐quality evidence</i> ). Overall, the risperidone group was 31% less likely to leave early compared to placebo group (12 RCTs, N = 2261, RR 0.69, 95% CI 0.62 to 0.78, <i>low‐quality evidence</i> ), but Incidence of significant extrapyramidal side effect was more likely to occur in the risperidone group (7 RCTs, N = 1511, RR 1.56, 95% CI 1.13 to 2.15, <i>very low‐quality evidence</i>). </p> <p>When risperidone and placebo were augmented with clozapine, there is no significant differences between groups for clinical response as defined by a less than 20% reduction in PANSS/BPRS scores (2 RCTs, N = 98, RR 1.15, 95% CI 0.93 to 1.42, <i>low‐quality evidence)</i> and attrition (leaving the study early for any reason) (3 RCTs, N = 167, RR 1.13, 95% CI 0.53 to 2.42, <i>low quality evidence)</i> . One study measured clinically significant responses using the CGI, no effect was evident (1 RCT, N = 68, RR 1.12 95% CI 0.87 to 1.44, <i>low quality evidence</i>). No data were available for extrapyramidal adverse effects. </p> </section> <section id="CD006918-sec-0007"> <h3 class="title" id="CD006918-sec-0007">Authors' conclusions</h3> <p>Based on low quality evidence, risperidone appears to be benefitial in improving mental state compared with placebo, but it also causes more adverse events. Eight out of the 15 included trials were funded by pharmaceutical companies. The currently available evidence is<i>very low</i> to <i>low quality</i>. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006918-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006918-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006918-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006918-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD006918-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006918-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD006918-abs-0004">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD006918-abs-0003">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006918-abs-0002" lang="en"> <h3>Risperidone versus placebo for schizophrenia</h3> <p><b>Review question</b> </p> <p>Is risperidone (tablet form) more effective than placebo in treating the symptoms of schizophrenia or schizophrenia‐like illnesses? </p> <p><b>Background</b> </p> <p>People with schizophrenia often hear voices and see things (hallucinations) and have strange beliefs (delusions). These are called ‘positive symptoms’. Mental illness also causes tiredness, apathy, emotional numbness, and withdrawal. These are called ‘negative symptoms’. The main treatment for the symptoms of schizophrenia are antipsychotic drugs. Antipsychotic drugs can be classified into typical (older) and atypical (newer) drugs. Typical antipsychotics such as chlorpromazine and haloperidol have been the mainstay of treatment for decades, and have been effective in reducing the positive symptoms of schizophrenia. Negative symptoms, however, have been fairly resistant to treatment. In addition, drug treatments are associated with unpleasant side effects that cause people to stop taking medication, which may lead to relapse. It is thought that newer atypical antipsychotics, such as risperidone, are more effective than the older antipsychotics as they reduce the positive symptoms but cause fewer side effects. </p> <p><b>Study characteristics</b> </p> <p>Searches for high‐quality randomised trials were carried out in 2008, 2013 and 2015. The review now includes 15 studies with 2428 participants. The studies randomised participants (in‐ and outpatients) with schizophrenia or schizophrenia‐like illnesses into treatment groups that received oral risperidone or placebo. </p> <p><b>Key results</b> </p> <p>Results from limited data suggest that risperidone is more effective than placebo for reducing the overall symptoms of schizophrenia, and participants receiving risperidone were more likely to comply with treatment. However, like the older typical antipsychotics, risperidone was also associated with serious side effects, such as parkinsonism. </p> <p><b>Quality of the evidence</b> </p> <p>The evidence available was very low quality. Information and data were limited, poorly reported, and probably biased in favour of risperidone . Nearly half of the included trials were funded by drug companies. Firm conclusions are difficult to make based on the results of this review. Better conduct and reporting of trials could increase confidence in the results. </p> <p>Ben Gray, Senior Peer Researcher, McPin Foundation. <a href="http://mcpin.org/" target="_blank">http://mcpin.org/</a> </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006918-sec-0308" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006918-sec-0308"></div> <h3 class="title" id="CD006918-sec-0309">Implications for practice</h3> <section id="CD006918-sec-0309"> <section id="CD006918-sec-0310"> <h5 class="title">1. For people with schizophrenia</h5> <p>Risperidone has a positive effect on the mental state of people with schizophrenia, but data in this review are of low to very low quality, suggesting that future research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> </section> <section id="CD006918-sec-0311"> <h5 class="title">2. For clinicians</h5> <p>While mental state and global state outcomes favoured risperidone, when used alone, there is a high amount of uncertainty regarding this these data and, even if credible, their direct clinical meaning is unclear. Due in large part to poor reporting, we are very uncertain about the effects of risperidone on adverse effects. </p> </section> <section id="CD006918-sec-0312"> <h5 class="title">3. For managers/policymakers</h5> <p>We found some low quality evidence, which supported the efficacy of risperidone compared to placebo. Based on the same body of evidence, it appears risperidone also causes more adverse events than placebo, and from the available evidence, it is unclear if the benefit out weight the harm. In summary, there is insufficient evidence from this review to support preferential use of risperidone over placebo. Policymakers are encouraged to allocate resources to fund bigger trials with greater methodological quality. </p> </section> </section> <h3 class="title" id="CD006918-sec-0313">Implications for research</h3> <section id="CD006918-sec-0313"> <section id="CD006918-sec-0314"> <h5 class="title">1. General</h5> <p>Strict adherence to the CONSORT statement may well have resulted in this review having more data. Full availability of all data from each study could greatly help future review authors. Many of the studies included in this review did not always clearly present denominator data, did not mention allocation concealment, and frequently described results as "significant" without original data. Multiple publications is another concern. Authors of this review inspectd a large number of publications, which eventually were identified as salami publication of the same trial. Multiple publication poses a risk for reviewers, as if not discovered, the data could be double counted which inadvertently results in biased summary. If mutiple publication is unavoidable, quoting specific trial identifiers such as the International Standard Randomised Controlled Trial Number would greatly reduce confusion over identification of the source of trial. </p> </section> <section id="CD006918-sec-0315"> <h5 class="title">2. Specific</h5> <p>Many excluded trials could find a place in new or existing systematic reviews, and although many of the 'risperidone versus (other antipsychotic)' reviews have been undertaken, there are many others still to do before a full overview of the effects of risperidone in every comparison is complete (<a href="#CD006918-tbl-0005">Table 3</a>). </p> <div class="table" id="CD006918-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reviews suggested by excluded studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Broad category of comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Excluded study/studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Existing Cochrane reviews</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><b>Augmentation [of]</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>risperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>by</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>antioxidants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0100" title="ZhangCZ . A study of the therapeutic effectiveness of risperidone in combination with antioxidants in the treatment of schizophrenia. Herald of Medicine2002;21(10):629‐30. ">Zhang 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>buflomedil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0101" title="ZhongZ‐Y , TaoJ , WangX‐L , WuX‐L , ZhangJ‐B . Effect of antipsychotic plus buflomedil hydrochloride in ameliorating the negative symptoms of patients with schizophrenia. Chinese Journal of Clinical Rehabilitation [Zhongguo lin chuang kang fu]2006;10(2):30‐2. ">Zhong 2006</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>celecoxib</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0087" title="RiedelM , MöllerHJ , MüllerN . Rational and efficacy of cox‐2‐inhibitors as adjunctive therapy in schizophrenia. European Neuropsychopharmacology2003;13(4):S96. ">Riedel 2003</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D‐alanine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0093" title="TsaiGE , YangP , ChangY‐C , ChongM‐Y . D‐alanine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry2006;59(3):230‐4. ">Tsai 2006</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sarcosine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0092" title="TsaiG , LaneHY , YangP , ChongMY , LangeN . Glycine transporter I inhibitor, N‐Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry2004;55(5):452‐6. ">Tsai 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>valproate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0095" title="WangG . 60 week, randomized, double‐blind, placebo‐controlled trial of valproate added to risperidone in 200 treatment‐naive, first‐episode patients with schizophrenia. Stanley Foundation Research Programs2003. ">Wang 2003</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clozapine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>risperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0071" title="McKennaPJ . An international study of improving treatment for the most severely ill with schizophrenia. National Research Register2004. ">McKenna 2004</a>, <a href="./references#CD006918-bbs2-0082" title="PeuskensJ , MollerHJ . Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. European Neuropsychopharmacology2001;11(3):255. ">Peuskens 2001a</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Long‐acting preparation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>depot risperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>versus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>olanzapine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0036" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Comparative efficacy and safety of long‐acting risperidone and risperidone oral tablets. European Neuropsychopharmacology2005;15(1):111‐7. ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tables. Schizophrenia Research2002;53(3 Suppl 1):174. ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Proceedings of the 11th Biennial Winter Workshop on Schizophrenia; 2002 Feb 24‐Mar 1; Davos, Switzerland. 2002. ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Poster supplied by Company2002. ">Chue 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD006918-bbs2-0151" title="HosalliP , DaviesJM . Depot risperidone for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD004161] ">Hosalli 2003</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0031" title="CadaDJ , LevienT , BakerDE . Risperidone long‐acting injection. Hospital Pharmacy2004;39(4):353‐62. ">Cada 2004</a>, <a href="./references#CD006918-bbs2-0037" title="CilibertoN , BossieCA , UriosteR , LasserRA . Lack of impact of race on the efficacy and safety of long‐acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. International Clinical Psychopharmacology2005;20(4):207‐12. ">Ciliberto 2005</a>, <a href="./references#CD006918-bbs2-0060" title="LaurielloJ , McEvoyJP , RodriguezS , BossieCA , LasserRA . Long‐acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophrenia Research2005;72(2‐3):249‐58. ">Lauriello 2005</a>, <a href="./references#CD006918-bbs2-0072" title="NasrallahHA , DuchesneI , MehnertA , JanagapC , EerdekensM . Correction. Journal of Clinical Psychiatry [linchuang jingshen yixue zazhi] [临床精神医学杂志]2004;65(8):1150. NasrallahHA , DuchesneI , MehnertA , JanagapC , EerdekensM . Health‐related quality of life in patients with schizophrenia during treatment with long‐acting, injectable risperidone. Journal of Clinical Psychiatry2004;65(4):531‐6. ">Nasrallah 2004a</a>, <a href="./references#CD006918-bbs2-0094" title="UriosteR , BossieC , ZhuY , CilibertoN , TrinhB , LasserR . Clinical improvement with long‐acting risperidone: no impact of race. Proceedings of the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. ">Urioste 2004</a>, <a href="./references#CD006918-bbs2-0076" title="NCT00249119 . Risperidone in the treatment of chronic schizophrenic patients: an international multicentre double‐blind parallel‐group comparative study versus haloperidol. clinicaltrials.gov/ct2/show/NCT00249119 (2005) (accessed 9 October 2013). ">NCT00249119</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Experimental compound</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>risperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>versus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BL‐1020</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT01363349a</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LY2140023</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT01086748a</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PF‐02545920</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DeMartinis 2012a, NCT01175135a</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><b>Versus another antipsychotic</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p>risperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p>versus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>amisulpride</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0055" title="HwangTJ , LeeS‐M , SunHJ , LinH‐N , TsaiS‐J , LeeY‐C , et al. Amisulpride versus risperidone in the treatment of schizophrenic patients: a double‐blind pilot study in Taiwan. Journal of the Formosan Medical Association2003;102(1):30‐6. ">Hwang 2003</a>, <a href="./references#CD006918-bbs2-0085" title="ReinW , FleurotO . Efficacy of amisulpride vs risperidone in the long‐term treatment of chronic schizophrenia: Results from a 12 month double‐blind study. European Neuropsychopharmacology2002;12(Suppl 3):S302. ReinW , FleurotO . Safety of amisulpride vs risperidone in the long‐term treatment of chronic schizophrenia: Results from a 12 month double‐blind study. European Neuropsychopharmacology2002;12(Suppl 3):S309. ">Rein 2002</a>, <a href="./references#CD006918-bbs2-0081" title="PeuskensJ , KasperS . Amisulpride versus risperidone in schizophrenia: comparing clinical and functional outcome in a 6 months study. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001. ">Peuskens 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0164" title="KomossaK , Rummel‐KlugeC , HungerH , SchmidF , SchwarzS , Silveira da Mota NetoJI , et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006624.pub2; PUBMED: 20091599] ">Komossa 2010</a>; <a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aripiprazole</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0048" title="DubitskyGM , HarrisR , LaughrenT , HardemanS . Abilify (aripiprazole) tablets; medical review part 1. www.fda.gov/cder/foi/nda/2002/21‐436_Abilify.htm 2002 (accessed 9 October 2013):1‐50. DubitskyGM , HarrisR , LaughrenT , HardemanS . Abilify (aripiprazole) tablets; medical review part 2. www.fda.gov/cder/foi/nda/2002/21‐436_Abilify.htm. U.S. Food and Drug Administration CDER, 2002 (accessed 9 October 2013):50‐110. DubitskyGM , HarrisR , LaughrenT , HardemanS . Abilify (aripiprazole) tablets; medical review part 3. www.fda.gov/cder/foi/nda/2002/21‐436_Abilify.htm. U.S. Food and Drug Administration CDER, 2002 (accessed 9 October 2013):111‐75. DubitskyGM , HarrisR , LaughrenT , HardemanS . Abilify (aripiprazole) tablets; medical review part 4. www.fda.gov/cder/foi/nda/2002/21‐436_Abilify.htm. U.S. Food and Drug Administration CDER, 2002 (accessed 9 October 2013):176‐232. ">Dubitsky 2002</a>, <a href="./references#CD006918-bbs2-0035" title="ChanH‐Y , LinW‐W , LinS‐K , HwangT‐J , SuT‐P , ChiangS‐C , et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. Journal of Clinical Psychiatry2007;68(1):29‐36. ">Chan 2007</a>, <a href="./references#CD006918-bbs2-0056" title="HwangTJ , ChanHY , LinWW , LinSK , HwuHG , ChengMY , et al. Aripiprazole versus risperidone in the treatment of acutely relapsed patients with schizophrenia in Taiwan: a randomized controlled trial. European Neuropsychopharmacology2005;15(Suppl 3):S497. ">Hwang 2005</a>, <a href="./references#CD006918-bbs2-0075" title="NCT00202007 . A multi‐center, randomized, double‐blind study, comparing with risperidone, to evaluate the efficacy and safety of aripiprazole in the treatment of patients with schizophrenia. clinicaltrials.gov/ct2/show/NCT00202007 (2005) (accessed 9 October 2013). ">NCT00202007</a>, <a href="./references#CD006918-bbs2-0057" title="KaneJ , CarsonWh , KujawaM , StringfellowJ , MarcusR , SanchezR , et al. Aripiprazole in treatment‐resistant schizophrenia: a 6‐week double‐blind comparison study versus perphenazine. Schizophrenia Research2004;67(1):155‐6. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of Risperdal Consta, a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cilag UK Ltd2002. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Proceedings of the 11th Biennial Winter Workshop on Schizophrenia; 2002 Feb 24‐Mar 1; Davos, Switzerland. 2002. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal constatm, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S188. KaneJ , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Schizophrenia Research2000;41(1):39. KaneJM . Preventing morbidity in first‐episode schizophrenia. clinicaltrials.gov/ct2/show/NCT00000374 (accessed 16 Feb 2001). KaneJM . The latest advance in long‐acting antipsychotic therapy. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. KaneJM , CarsonWH , SahaAR , McQuadeRD , IngenitoGG , ZimbroffDL , et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry2002;63(9):763‐71. KaneJM , ConleyRR , KeithSJ , NasrallahHA , TurnerM . Guidelines for the use of long‐acting injectable atypical antipsychotics. Journal of Clinical Psychiatry2004;65(1):120‐31. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research2002;53(3 Suppl 1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology2002;12(Suppl 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160:1125‐32. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [NR345 Tuesday, May 16, 3:00 p.m.‐5:00 p.m] KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S124. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. KaneJM , PotkinS , BuckleyP , DanielDG . Safety and efficacy of sertindole and risperidone in treatment resistant patients with schizophrenia. Schizophrenia Bulletin2005;31:490. KaneJM , WilliamHCJ , KujawaMJ , StringfellowJ , MarcusRN , SanchezR , et al. Aripiprazole vs perphenazine in treatment‐resistant schizophrenia. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. ">Kane 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0161" title="KhannaP , SuoT , KomossaK , MaH , Rummel‐KlugeC , El‐SayehHG , et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD006569.pub5; PUBMED: 24385408] ">Khanna 2014</a>; <a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>asenapine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0050" title="FlemingK , PotkinSG , BinnemanB , KellerD , AlphsL , PanagidesJ . Effects of asenapine on cognitive function in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. European Neuropsychopharmacology2007;17(Suppl 4):S466. ">Fleming 2007a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cariprazine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bose 2010b</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Protocol underway</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clozapine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0027" title="BondolfiG , BaumannP , DufourH . Treatment‐resistant schizophrenia ‐ clinical experience with new antipsychotics. European Neuropsychopharmacology1996;6(Suppl 2):S21‐5. BondolfiG , BaumannP , PatrisM , MayJ , BilleterU , DufourH , et al. A randomized double‐bind trial of risperidone versus clozapine for treatment‐resistant chronic schizophrenia. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30‐Oct 4; Venice, Italy. 1995. BondolfiG , BaumannP , PatrisM , MayJP , BilleterU , DufourH . A randomised double‐blind trial of risperidone versus clozapine for treatment‐resistant chronic schizophrenia. Proceedings of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20‐25; Miami, Florida, USA. 1995. BondolfiG , BaumannP , PatrisM , MayJP , BilleterU , DufourH . A randomized double‐blind trial of risperidone versus clozapine for treatment‐resistant chronic schizophrenia. Proceedings of the Workshop on Critical Issues in the Treatment of Schizophrenia; 1995 Mar 10‐12; Florence, Italy. 1995. BondolfiG , DufourH , PatrisM , MayJP , BilleterU , EapCB , et al. Risperidone versus clozapine in treatment‐resistant chronic schizophrenia: a randomized double‐blind study. The Risperidone Study Group. American Journal of Psychiatry1998;155(4):499‐504. ">Bondolfi 1998</a>, Cavazzoni 2002a </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clocapramine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0099" title="YamawakiS , HayashiT , YokotaN , TakahashiT , SatoG , TaharaY . Serotonin‐dopamine antagonists in elderly schizophrenics. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. ">Yamawaki 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>haloperidol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0039" title="ClausA , BollenJ , DeCuyperH , EnemanM , MalfroidM , PeuskensJ , et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double‐blind comparative study. Acta Psychiatrica Scandinavica1992;85(4):295‐305. ">Claus 1992</a>, <a href="./references#CD006918-bbs2-0051" title="FriedmanJ , AdlerD , TemporiniH , HarveyP , KemetherE , DavisK . Alpha2 agonists enhance cognition of schizophrenia patients in combination with atypical but not typical neuroleptics. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S155. FriedmanJI , AdlerD , TemporiniHD , HarveyPD , KemetherEM , DavisKL . Alpha‐2 agonists enhance cognition of schizophrenia patients in combination with atypical but not typical neuroleptics. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. FriedmanJI , AdlerDN , HowanitzE , HarveyPD , BrennerG , TemporiniH , et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biological Psychiatry2002;51:349‐57. FriedmanJI , AdlerDN , HowanitzE , HarveyPD , BrennerG , TemporiniH , et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Schizophrenia Research2002;53(3 Suppl 1):9. FriedmanJI , AdlerDN , HowanitzE , TemporiniH , HarveyPD , DavisKL . Effects of donepezil on cognition, symptoms, and movement disorders in patients with chronic schizophrenia. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. FriedmanJI , AdlerDN , TemporiniHD , HarveyPD , DavisKL . Alpha‐2 agonists enhance cognition of schizophrenic patients in combination with atypical but not typical neuroleptics. Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12‐16; Acapulco, Mexico. 1999. FriedmanJI , AdlerDN , TemporiniHD , KemetherE , HarveyPD , WhiteL , et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropyschopharmacology2001;25(3):402‐9. NCT00488163 . Pilot study of atomoxetine to enhance cognition in patients with schizophrenia. clinicaltrials.gov/show/NCT00488163(2007). ">Friedman 2000</a>, <a href="./references#CD006918-bbs2-0063" title="LindstromE , vonKnorringL . Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol. Pharmacopsychiatry1994;27(3):108‐13. ">Lindstrom 1994</a>, <a href="./references#CD006918-bbs2-0065" title="Lopez IborJJ , AyusoJL , GutierrezM , GuimonJ , HerraizML , ChinchillaA , et al. Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol [Risperidona en el tratamiento de la esquizofrenia cronica: estudio multicentrico comparativo versus haloperidol]. Actas Luso Espanolas de Neurologia Psiquiatria y Ciencias Afines1996;24(4):165‐72. ">Lopez 1996</a>, <a href="./references#CD006918-bbs2-0066" title="Lopez‐IborJJ . Safety profile of risperidone in the multicentre trials. Proceedings of the 1st International Risperidone Investigators' Meeting; 1992 Mar 9‐10; Paris, France. 1992. ">Lopez‐Ibor 1992</a>, <a href="./references#CD006918-bbs2-0077" title="NCT00253136 . Risperidone depot (microspheres) vs placebo in the treatment of subjects with schizophrenia. clinicaltrials.gov/ct2/show/NCT00253136 (2005) (accessed 9 October 2013). ">NCT00253136</a>, <a href="./references#CD006918-bbs2-0080" title="PeuskensJ , Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi‐national, multi‐centre, double‐blind, parallel‐group study versus haloperidol. British Journal of Psychiatry1995;166:712‐26. ">Peuskens 1995</a>, <a href="./references#CD006918-bbs2-0084" title="RabinowitzJ , DavidsonM . Risperidone versus haloperidol in long‐term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis. Schizophrenia Research2001;50(1‐2):89‐93. ">Rabinowitz 2001</a>, <a href="./references#CD006918-bbs2-0098" title="WirshingDA , MarshallBDJr , GreenMF , MintzJ , MarderSR , WirshingWC . Risperidone in treatment‐refractory schizophrenia. American Journal of Psychiatry1999;156(9):1374‐9. WirshingWC , AmesD , GreenM , MarshallBD , MarderSR . Risperidone versus haloperidol in treatment‐refractory schizophrenia: preliminary results. Psychopharmacology Bulletin1995;31(3):633. WirshingWC , AmesD , MarderSR , MarshallBD , GreenMF , McGurkS . Risperidone vs haloperidol in treatment resistant schizophrenia: preliminary results. Schizophrenia Research1996;18(2, 3):130. WirshingWC , AmesD , MarderSR , MarshallBD , GreenMF , McGurkSR . Risperidone in treatment resistant schizophrenia. Proceedings of the 34th Annual Meeting of the American College of Neuropsychopharmacology; 1995 Dec 11‐15; San Juan, Puerto Rico. 1995. WirshingWC , AmesD , MarshallBD , GreenMF , McGurkS . Risperidone in treatment resistant schizophrenia. Proceeding of the 8th Biennial Winter Workshop on Schizophrenia; 1996 Mar 16‐22; Crans Montana, Switzerland. 1996. WirshingWC , AmesD , Palmer BrayM , MarshallBD , GreenMF , MarderSR . Risperidone versus haloperidol in treatment refractory schizophrenia: preliminary results. Proceeding of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20‐25; Miami, Florida, USA. 1995. WirshingWC , GreenMF , AmesD , MarshallBD , McGurkSR , MintzJ , et al. Risperidone vs. haloperidol in treatment‐resistant schizophrenia. Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22‐27; Nice, France. 1997. ">Wirshing 1995</a>, <a href="./references#CD006918-bbs2-0028" title="BorisonR . Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. Proceedings of the 1st International Risperidone Investigators' Meeting; 1992 Mar 9‐10; Paris, France. 1992. BorisonR , PathirajaA , DiamondB , MeibachR . Risperidone and schizophrenia. Biological Psychiatry1991;29:417. BorisonRL , DiamondBI , AugustaGA . Serotonin modulation of dopaminergic‐medicated extrapyramidal side effects. Neurology1991;41(Suppl 1):396. BorisonRL , DiamondBI , PathirajaA , MeibachRC . Clinical profile of risperidone in chronic schizophrenia. Proceedings of the 17th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1990 Sep 10‐14; Kyoto, Japan. 1991. BorisonRL , PathirajaAP , DiamondBI , MeibachRC . Risperidone ‐ clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin1992;28(2):213‐8. BorisonRL , PathirajaAP , DiamondBI , MeibachRC . Risperidone in the treatment of acute exacerbation of chronic schizophrenia. Schizophrenia Research1991;4(3):314‐5. BorisonRl , PathirajaAP , DiamondBI , MeibachRC . Antidopaminergic and antiserotonergic actions of risperidone in schizophrenia. Biological Psychiatry1991;29(Suppl):114a. ">Borison 1992a</a>, <a href="./references#CD006918-bbs2-0044" title="CsernanskyJ . Do novel antipsychotics optimize long term outcomes in schizophrenia. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S1. CsernanskyJ , BrecherM , OkamotoA . Risperidone vs haloperidol: relapse prevention in schizophrenia and schizoaffective disorders: a long‐term double‐blind comparison. Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6‐11; Hamburg, Germany. 1999. CsernanskyJ , OkamotoA . A long term double blind comparison of risperidone and haloperidol in stable outpatients with schizophrenia or schizoaffective disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S155. CsernanskyJ , OkamotoA . Risperidone versus haloperidol for prevention of relapse in schizophrenia and schizoaffective disorders: long term double blind comparison. Proceedings of the 22nd Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2000 Jul 9‐13; Brussels, Belgium. 2000. CsernanskyJ , OkamotoA . Risperidone versus haloperidol for prevention of relapse in schizophrenia and schizoaffective disorders: long term double blind comparison. Schizophrenia Research2000;41(1):198. CsernanskyJG , MahmoudR , BrennerR , The Risperidone‐USA‐79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. The New England Journal of Medicine2002;346(1):16‐22. CsernanskyJG , OkamotoA . Risperidone versus haloperidol for prevention of relapse in patients with schizophrenia and schizoaffective disorder: a long‐term double blind comparison. Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12‐16; Acapulco, Mexico. 1999. CsernanskyJG , OkamotoA . Risperidone versus haloperidol for relapse prevention in schizophrenia and schizoaffective disorder: a long‐term double‐blind placebo controlled comparison. Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30‐Jun 2; Boca Raton, Florida, USA. 2000. CsernanskyJG , OkamotoA . Risperidone vs haloperidol for relapse prevention in schizophrenia and schizoaffective disorder: a long‐term double‐blind comparison. Biological Psychiatry2000;47:31‐2S. CsernanskyJG , OkamotoA , BrecherM . Risperidone vs haloperidol: prevention of relapse in schizophrenia. European Neuropsychopharmacology1999;9:S268. CsernanskyJG , OkamotoA , BrecherMB . Risperidone versus haloperidol for prevention of relapse in schizophrenia and schizoaffective disorder: a long‐term, double‐blind comparison. Proceedings of the 51st Institute on Psychiatric Services; 1999 Oct 25‐Nov 2; New Orleans, Louisiana, USA. 1999. ">Csernansky 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0152" title="HunterRH , JoyCB , KennedyE , GilbodySM , SongF . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000440] ">Hunter 2003</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>molindone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0069" title="McClellanJ . Risperidone for schizophrenia. Stanley Foundation Research Programs2009. ">McClellan 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0124" title="BagnallA , FentonM , KleijnenJ , LewisR . Molindone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD002083.pub2; PUBMED: 17253473] ">Bagnall 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>olanzapine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0090" title="TollefsonG , BeasleyC , TranP , DellvaMA , KruegerJ , TamuraR . Olanzapine versus haloperidol: acute results of the multicenter international trial. Psychopharmacology Bulletin1996;32(3):401. TollefsonG , BeasleyC , TranP , SangerT . Olanzapine: an exciting atypical antipsychotic; the clinical experience. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30‐Oct 4; Venice, Italy. 1995. TollefsonG , LuY . Comorbid mood disturbance in schizophrenia. Schizophrenia Research1997;24:192. TollefsonGD . Olanzapine: a novel antipsychotic with a broad spectrum profile. Neuropyschopharmacology1994;10(Suppl 3 Pt 1):805S. TollefsonGD . The value of atypical antipsychotic medications. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17‐22; San Diego, California, USA. 1997. TollefsonGD . Treatment consideration for comorbid mood disorders in schizophrenic patients. Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22‐27; Nice, France. 1997. TollefsonGD . Update on new atypical antipsychotics. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30‐Oct 4; Venice, Italy. 1995. TollefsonGD , AndersenSW . Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?. Journal of Clinical Psychiatry1999;60(Suppl 5):23‐9. TollefsonGD , AndersenSW , TranPV . The course of depressive symptoms in predicting relapse in schizophrenia: a double blind, randomized comparison of olanzapine and risperidone. Biological Psychiatry1999;46(3):365‐73. TollefsonGD , BeasleyCM , TamuraRN , TranPV , PotvinJH . Blind, controlled, long term study of the comparative incidence of treatment emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry1997;154(9):1248‐54. TollefsonGD , BeasleyCM , TranPV , StreetJS , KruegerJA , TamuraRN , et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry1997;154(4):457‐65. TollefsonGD , LuY . Comorbid mood disturbance in schizophrenia. Biological Psychiatry1997;41:101S. TollefsonGD , LuY . Comorbid mood disturbance in schizophrenia. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. TollefsonGD , LuY . Comorbid mood disturbance in schizophrenia. Proceedings of the 9th European College of Neuropsychopharmacology Congress; 1996 Sep 21‐25; Amsterdam, Netherlands. 1996. TollefsonGD , LuY , SangerTM , BeasleyCM , TranPV . Olanzapine in the treatment of schizoaffective disorder. Schizophrenia Research1997;24(1, 2):92‐3. TollefsonGD , SangerTD , LiebermanJA . Olanzapine versus haloperidol in the treatment of first episode psychosis. Biological Psychiatry1997;41:73S. TollefsonGD , SangerTM . A blinded trial on the course and relationship of depressive symptoms in schizophrenia. Schizophrenia Research1998;29(1, 2):205. TollefsonGD , SangerTM . Negative symptoms: a path analytic approach to a double‐blind, placebo‐ and haloperidol‐controlled clinical trial with olanzapine. American Journal of Psychiatry1997;154(4):466‐74. TollefsonGD , SangerTM , BeasleyCM . The course of primary and secondary negative symptoms in a controlled trial with olanzapine. 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. [MEDLINE: 97245664] TollefsonGD , SangerTM , BeasleyCM . The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4‐9, New York, New York, USA. 1996. TollefsonGD , SangerTM , BeasleyCM . The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Schizophrenia Research1997;24(1, 2):192. TollefsonGD , SangerTM , BeasleyCM . The course of primary and secondary negative symptoms in a placebo‐ and comparator‐controlled trial of the typical antipsychotic olanzapine. Proceedings of the 9th European College of Neuropsychopharmacology Congress; 1996 Sep 21‐25; Amsterdam, Netherlands. 1996. TollefsonGD , SangerTM , BeasleyCM , TranPV . A double blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biological Psychiatry1998;43(11):803‐10. TollefsonGD , SangerTM , LeibermanJA . Olanzapine versus haloperidol in the treatment of first episode psychosis. Schizophrenia Research1997;24(1, 2):193. TollefsonGD , TranPV , HamiltonS , KuntzA . Olanzapine versus risperidone in the treatment of psychosis. Preliminary report. Biological Psychiatry1997;41:20S. TollefsonGD , TranPV , HamiltonS , KuntzA . Olanzapine versus risperidone in the treatment of psychosis. Preliminary report. Schizophrenia Research1997;24(1, 2):191‐2. ">Tollefson 1996</a>, <a href="./references#CD006918-bbs2-0049" title="EdgellET , AndersenSW , GraingerD , WangJ . Resource use and quality of life of olanzapine compared with risperidone: results from an international randomized clinical trial. Proceedings of the 21st Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1998 Jul 12‐16; Glasgow, UK. 1998. EdgellET , AndersenSW , JohnstoneBM , DulisseB , RevickiD , BreierA . Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S92. EdgellET , AndersenSW , JohnstoneBM , DulisseB , RevickiD , BreierA . Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics2000;18(6):567‐79. EdgellET , AndersenSW , JohnstoneBM , DulisseB , RevickiD , BreierA , et al. Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. European Psychiatry2000;15(Suppl 2):408s. EdgellET , GraingerDL , AndersenSW , WangJ . Resource use and quality of life associated with olanzapine compared with risperidone. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐Jun 4; Toronto, Ontario, Canada. 1998. EdgellET , HamiltonSH , RevickiDA , GendusoLA , TollefsonGD . Costs of olanzapine treatment compared with haloperidol for schizophrenia: results from a randomized clinical trial. Proceedings of the 21st Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1998 Jul 12‐6; Glasgow, UK. 1998. ">Edgell 2000</a>, <a href="./references#CD006918-bbs2-0091" title='TranP , BeasleyC , StreetJ , TamuraR , DellvaMA , GraffeoK , et al. Olanzapine versus haloperidol: acute results of the multi‐center international trial. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. TranP , BeasleyC , TollefsonG , BeuzenJ , DellvaM , SangerT , et al. Acute and long‐term results of the North American double‐blind olanzapine trial. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30‐Oct 4; Venice, Italy. 1995. TranP , BeasleyC , TollefsonG , CrawfordA , DellvaM , GusmanS , et al. Acute and long‐term results of the dose ranging double‐blind olanzapine trial. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. TranP , LuY , SangerT , BeasleyC , TollefsonG . Olanzapine in the treatment of schizoaffective disorder. Proceedings of the 21st Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1998 Jul 12‐16; Glasgow, UK. 1998. TranP , SangerTM , SatterleeW , BeasleyCJr , TamuraRN , TollefsonGD . Olanzapine vs haloperidol ‐ results of a large multi‐centre international trial. Proceedings of the 4th International Conference on Schizophrenia ‐ 1996: Breaking down the Barriers; 1996 Oct 6‐9; Vancouver, Canada. 1996. TranPV , BassonBR , KennedyJS , Beasley JrCM , BymasterFP , TollefsonGD . The comparative anti‐muscarinic‐like side effect profiles of olanzapine and risperidone treatment in patients with schizophrenia spectrum psychosis. European Neuropsychopharmacology1999;9:S290. TranPV , BeasleyCM , TollefosnGD , SangerT , SatterleeWG . Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent. Neuropsychopharmacology1994;10(3S):267S. TranPV , BeasleyCM , TollefsonGD , BeuzenJN , HolmanSL , SangerTM , et al. Olanzapine: a promising "atypical" antipsychotic agent. Schizophrenia Research1995;15(1, 2):169. TranPV , DellvaMA , BeasleyCMJr , SatterleeWG , CousinsLM , TollefsonGD . Clinical experience with long‐term continuation treatment with olanzapine. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4‐9, New York, New York, USA. 1996. TranPV , DellvaMA , TollefsonGD , BeasleyCMJr , PotvinJH , KieslerGM . Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. Journal of Clinical Psychiatry1997;58(5):205‐11. TranPV , HamilitonSH , KuntzAJ , TollefsonGD . Olanzapine versus risperidone in the treatment of psychosis disorders: a preliminary report. Proceedings of the 35th Annual Meeting of the American College of Neuropsychopharmacology; 1996 Dec 9‐13; San Juan, Puerto Rico. 1996. TranPV , HamiltonSH , KuntzAJ , PotvinJH , AndersenSW , BeasleyC , et al. Double‐blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology1997;17(5):407‐18. TranPV , TollefsonGD , AndersenSW , KuntzAJ , HamiltonSH . Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17; Vienna, Austria. 1997. TranPV , TollefsonGD , AndersonSW , KuntzA , HamiltonSH . Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Schizophrenia Research1998;29(1, 2):205. TranPV , TollefsonGD , CrawfordAM , DossenbachM , FriedelP , FolnegovicV , et al. Olanzapine versus fluphenazine in schizophrenia. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐Jun 4; Toronto, Ontario, Canada. 1998. TranPV , TollefsonGD , HamiltonS . Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17‐22; San Diego, California, USA. 1997. TranPV , TollefsonGD , HamiltonS , KuntzA . Olanzapine vs. risperidone in the treatment of psychosis. Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22‐27; Nice, France. 1997. '>Tran 1997</a>, <a href="./references#CD006918-bbs2-0040" title="ConleyRR , BrecherM , The Risperidone/Olanzapine Study Group. Risperidone versus olanzapine in patients with schizophrenia or schizoaffective disorders. Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4; Paris, France. 1998. ConleyRR , BrecherMB , Olanzapine‐Risperidone Study Group. Risperidone versus olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. ConleyRR , MahmoudR . A randomized double‐blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. American Journal of Psychiatry2001; Vol. 158, issue 5:765‐74. ConleyRR , MahmoudR . Efficacy of risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder. European Neuropsychopharmacology2000;10(Suppl 3):S343. [13th Congress of the European College of Neuropsychopharmacology [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2000 P3021] ConleyRR , MahmoudR . Efficacy of risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S151. ConleyRR , MahmoudR . Risperidone and olanzapine in people with schizophrenia or schizoaffective disorder: a randomised double‐blind study. Poster supplied by Company2001. ConleyRR , MahmoudR . Risperidone vs olanzapine in patients with schizophrenia &amp; schizoaffective disorder. Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30‐Jun 2; Boca Raton, Florida, USA. 2000. ConleyRR , MahmoudR . Risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder: safety comparisons. European Neuropsychopharmacology2000;10(Suppl 3):S342. [13th Congress of the European College of Neuropsychopharmacology [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2000 P3020] ConleyRR , MahmoudR . Risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder: safety comparisons. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S151. ConleyRR , MahmoudR , Risperidone Study Group. Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder. Proceedings of the 10th Biennial Winter Workshop on Schizophrenia; 2000 Feb 5‐11; Davos, Switzerland. 2000. ConleyRR , MahmoudR , Risperidone Study Group. Risperidone versus olanzapine in patients with schizophrenia and schizoaffective psychosis [Risperidon versus olanzapin bei patienten mit schizophrenie und schizoaffektiven psychosen]. Nervenheilkunde2000;19(5):110‐2. ConleyRR , MahmoudR , Risperidone Study Group. Risperidone vs. olanzapine in patients with schizophrenia and schizoaffective disorder. Biological Psychiatry2000;47:32S. ConleyRR , MahmoudRA . Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [NR1 Monday, May 15, 9:00 a.m.‐10:30 a.m] ConleyRR , MahmoudRA . Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. ConleyRR , MahmoudRA . Risperidone vs olanzapine in patients with schizophrenia and schizo‐affective disorder. International Drug Therapy Newsletter2000;35(10):77‐8. ">Conley 1998</a>, <a href="./references#CD006918-bbs2-0054" title="HarveyK , BurnsT , SedgwickP , HiggittA , CreedF , FahyT . Relatives of patients with severe psychotic disorders: factors that influence contact frequency. Report from the UK700 trial. British Journal of Psychiatry2001;178:248‐54. HarveyP , MeltzerH , GreenM . Long term cognitive effects of risperidone treatment in schizophrenia. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S154. HarveyP , MeltzerH , GreenM . Risperidone cognitive effects in schizophrenia and schizoaffective patients. International Drug Therapy Newsletter2001;36(8):59. HarveyP , MeltzerHY , GreenMP . Cognitive effects of risperidone versus olanzapine in patients with schizophrenia or schizoaffective disorder. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001. HarveyP , MelzerH , GreenM . Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder. Biological Psychiatry2001;49(8):123S. HarveyPD . Cognitive effects of risperidone and olanzapine in patients with schizophrenia. Proceedings of the 52nd Institute on Psychiatric Services; 2000 Oct 25‐29; Philadelphia, Pennsylvania, USA. 2000. HarveyPD . Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. HarveyPD . Long‐term cognitive effects of risperidone treatment in schizophrenia. Proceedings of the 52nd Institute on Psychiatric Services; 2000 Oct 25‐29; Philadelphia, Pennsylvania, USA. 2000. HarveyPD , GharabawiG . Risperidone and cognition in schizophrenic elderly. Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. HarveyPD , GreenMF , McGurkSR , MeltzerHY . Changes in cognitive functioning with risperidone and olanzapine treatment: a large‐scale, double‐blind, randomized study. Psychopharmacology2003;169(3‐4):404‐11. HarveyPD , LyonsBE , MahmoudR . Long term cognitive effects of risperidone. Schizophrenia Research2000;41(1):200‐1. HarveyPD , MahmoudR , MeltzerHY , GreenMP . Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder. European Neuropsychopharmacology2001;11(3):257. HarveyPD , MeltzerHY , GreenM . Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. HarveyPD , MeltzerHY , GreenMF . Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder. Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30‐Jun 2; Boca Raton, Florida, USA. 2000. HarveyPD , MeltzerHY , GreenMF . Long‐term cognitive effects of risperidone treatment in schizophrenia. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. ">Harvey 2001</a>, <a href="./references#CD006918-bbs2-0030" title="BrecherM . Risperidone versus olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder. Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4; Paris, France. 1998. BrecherM , The Risperidone Olanzapine Study Group. Risperidone versus olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder. Proceedings of the 21st Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1998 Jul 12‐16; Glasgow, UK. 1998. BrecherM , The Risperidone‐Olanzapine Study Group. Risperidone versus olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder conference abstract. Schizophrenia Research1999;36(1‐3):271. ">Brecher 1998</a>, <a href="./references#CD006918-bbs2-0069" title="McClellanJ . Risperidone for schizophrenia. Stanley Foundation Research Programs2009. ">McClellan 2009</a>, Cavazzoni 2002a, <a href="./references#CD006918-bbs2-0041" title="CooperSJ , ButlerA , TweedJ , RaniwallaJ , WelchC . Zotepine in the prevention of relapse. Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22‐27; Nice, France. 1997. CooperSJ , ButlerA , TweedJA , WelchCP , WightonAJ , ApplebyP , et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4; Paris, France. 1998. CooperSJ , ButlerA , TweedJA , WelchCP , WightonAJ , ApplebyP , et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. Schizophrenia Research2000;41(1):207‐8. CooperTB , VolavkaJ , CzoborP . Plasma drug level and clinical response. Journal of Clinical Psychopharmacology1992;12(2):134‐6. ">Cooper 1997</a>, <a href="./references#CD006918-bbs2-0073" title="NCT00034892 . Efficacy and tolerability of olanzapine, quetiapine and risperidone in the treatment of first episode psychosis: a randomized double blind 52‐week comparison. clinicaltrials.gov/ct2/show/NCT00034892 (2002) (accessed 9 October 2013). ">NCT00034892</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a>; <a href="./references#CD006918-bbs2-0156" title="JayaramMB , HosalliPM , StroupTS . Risperidone versus olanzapine for treatment of schizophrenia. Schizophrenia Bulletin2007;33(6):1274‐6. [PUBMED: 17921477] ">Jayaram 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>quetiapine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0041" title="CooperSJ , ButlerA , TweedJ , RaniwallaJ , WelchC . Zotepine in the prevention of relapse. Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22‐27; Nice, France. 1997. CooperSJ , ButlerA , TweedJA , WelchCP , WightonAJ , ApplebyP , et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4; Paris, France. 1998. CooperSJ , ButlerA , TweedJA , WelchCP , WightonAJ , ApplebyP , et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. Schizophrenia Research2000;41(1):207‐8. CooperTB , VolavkaJ , CzoborP . Plasma drug level and clinical response. Journal of Clinical Psychopharmacology1992;12(2):134‐6. ">Cooper 1997</a>, <a href="./references#CD006918-bbs2-0073" title="NCT00034892 . Efficacy and tolerability of olanzapine, quetiapine and risperidone in the treatment of first episode psychosis: a randomized double blind 52‐week comparison. clinicaltrials.gov/ct2/show/NCT00034892 (2002) (accessed 9 October 2013). ">NCT00034892</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0123" title="AsmalL , FlegarSJ , WangJ , Rummel‐KlugeC , KomossaK , LeuchtS . Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD006625.pub3; PUBMED: 24249315] ">Asmal 2013</a>; <a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sertindole</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0057" title="KaneJ , CarsonWh , KujawaM , StringfellowJ , MarcusR , SanchezR , et al. Aripiprazole in treatment‐resistant schizophrenia: a 6‐week double‐blind comparison study versus perphenazine. Schizophrenia Research2004;67(1):155‐6. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of Risperdal Consta, a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cilag UK Ltd2002. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Proceedings of the 11th Biennial Winter Workshop on Schizophrenia; 2002 Feb 24‐Mar 1; Davos, Switzerland. 2002. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal constatm, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S188. KaneJ , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Schizophrenia Research2000;41(1):39. KaneJM . Preventing morbidity in first‐episode schizophrenia. clinicaltrials.gov/ct2/show/NCT00000374 (accessed 16 Feb 2001). KaneJM . The latest advance in long‐acting antipsychotic therapy. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. KaneJM , CarsonWH , SahaAR , McQuadeRD , IngenitoGG , ZimbroffDL , et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry2002;63(9):763‐71. KaneJM , ConleyRR , KeithSJ , NasrallahHA , TurnerM . Guidelines for the use of long‐acting injectable atypical antipsychotics. Journal of Clinical Psychiatry2004;65(1):120‐31. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research2002;53(3 Suppl 1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology2002;12(Suppl 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160:1125‐32. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [NR345 Tuesday, May 16, 3:00 p.m.‐5:00 p.m] KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S124. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. KaneJM , PotkinS , BuckleyP , DanielDG . Safety and efficacy of sertindole and risperidone in treatment resistant patients with schizophrenia. Schizophrenia Bulletin2005;31:490. KaneJM , WilliamHCJ , KujawaMJ , StringfellowJ , MarcusRN , SanchezR , et al. Aripiprazole vs perphenazine in treatment‐resistant schizophrenia. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. ">Kane 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0163" title="KomossaK , Rummel‐KlugeC , HungerH , SchwarzS , SchmidtF , LewisR , et al. Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD006752.pub2; PUBMED: 19370652] ">Komossa 2009</a>; <a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>zuclopenthixol dihydrochloride</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0061" title="LemmensP , deSmedtG , GheuensJ , TritsmansL . Efficacy of risperidone in the treatment of schizophrenia. Proceedings of the 7th Biennial Winter Workshop on Schizophrenia; 1994 Jan 23‐28; Les Diablerets, Switzerland1994; Vol. 11, issue 2:106. ">Lemmens 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0152" title="HunterRH , JoyCB , KennedyE , GilbodySM , SongF . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000440] ">Hunter 2003</a>; <a href="./references#CD006918-bbs2-0165" title="KumarA , StrechD . Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD005474; PUBMED: 16235403] ">Kumar 2005</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p><b>Not risperidone</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>amisulpride</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p>versus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0029" title="BoyerP , LecrubierY , PuechAJ . Treatment of positive and negative symptoms: pharmacologic approaches. In: AndreasenNC editor(s). Modern problems of pharmacopsychiatry. Vol. 24, Basel, Switzerland: S. Karger, 1990:152‐74. BoyerP , LecrubierY , PuechAJ , DewaillyJ , AubinF . Treatment of negative symptoms in schizophrenia with amisulpride. British Journal of Psychiatry1995;166(1):68‐72. BoyerP , PuechAJ . Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools [Modalities d'action clinique des neuroleptiques: substances, doses, instruments de mesure utilises]. Psychiatrie and Psychobiologie1987;2(4):296‐305. BoyerP , PuechAJ , LecrubierY . Double blind trial versus placebo of low dose amisulpride (Solian 50) in schizophrenia with exclusively negative symptoms. Preliminary analysis of results [Etude en double insu contre placebo de l'amisulpride (Solian (r) 50) a faible dose chez des schizophrenes purement deficitaires. Premiere analyse des resultats]. Annales de Psychiatrie1988;3(3):321‐5. ">Boyer 1995</a>, <a href="./references#CD006918-bbs2-0064" title="LooH , Poirier LittreMF , TheronM , ReinW , FleurotO . Amisulpride versus placebo in the medium‐term treatment of the negative symptoms of schizophrenia. British Journal of Psychiatry1997;170:18‐22. [MEDLINE: 9068769] ">Loo 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0175" title="MotaNE , LimaMS , SoaresBG . Amisulpride for schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD001357; PUBMED: 12076408] ">Mota 2002</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>aripiprazole</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>haloperidol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0032" title="CarsonW , CornblattB , SahaA , AliM , KernR , GreenM . Neurocognitive benefits of aripiprazole versus olanzapine in stable psychosis. European Neuropsychopharmacology2002;12(Suppl 3):S291. CarsonW , McQuadeR , SahaA , TorbeynsA , StockE . Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia. European Neuropsychopharmacology2002;12(Suppl 3):S288. CarsonW , PigottT , SahaA , AliM , McQuadeRD , TorbeynsAF , et al. Aripiprazole vs placebo in the treatment of stable, chronic schizophrenia. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. CarsonWH , AliM , DunbarG , IngenitoG , SahaAR . A double‐blind, placebo‐controlled trial of aripiprazole and haloperidol. Schizophrenia Research2001;49(1,2):221‐2. CarsonWH , AliM , SahaAR , DunbarGC , IngenitoG . A double‐blind, placebo‐controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. CarsonWH , IngenitoGG , McquadeRD , StockEG , IwamotoT . Schizophrenia: safety / tolerability of aripiprazole. Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. CarsonWH , KaneJM , AliM , DunbarGC , IngenitoG . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. European Neuropsychopharmacology2000;10(Suppl 3):S309. CarsonWH , PigottTA , SahaAR , AliMW , McQuadeRD , TorbeynsAF , et al. Aripiprazole vs placebo in the treatment of chronic schizophrenia. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S187. CarsonWH , SahaAR , AliM , DunbarGC , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. 2001. CarsonWHJ , SahaAR , AliM , DunbarGC , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Carson 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0129" title="BhattacharjeeJ , El‐SayehHG . Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD006617.pub3; PUBMED: 18646161] ">Bhattacharjee 2008</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>olanzapine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0042" title="CornblattB , KernRS , CarsonWH , AliMW , LuoX , GreenM . Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S185. CornblattB , KernRS , CarsonWH , StockE , AliM , IngenitoG , et al. Neurocognitive effects of aripiprazole versus olanzapine in patients with stabile psychosis. Journal of Psychopharmacology2002;16(Suppl 3):A15. CornblattB , KernRS , CarsonWH , StockE , AliM , IngenitoG , et al. Neurocognitive effects of aripiprazole versus olanzapine in patients with stable psychosis. Schizophrenia Research2002;53(3 Suppl 1):27. ">Cornblatt 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0161" title="KhannaP , SuoT , KomossaK , MaH , Rummel‐KlugeC , El‐SayehHG , et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD006569.pub5; PUBMED: 24385408] ">Khanna 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>perphenazine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0052" title="GismondiR , MeltzerH , KujawaM , CarsonW , StringfellowJ , IwamotoT , et al. Aripiprazole versus perphenazine in treatment‐resistant schizophrenia. Proceedings of the XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. ">Gismondi 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0129" title="BhattacharjeeJ , El‐SayehHG . Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD006617.pub3; PUBMED: 18646161] ">Bhattacharjee 2008</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0032" title="CarsonW , CornblattB , SahaA , AliM , KernR , GreenM . Neurocognitive benefits of aripiprazole versus olanzapine in stable psychosis. European Neuropsychopharmacology2002;12(Suppl 3):S291. CarsonW , McQuadeR , SahaA , TorbeynsA , StockE . Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia. European Neuropsychopharmacology2002;12(Suppl 3):S288. CarsonW , PigottT , SahaA , AliM , McQuadeRD , TorbeynsAF , et al. Aripiprazole vs placebo in the treatment of stable, chronic schizophrenia. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. CarsonWH , AliM , DunbarG , IngenitoG , SahaAR . A double‐blind, placebo‐controlled trial of aripiprazole and haloperidol. Schizophrenia Research2001;49(1,2):221‐2. CarsonWH , AliM , SahaAR , DunbarGC , IngenitoG . A double‐blind, placebo‐controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. CarsonWH , IngenitoGG , McquadeRD , StockEG , IwamotoT . Schizophrenia: safety / tolerability of aripiprazole. Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. CarsonWH , KaneJM , AliM , DunbarGC , IngenitoG . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. European Neuropsychopharmacology2000;10(Suppl 3):S309. CarsonWH , PigottTA , SahaAR , AliMW , McQuadeRD , TorbeynsAF , et al. Aripiprazole vs placebo in the treatment of chronic schizophrenia. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S187. CarsonWH , SahaAR , AliM , DunbarGC , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. 2001. CarsonWHJ , SahaAR , AliM , DunbarGC , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Carson 2002</a>, <a href="./references#CD006918-bbs2-0033" title="CaseyD , BarbatoLM , HeisterbergJ , YeungPP , ShapiraNA . Results of a bifeprunox dose‐finding study in patients with acutely exacerbated schizophrenia. Schizophrenia Bulletin2007;33(2):425. CaseyD , SahaA , MarcusR , CarsonWH , McQuadeRD , TorbeynsAF , et al. Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia. Schizophrenia Research2003;60(1):276. CaseyD , SahaAR , AliMW , JodyDN , KujawaMJ , StockEG , et al. Switching to aripiprazole monotherapy. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S187. CaseyDE , BarbatoLM , HeisterbergJ , YeungPP , ShapiraNA . Results of a bifeprunox dose‐finding study in patients with acutely exacerbated schizophrenia. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28‐Apr 1, Colorado Springs, Colorado, USA2007. CaseyDE , CarsonWH , SahaAR , LiebeskindA , AliMW , JodyD , et al. Switching patients to aripiprazole from other antipsychotic agents: A multicenter randomized study. Psychopharmacology2003;166(4):391‐9. CaseyDE , DanielDG , WassefAA , TracyKA , WozniakP , SommervilleKW . Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropyschopharmacology2003;28(1):182‐92. CaseyDE , SahaAR , AliMW , JodyD , KujawaMJ , StockEG , et al. Switching to aripiprazole monotherapy. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Casey 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0127" title="BelgamwarRB , El‐SayehHG . Aripiprazole versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 8. [DOI: 10.1002/14651858.CD006622.pub2; PUBMED: 21833956] ">Belgamwar 2011</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>haloperidol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0026" title="BeasleyCJr , TollefsonGD , BeuzenJN , DellvaMA , SangerTM , PaulS . Acute and long‐term results of the North American double‐blind olanzapine trial. Proceedings of the 4th International Conference on Schizophrenia: Breaking Down the Barriers; 1996 Oct 6‐9; Vancouver, Canada. 1996. BeasleyC , TranP , BeuzenJN , TamuraR , DellvaMA , BaileyJ , et al. Olanzapine versus haloperidol: long‐term results of the multi‐center international trial. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. BeasleyC , TranP , SatterleeW , TollefsonG , LuY , KuntzA , et al. Olanzapine versus placebo, results of the United States double‐blind olanzapine trial. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. BeasleyCM . Safety of olanzapine. Journal of Clinical Psychiatry1997;15(2):19‐21. BeasleyCMJr , SangerT , SatterleeW , TollefsonG , TranP , HamiltonS . Olanzapine versus placebo ‐ results of a double‐blind, fixed dose olanzapine trial. Psychopharmacology1996;124(1‐2):159‐67. BeasleyCM , BergPH , DananbergJ , KwongKC , TaylorCCM , BreierA . Treatment‐emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo. Biological Psychiatry2001;49(8):121S. BeasleyCM , DellvaMA , TamuraRN , MorgensternH , GlazerWM , FergusonK , et al. A randomised double‐blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long‐term treatment with olanzapine or haloperidol. British Journal of Psychiatry1999;174:23‐30. BeasleyCM , HamiltonSH , CrawfordAM , DellvaMA , TollefsonGD , TranPV , et al. Olanzapine versus haloperidol: acute phase results of the international double‐blind olanzapine trial. European Neuropsychopharmacology1997;7(2):125‐37. BeasleyCM , SaylerME , KeislerGM , PotvinJH , SangerTM , TollefsonGD . The influence of pharamacotherapy on self‐directed and externally‐directed aggression in schizophrenia. Schizophrenia Research1998;29(1‐2):28. BeasleyCM , SowellMO , CarlsonC , MukhopadhyayN , DananbergJ , HenryR , et al. Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone or placebo. Schizophrenia Research2003;60(1):309. BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double‐blind, randomized, placebo‐controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23(6):582‐94. BeasleyCM , TollefsonG , TranP , SatterleeW , SangerT , HamiltonS . Olanzapine versus placebo and haloperidol: acute phase results of the North American double‐blind olanzapine trial. Neuropyschopharmacology1996;14(2):111‐23. BeasleyCM , TollefsonGD , DellvaMA , TamuraR , GlazerWM , MorgensternH . The differential risk of tardive dyskinesia with olanzapine. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐Jun 4; Toronto, Ontario, Canada. 1998. ">Beasley 1996</a>, <a href="./references#CD006918-bbs2-0032" title="CarsonW , CornblattB , SahaA , AliM , KernR , GreenM . Neurocognitive benefits of aripiprazole versus olanzapine in stable psychosis. European Neuropsychopharmacology2002;12(Suppl 3):S291. CarsonW , McQuadeR , SahaA , TorbeynsA , StockE . Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia. European Neuropsychopharmacology2002;12(Suppl 3):S288. CarsonW , PigottT , SahaA , AliM , McQuadeRD , TorbeynsAF , et al. Aripiprazole vs placebo in the treatment of stable, chronic schizophrenia. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. CarsonWH , AliM , DunbarG , IngenitoG , SahaAR . A double‐blind, placebo‐controlled trial of aripiprazole and haloperidol. Schizophrenia Research2001;49(1,2):221‐2. CarsonWH , AliM , SahaAR , DunbarGC , IngenitoG . A double‐blind, placebo‐controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. CarsonWH , IngenitoGG , McquadeRD , StockEG , IwamotoT . Schizophrenia: safety / tolerability of aripiprazole. Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. CarsonWH , KaneJM , AliM , DunbarGC , IngenitoG . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. European Neuropsychopharmacology2000;10(Suppl 3):S309. CarsonWH , PigottTA , SahaAR , AliMW , McQuadeRD , TorbeynsAF , et al. Aripiprazole vs placebo in the treatment of chronic schizophrenia. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S187. CarsonWH , SahaAR , AliM , DunbarGC , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. 2001. CarsonWHJ , SahaAR , AliM , DunbarGC , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Carson 2002</a>, <a href="./references#CD006918-bbs2-0043" title="CrawfordAM , BeasleyCM , TollefsonGD . Olanzapine ‐ impact of an atypical antipsychotic candidate on prolactin release. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4‐9, New York, New York, USA. 1996. CrawfordAM , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. European Neuropsychopharmacology1997;7(Suppl 2):199. CrawfordAM , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research1997;26(1):41‐54. CrawfordAMK , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17; Vienna, Austria. 1997. CrawfordAMK , GomezJC , BeasleyCMJr , TollefsonGD . Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi‐center international trial. European Neuropsychopharmacology1997;7:2.015. ">Crawford 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0117" title="AdamsCE , BergmanH , IrvingCB , LawrieS . Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD003082.pub3; PUBMED: 24242360] ">Adams 2013</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>olanzapine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>fluphenazine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0047" title="DossenbachM , FriedelP , JakovljevicM , HotujacL , FolnegovicV , UglesicB , et al. Olanzapine versus fluphenazine ‐ six weeks' treatment of acute schizophrenia. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17; Vienna, Austria. 1997. DossenbachM , JakovljevicM , FolnegovicF , UglesicB , DodigG , FriedelP , et al. Olanzapine versus fluphenazine ‐ 6 weeks treatment of anxiety symptoms during acute schizophrenia. Schizophrenia Research1998;29(1,2):203. ">Dossenbach 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD006918-bbs2-0141" title="DugganL , FentonM , RathboneJ , DardennesR , El‐DosokyA , IndranS . Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2; PUBMED: 15846619] ">Duggan 2005</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>haloperidol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0026" title="BeasleyCJr , TollefsonGD , BeuzenJN , DellvaMA , SangerTM , PaulS . Acute and long‐term results of the North American double‐blind olanzapine trial. Proceedings of the 4th International Conference on Schizophrenia: Breaking Down the Barriers; 1996 Oct 6‐9; Vancouver, Canada. 1996. BeasleyC , TranP , BeuzenJN , TamuraR , DellvaMA , BaileyJ , et al. Olanzapine versus haloperidol: long‐term results of the multi‐center international trial. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. BeasleyC , TranP , SatterleeW , TollefsonG , LuY , KuntzA , et al. Olanzapine versus placebo, results of the United States double‐blind olanzapine trial. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. BeasleyCM . Safety of olanzapine. Journal of Clinical Psychiatry1997;15(2):19‐21. BeasleyCMJr , SangerT , SatterleeW , TollefsonG , TranP , HamiltonS . Olanzapine versus placebo ‐ results of a double‐blind, fixed dose olanzapine trial. Psychopharmacology1996;124(1‐2):159‐67. BeasleyCM , BergPH , DananbergJ , KwongKC , TaylorCCM , BreierA . Treatment‐emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo. Biological Psychiatry2001;49(8):121S. BeasleyCM , DellvaMA , TamuraRN , MorgensternH , GlazerWM , FergusonK , et al. A randomised double‐blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long‐term treatment with olanzapine or haloperidol. British Journal of Psychiatry1999;174:23‐30. BeasleyCM , HamiltonSH , CrawfordAM , DellvaMA , TollefsonGD , TranPV , et al. Olanzapine versus haloperidol: acute phase results of the international double‐blind olanzapine trial. European Neuropsychopharmacology1997;7(2):125‐37. BeasleyCM , SaylerME , KeislerGM , PotvinJH , SangerTM , TollefsonGD . The influence of pharamacotherapy on self‐directed and externally‐directed aggression in schizophrenia. Schizophrenia Research1998;29(1‐2):28. BeasleyCM , SowellMO , CarlsonC , MukhopadhyayN , DananbergJ , HenryR , et al. Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone or placebo. Schizophrenia Research2003;60(1):309. BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double‐blind, randomized, placebo‐controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23(6):582‐94. BeasleyCM , TollefsonG , TranP , SatterleeW , SangerT , HamiltonS . Olanzapine versus placebo and haloperidol: acute phase results of the North American double‐blind olanzapine trial. Neuropyschopharmacology1996;14(2):111‐23. BeasleyCM , TollefsonGD , DellvaMA , TamuraR , GlazerWM , MorgensternH . The differential risk of tardive dyskinesia with olanzapine. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐Jun 4; Toronto, Ontario, Canada. 1998. ">Beasley 1996</a>, <a href="./references#CD006918-bbs2-0043" title="CrawfordAM , BeasleyCM , TollefsonGD . Olanzapine ‐ impact of an atypical antipsychotic candidate on prolactin release. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4‐9, New York, New York, USA. 1996. CrawfordAM , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. European Neuropsychopharmacology1997;7(Suppl 2):199. CrawfordAM , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research1997;26(1):41‐54. CrawfordAMK , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17; Vienna, Austria. 1997. CrawfordAMK , GomezJC , BeasleyCMJr , TollefsonGD . Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi‐center international trial. European Neuropsychopharmacology1997;7:2.015. ">Crawford 1997</a>, <a href="./references#CD006918-bbs2-0053" title="GregorK , HamiltonS , EdgellE . Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol. Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6‐11; Hamburg, Germany. 1999. GregorKJ , AllicarMP , LilliuH , OlivierV , LePenC , GavartS . An economic comparison of olanzapine versus haloperidol in the treatment of schizophrenia in France. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S161. GregorKJ , HamiltonSH , EdgellET . Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol. European Neuropsychopharmacology1999;9(Suppl 1):S11. GregorKJ , HamiltonSH , EdgellET . Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol. European Neuropsychopharmacology1999;9:S289. GregorKJ , HamiltonSH , EdgellET . Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol. Schizophrenia Research2000;41(1):189. ">Gregor 2000</a>, <a href="./references#CD006918-bbs2-0058" title="KinonB , BassonB , MalcolmS , BreierA . Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. Proceedings of the 39th Annual Meeting of the New Clinical Drug Evaluation Unit; 1999 Jun 1‐4; Boca Raton, Florida, USA. 1999. KinonB , BassonB , TollefsonGD . Gender‐specific prolactin olanzapine versus haloperidol in schizophrenia. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐Jun 4; Toronto, Ontario, Canada. 1998. [151st Annual Meeting of the American Psychiatric Association [CD‐ROM]: MARATHON Multimedia, 1988 NR449; 151st Annual Meeting of the American Psychiatric Association [CD‐ROM]: MARATHON Multimedia, 1988 NR739] KinonB , BassonB , TollefsonGD . Gender‐specific prolactin olanzapine versus haloperidol in schizophrenia. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐Jun 4; Toronto, Ontario, Canada. 1998. KinonB , BassonBR , MalcolmSK , TollefsonG . Strategies for switching from conventional antipsychotic drugs to olanzapine. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington, DC, USA. 1999. KinonB , BreierA , MalcolmS , BassonB . Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6‐11; Hamburg, Germany. 1999. KinonBJ , BassonB , HillAL , BergPH . Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine. European Neuropsychopharmacology2000;10(Suppl 3):S305. KinonBJ , BassonB , SzymanskiK , TollefsonGD . Predictors of weight gain during olanzapine treatment. Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4; Paris, France. 1998. KinonBJ , BassonB , WangJ , MalcolmSK . Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. Schizophrenia Research2000;41(1):194‐5. KinonBJ , BassonB , WangJ , MalcolmSK , StaufferVL . Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. European Neuropsychopharmacology2000;10(Suppl 3):S306. KinonBJ , BassonB , WangJ , MalcolmSK , StaufferVL . Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S155. KinonBJ , BassonB , WangJ , MalcolmSK , StaufferVL . Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30‐Jun 2; Boca Raton, Florida, USA. 2000. KinonBJ , BassonBR , GilmoreJA , MalcolmS , StaufferVL . Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. Journal of Clinical Psychiatry2000;61(11):833‐40. KinonBJ , BassonBR , GilmoreJA , TollefsonGD . Long‐term olanzapine treatment: weight change and weight‐related health factors in schizophrenia. Journal of Clinical Psychiatry2001;62(2):92‐100. KinonBJ , BassonBR , MalcolmSK , TollefsonGD . Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine conference abstract. Schizophrenia Research1999;36(1‐3):285‐6. KinonBJ , BassonBR , WangJ . Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. Proceedings of the 52nd Institute on Psychiatric Services; 2000 Oct 25‐29; Philadelphia, Pennsylvania, USA. 2000. KinonBJ , BassonBR , WangJ , MalcolmSK , StaufferVL . Rapid reduction in hyperprolactinemia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. KinonBJ , BassonMS , TollefsonGD . Gender‐specific prolactin response to treatment with olanzapine versus haloperidol in schizophrenia. Proceedings of the 9th Biennial Winter Workshop on Schizophrenia; 1998 Feb 7‐13; Davos, Switzerland1998. KinonBJ , GilmoreJA , GottschalkLA . Continued improvement in quality of life despite weight change during olanzapine treatment. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. KinonBJ , Liu‐SeifertH , AhlJ , AhmedS , BakerRW . Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4‐month study. Annals of the New York Academy of Sciences2004;1032:295‐6. KinonBJ , MiltonDR , GilmoreJA . Continued improvement in quality of life despite weight change during olanzapine treatment. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S154. KinonBJ , MiltonDR , HillAL . Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S154. KinonBJ , MiltonDR , HillAL , WilliamsonDJ . Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine. Journal of Psychopharmacology2000;14(3 Suppl):A60. KinonBJ , RoychowdhurySM , MiltonDR , HillAL . Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. Journal of Clinical Psychiatry2001;62(Suppl 2):17‐21. ">Kinon 1998</a>, <a href="./references#CD006918-bbs2-0062" title="LiebermanJ , McEnvoyJ , StroupS . Protocol: comparative effectiveness of antipsychotic medications in patients with schizophrenia: revised in response to DSMB comments. National Institute of Mental Health. Chapel Hill, USA: University of North Carolina, 2000. LiebermanJ , McEvoyJ , StroupS . Trial design summary: Comparative effectiveness of antipsychotic medications in patients with schizophrenia: Draft. National Institute of Mental Health. Chapel Hill, USA: University of North Carolina, 2002. LiebermanJ , McEvoyJP , PerkinsD , HamerRH . Comparison of atypicals in first‐episode psychosis: a randomized, 52‐week comparison of olanzapine, quetiapine, and risperidone. European Neuropsychopharmacology2005;15(Suppl 3):S525. LiebermanJA . Comparative effectiveness of antipsychotic medications in patients with schizophrenia (CATIE schizophrenia trial). clinicaltrials.gov/ct2/show/NCT00014001 2001 (accessed 9 October 2013). LiebermanJA . Research gaps and current research initiatives to improve the treatment of schizophrenia. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. LiebermanJA , SchneiderLS , McEroyJ , PariotP , StroupS , AdiaoJ , et al. Effectiveness trials of antipsychotic drugs. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [No. 103D] LiebermanJA , SchneiderLS , McEroyJ , PariotP , StroupS , AdiaoJ , et al. Effectiveness trials of antipsychotic drugs. Proceeding of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. LiebermanJA , StroupTS . Schizophrenia, VI: treatments. American Journal of Psychiatry2003;160(10):1748. LiebermanJA , StroupTS , McEvoyJP , SwartzMS , KeefeR , PerkinsDO , et al. CATIE trial results. European Neuropsychopharmacology2006;16(Suppl 4):S184. LiebermanJA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine2005;353(12):1209‐23. LiebermanJA , TollefsonG , TohenM , GreenAI , GurRE , KahnR , et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first‐episode psychosis: a randomized, double‐blind trial of olanzapine versus haloperidol. American Journal of Psychiatry2003;160(8):1396‐404. ">Lieberman 2005</a>, <a href="./references#CD006918-bbs2-0086" title="RevickiD , GendusoLA , HamiltonSL , MartinC , ReblandoJ , TranPV . Quality of life outcomes for olanzapine and haloperidol treatment for schizophrenia and related psychotic disorders. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4‐9, New York, New York, USA. 1996. ">Revicki 1996</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>paliperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0067" title="罗燕 . Palley risperidone sustained release tablets and olanzapine tablets in the treatment of exacerbations and readmission of patients with schizophrenia in a randomized double‐blind placebo‐controlled study. Chinese Journal of Mental Health [中国民康医学]2011;23(05):560‐3. ">Luo 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a>; <a href="./references#CD006918-bbs2-0176" title="NussbaumAM , StroupTS . Paliperidone palmitate for schizophrenia. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD008296.pub2; PUBMED: 22696377] ">Nussbaum 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0026" title="BeasleyCJr , TollefsonGD , BeuzenJN , DellvaMA , SangerTM , PaulS . Acute and long‐term results of the North American double‐blind olanzapine trial. Proceedings of the 4th International Conference on Schizophrenia: Breaking Down the Barriers; 1996 Oct 6‐9; Vancouver, Canada. 1996. BeasleyC , TranP , BeuzenJN , TamuraR , DellvaMA , BaileyJ , et al. Olanzapine versus haloperidol: long‐term results of the multi‐center international trial. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. BeasleyC , TranP , SatterleeW , TollefsonG , LuY , KuntzA , et al. Olanzapine versus placebo, results of the United States double‐blind olanzapine trial. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. BeasleyCM . Safety of olanzapine. Journal of Clinical Psychiatry1997;15(2):19‐21. BeasleyCMJr , SangerT , SatterleeW , TollefsonG , TranP , HamiltonS . Olanzapine versus placebo ‐ results of a double‐blind, fixed dose olanzapine trial. Psychopharmacology1996;124(1‐2):159‐67. BeasleyCM , BergPH , DananbergJ , KwongKC , TaylorCCM , BreierA . Treatment‐emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo. Biological Psychiatry2001;49(8):121S. BeasleyCM , DellvaMA , TamuraRN , MorgensternH , GlazerWM , FergusonK , et al. A randomised double‐blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long‐term treatment with olanzapine or haloperidol. British Journal of Psychiatry1999;174:23‐30. BeasleyCM , HamiltonSH , CrawfordAM , DellvaMA , TollefsonGD , TranPV , et al. Olanzapine versus haloperidol: acute phase results of the international double‐blind olanzapine trial. European Neuropsychopharmacology1997;7(2):125‐37. BeasleyCM , SaylerME , KeislerGM , PotvinJH , SangerTM , TollefsonGD . The influence of pharamacotherapy on self‐directed and externally‐directed aggression in schizophrenia. Schizophrenia Research1998;29(1‐2):28. BeasleyCM , SowellMO , CarlsonC , MukhopadhyayN , DananbergJ , HenryR , et al. Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone or placebo. Schizophrenia Research2003;60(1):309. BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double‐blind, randomized, placebo‐controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23(6):582‐94. BeasleyCM , TollefsonG , TranP , SatterleeW , SangerT , HamiltonS . Olanzapine versus placebo and haloperidol: acute phase results of the North American double‐blind olanzapine trial. Neuropyschopharmacology1996;14(2):111‐23. BeasleyCM , TollefsonGD , DellvaMA , TamuraR , GlazerWM , MorgensternH . The differential risk of tardive dyskinesia with olanzapine. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐Jun 4; Toronto, Ontario, Canada. 1998. ">Beasley 1996</a>, <a href="./references#CD006918-bbs2-0043" title="CrawfordAM , BeasleyCM , TollefsonGD . Olanzapine ‐ impact of an atypical antipsychotic candidate on prolactin release. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4‐9, New York, New York, USA. 1996. CrawfordAM , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. European Neuropsychopharmacology1997;7(Suppl 2):199. CrawfordAM , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research1997;26(1):41‐54. CrawfordAMK , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17; Vienna, Austria. 1997. CrawfordAMK , GomezJC , BeasleyCMJr , TollefsonGD . Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi‐center international trial. European Neuropsychopharmacology1997;7:2.015. ">Crawford 1997</a>, <a href="./references#CD006918-bbs2-0067" title="罗燕 . Palley risperidone sustained release tablets and olanzapine tablets in the treatment of exacerbations and readmission of patients with schizophrenia in a randomized double‐blind placebo‐controlled study. Chinese Journal of Mental Health [中国民康医学]2011;23(05):560‐3. ">Luo 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Protocol underway</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>paliperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0067" title="罗燕 . Palley risperidone sustained release tablets and olanzapine tablets in the treatment of exacerbations and readmission of patients with schizophrenia in a randomized double‐blind placebo‐controlled study. Chinese Journal of Mental Health [中国民康医学]2011;23(05):560‐3. ">Luo 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0176" title="NussbaumAM , StroupTS . Paliperidone palmitate for schizophrenia. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD008296.pub2; PUBMED: 22696377] ">Nussbaum 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Single vs polypharmacy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>risperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>versus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>amisulpride + haloperidol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0082" title="PeuskensJ , MollerHJ . Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. European Neuropsychopharmacology2001;11(3):255. ">Peuskens 2001a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Miscellaneous</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>antipsychotic drugs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>versus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miscellaneous (risperidone, olanzapine, quetiapine)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0096" title="WeickertTW , GoldbergTE , MarencoS , BigelowLB , EganMF , WeinbergerDR . Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology2003;28(8):1491‐500. ">Weickert 2003</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>risperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>valproate + miscellaneous antipsychotic drugs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0038" title="CitromeL , CaseyDE , DanielDG , WozniakP , KochanLD , TracyKA . Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatric Services2004;55(3):290‐4. CitromeLL , DanielDG , WassefAA , TracyKA , WozniakP , CaseyDE . Antipsychotic monotherapy versus combination treatment with valporate in hospitalized patients with acute schizophrenia: a double‐blind, multi‐center study. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Citrome 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>riluzole (a drug used to treat amyotrophic lateral sclerosis)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rujescu 2009a</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>talnetant (a</p> <p>neurokinin 3 receptor antagonist)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GlaxoSmithKline 2006a</p> </td> </tr> </tbody> </table> </div> <p>More independent well‐planned, well‐conducted, and well‐reported RCTs of longer duration are needed to address important, unanswered clinically relevant outcomes. In <a href="#CD006918-tbl-0006">Table 4</a>, we have a recommended study design for future trials. Even though we included 15 studies in this review, we could present few clinically meaningful results. As a result, we are uncertain of the short‐, medium‐, and long‐term efficacy of using this popular treatment. </p> <div class="table" id="CD006918-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Suggested design of study</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Methods</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allocation: randomised, clearly described and concealed.<br/> Blinding: double, tested.<br/> Duration: 1 year or more. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis: schizophrenia, schizotypal, schizoaffective, delusional disorder, acute psychosis, comorbid alcohol problems, and substance misuse.<br/> N = 300.<br/> Age: adults.<br/> Sex: men or women.<br/> History: perhaps once an early episode of moderate severity has subsided and after a period of stable washout of the medications used during the acute phase, living anywhere and not just in hospital. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Risperidone: dose 4 mg/day or above.<br/> 2. Placebo. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthy days.<br/> Mental state: improved to important degree.<br/> Global state: improved to important degree, relapse.<br/> Service use: in hospital.<br/> Social functioning: employment status, relationships.<br/> Quality of life: improved to important degree.<br/> Economic outcomes: cost. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Notes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Free of all industry influence.</p> </td> </tr> </tbody> </table> </div> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006918-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006918-sec-0015"></div> <div class="table" id="CD006918-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">RISPERIDONE compared to PLACEBO for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE compared to PLACEBO for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> RISPERIDONE<br/> <b>Comparison:</b> PLACEBO </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PLACEBO</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mental state: no clinically significant response in psychotic symptoms (defined by various scale total score change) ‐ short term (up to 12 weeks) ‐ defined by PANSS/BPRS &lt;20% decline</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.64</b> <br/> (0.52 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>864<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very Low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>692 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>443 per 1000</b> <br/> (360 to 540) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>733 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>469 per 1000</b> <br/> (381 to 572) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early ‐ short term (up to 12 weeks) ‐ any reason</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.69</b> <br/> (0.62 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2261<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>495 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>342 per 1000</b> <br/> (307 to 386) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>486 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>335 per 1000</b> <br/> (301 to 379) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global state: 2. no significant clinical improvement ‐ CGI, short term (up to 12 weeks)</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.69</b> <br/> (0.57 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>594<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>744 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>513 per 1000</b> <br/> (424 to 618) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>732 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>505 per 1000</b> <br/> (417 to 608) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term (up to 12 weeks) ‐ general ‐ any significant EPS</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.56</b> <br/> (1.13 to 2.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1511<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>113 per 1000</b> <br/> (82 to 156) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>106 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>165 per 1000</b> <br/> (120 to 228) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to risk of bias: studies contributing data to this body of evidence have unclear or high risk of bias in one or more domains, some were also sponsored by pharmaceutical companies.<br/> <sup>2</sup> Downgraded one level due to inconsistency: some concerns of heterogeneity were identified.<br/> <sup>3</sup> Downgraded one level due to publication bias: 'strongly suspected' ‐ most studies were sponsored by pharmaceutical companies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006918-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">RISPERIDONE + CLOZAPINE compared to PLACEBO + CLOZAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE + CLOZAPINE compared to PLACEBO + CLOZAPINE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> RISPERIDONE + CLOZAPINE<br/> <b>Comparison:</b> PLACEBO + CLOZAPINE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PLACEBO + CLOZAPINE</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE + CLOZAPINE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mental state: no clinically significant response in psychotic symptoms ‐ short term</b> <br/> PANSS/BPRS &lt; 20% decline<br/> Follow‐up: 6‐8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.15</b> <br/> (0.93 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>98<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>725 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>834 per 1000</b> <br/> (674 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early due to any reason ‐ short term</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>119 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>135 per 1000</b> </p> <p>(63 to 288)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR1.13</b> </p> <p>(0.53 to 2.42)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: no significant clinical improvement ‐ CGI short term</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>735 per 1000</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>824 per 1000</b> <br/> (640 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/> (0.87 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: extrapyramidal ‐ short term</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to risk of bias: studies contributing data to this body of evidence have unclear risk of bias in one or more domains.<br/> <sup>2</sup> Downgraded one level due to imprecision: wide confidence interval including no effect and appreciable harm, and less than optimal information size. <br/> <sup>3</sup> Downgraded one level due to publication bias: 'strongly suspected' ‐ most studies were sponsored by pharmaceutical companies. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006918-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006918-sec-0016"></div> <p>Risperidone (<a href="#CD006918-fig-0001">Figure 1</a>) is the first new‐generation antipsychotic drug made available in the market in its generic form. It has been used in the treatment of schizophrenia and related psychotic disorders for over a decade. </p> <div class="figure" id="CD006918-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risperidone" data-id="CD006918-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risperidone</p> </div> </div> </div> <section id="CD006918-sec-0017"> <h3 class="title" id="CD006918-sec-0017">Description of the condition</h3> <p>Schizophrenia is a serious, chronic, and relapsing mental illness with a worldwide lifetime prevalence of about 1%. It is characterised by positive symptoms such as hallucinations and delusions, and negative symptoms such as emotional numbness and withdrawal. One‐third of those who experience an episode of schizophrenia recover and the illness does not recur. Another 30% experience an unremitting illness. The remainder have a recurrent illness but with long episodes of considerable recovery from the positive symptoms. The overall cost of the illness to the individuals, their families, and the community is considerable. </p> </section> <section id="CD006918-sec-0018"> <h3 class="title" id="CD006918-sec-0018">Description of the intervention</h3> <p>Conventional antipsychotic drugs were introduced into widespread use in the 1950s, and have since formed the mainstay of drug treatment for schizophrenia. Although these drugs were indeed a revolution, their early promise of complete recovery was unfulfilled. Continued interests in further developments led to the formulation of clozapine in the early 1960s, which, in turn, paved the way for a series of new atypical antipsychotic drugs. This disparate grouping was said to be 'atypical' because they did not seem to cause movement disorders to the same extent as the older generation of drugs. </p> <p>This series of newer drugs appeared on the market in the early 1990s, risperidone being one of the first. Initially, risperidone was compared with placebo and then with the older‐generation antipsychotic drugs, especially haloperidol (<a href="./references#CD006918-bbs2-0152" title="HunterRH , JoyCB , KennedyE , GilbodySM , SongF . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000440] ">Hunter 2003</a>). More recently, risperidone has been used as the control compound when other new antipsychotic drugs are compared with a 'standard atypical'. In 2007 risperidone became off‐licence, and it seems likely that this drug will emerge as the new standard care comparator, replacing the older and more problematic haloperidol (<a href="./references#CD006918-bbs2-0157" title="JoyCB , AdamsCE , LawrieSM . Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD003082.pub2] ">Joy 2006</a>). </p> <p>The absolute effects of a drug are often less well investigated when a standard treatment is widely used, and it is seen as unethical not to treat with drug therapy. With almost everyone having access to older drug treatments for schizophrenia, placebo‐controlled trials in this area are now difficult to justify (<a href="./references#CD006918-bbs2-0133" title="CarpenterWT , AppelbaumPS , LevineRJ . The Decleration of Helsinki and clinical trials: a focus on placebo‐controlled trials in schizophrenia. American Journal of Psychiatry2003;160(2):356‐62. ">Carpenter 2003</a>; <a href="./references#CD006918-bbs2-0166" title="LaughrenTP . The scientific and ethical basis for placebo‐controlled trials in depression and schizophrenia: an FDA perspective. European Psychiatry2001;16(7):418‐23. ">Laughren 2001</a>). Yet in many physical diseases, such as angina pectoris, bronchial asthma, herpes simplex, and duodenal ulcers, placebo effects can account for up to 33% of clinical improvement (<a href="./references#CD006918-bbs2-0128" title='BensonH , FriedmanR . Harnessing the power of the placebo effect and renaming it "remembered wellness". Annual Review of Medicine1996;47:193‐9. '>Benson 1996</a>). When it comes to new drugs such as risperidone, clinicians and the public are often provided the evidence for the comparative effects, but the newer drug has been compared with a less‐than‐ideal drug (<a href="./references#CD006918-bbs2-0152" title="HunterRH , JoyCB , KennedyE , GilbodySM , SongF . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000440] ">Hunter 2003</a>). We argue that knowledge of the effects of a drug compared with placebo assists development of a rational therapeutic approach (<a href="./references#CD006918-bbs2-0181" title="VallanceAK . Something out of nothing: the placebo effect. Advances in Psychiatric Treatment2006;12:287‐96. ">Vallance 2006</a>). </p> </section> <section id="CD006918-sec-0019"> <h3 class="title" id="CD006918-sec-0019">How the intervention might work</h3> <p>Risperidone (4‐[2‐[4‐(6‐fluorobenzo[d]isoxazol‐3‐yl)‐1‐piperidyl]ethyl]‐3‐methyl‐2,6‐diazabicyclo[4.4.0]deca‐1,3‐dien‐5‐one) is a strong postsynaptic dopamine receptor antagonist, but also acts as a 5‐HT2A antagonist and is called a serotonin/dopamine antagonist (<a href="./references#CD006918-bbs2-0169" title="LeysenJE , JanssenPM , MegensAA , SchotteA . Risperidone: a novel antipsychotic with balanced serotonin‐dopamine antagonism, receptor occupancy profile, and pharmacologic activity. Journal of Clinical Psychiatry1994;55(Suppl):5‐12. ">Leysen 1994</a>). Risperidone is rapidly and very well absorbed after administration orally, and less than 1% is excreted unchanged in the faeces (<a href="./references#CD006918-bbs2-0147" title="HeykantsJ , HuangML , MannensG , MeuldermansW , SnoeckE , VanBeijsterveldtL , et al. The pharmacokinetics of risperidone in humans: a summary. Journal of Clinical Psychiatry1994;55(Suppl):13‐7. ">Heykants 1994</a>). It reaches peak plasma levels quickly regardless of whether it is administered as a liquid or pill. It is 90% plasma protein bound (<a href="./references#CD006918-bbs2-0136" title="DarbyJK , PastaDJ , ElfandL , DabiriL , ClarkL , HerbertJ . Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. Journal of Clinical Psychopharmacology1997;17(6):478‐84. ">Darby 1997</a>). Risperidone binds to D2 and D3 receptors with 50 and 20 times greater affinity than clozapine and is only 2 to 3 times less potent than haloperidol. Also, its affinity for D1 receptors is 100 times lower than for D4 receptors (<a href="./references#CD006918-bbs2-0169" title="LeysenJE , JanssenPM , MegensAA , SchotteA . Risperidone: a novel antipsychotic with balanced serotonin‐dopamine antagonism, receptor occupancy profile, and pharmacologic activity. Journal of Clinical Psychiatry1994;55(Suppl):5‐12. ">Leysen 1994</a>). </p> </section> <section id="CD006918-sec-0020"> <h3 class="title" id="CD006918-sec-0020">Why it is important to do this review</h3> <p>Comparing any drug with a placebo has always been an intriguing aspect of drug trials, and some authors, such as <a href="./references#CD006918-bbs2-0181" title="VallanceAK . Something out of nothing: the placebo effect. Advances in Psychiatric Treatment2006;12:287‐96. ">Vallance 2006</a>, feel that outcome measures are best measured when compared with a placebo as it partly accounts for the philosophical obstacles such as the mind/body dichotomy, which are inherent in conceptualising these effects. In 60% to 90% of diseases, including angina pectoris, bronchial asthma, herpes simples, and duodenal ulcers, placebo effects can account for up to 33% of clinical improvement and yield clinical results (<a href="./references#CD006918-bbs2-0128" title='BensonH , FriedmanR . Harnessing the power of the placebo effect and renaming it "remembered wellness". Annual Review of Medicine1996;47:193‐9. '>Benson 1996</a>). The placebo effect ultimately allows a rationalised therapeutic approach to be developed to maximise the clinical benefit of the therapeutic encounter and evaluate various outcome measures (<a href="./references#CD006918-bbs2-0181" title="VallanceAK . Something out of nothing: the placebo effect. Advances in Psychiatric Treatment2006;12:287‐96. ">Vallance 2006</a>). </p> <p>Cochrane reviews to date have evaluated the efficacy of risperidone for schizophrenia by comparing it with typical and other atypical antipsychotics. This comparison of risperidone versus placebo is one of a set of reviews on risperidone (<a href="#CD006918-tbl-0003">Table 1</a>). </p> <div class="table" id="CD006918-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risperidone reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Oral risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>vs other atypical drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0144" title="GilbodySM , BagnallAM , DugganL , TuunainenA . Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD002306] ">Gilbody 2000</a>; <a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>vs olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0155" title="JayaramMB , HosalliP , StroupS . Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD005237] ">Jayaram 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>vs typical drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0160" title="KennedyE , SongF , HunterR , ClarkeA , GilbodyS . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD002306] ">Kennedy 2000</a>; <a href="./references#CD006918-bbs2-0152" title="HunterRH , JoyCB , KennedyE , GilbodySM , SongF . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000440] ">Hunter 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Depot risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0151" title="HosalliP , DaviesJM . Depot risperidone for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD004161] ">Hosalli 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Risperidone dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0170" title="LiC , XiaJ , WangJ . Risperidone dose for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007474.pub2] ">Li 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Risperidone for acute aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0119" title="AhmedU , RehmanF , JonesH , Adams CliveE . Risperidone for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.CD009412; CD009412] ">Ahmed 2011</a> </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006918-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006918-sec-0021"></div> <p>To determine the clinical effects, safety, and cost‐effectiveness of risperidone compared with placebo for treating schizophrenia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006918-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006918-sec-0022"></div> <section id="CD006918-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006918-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included all relevant RCTs. If a trial was described as 'double‐blind', but only implied that the study is randomised, then we included it in a sensitivity analysis. If in such a trial there was no implied randomisation, we contacted the authors to clarify the randomisation. We excluded trials where randomisation did not occur. If there was no substantive difference within primary outcomes (see <a href="#CD006918-sec-0029">Types of outcome measures</a>) when these 'implied randomisation' studies were added, then we included these in the final analysis. If there was a substantive difference, we only used clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi‐randomised studies, such as those allocated by using alternate days of the week. </p> </section> <section id="CD006918-sec-0025"> <h4 class="title">Types of participants</h4> <p>We included people (above 17 years of age) with schizophrenia and other types of schizophrenia‐like psychoses (schizophreniform and schizoaffective disorders), as evidence suggests that they are fundamentally not too dissimilar (<a href="./references#CD006918-bbs2-0132" title="CarpenterWTJr , BuchananRW . Schizophrenia. The New England Journal of Medicine1994;330(10):681‐90. ">Carpenter 1994</a>). </p> </section> <section id="CD006918-sec-0026"> <h4 class="title">Types of interventions</h4> <section id="CD006918-sec-0027"> <h5 class="title">1. Oral risperidone: any dose or form</h5> </section> <section id="CD006918-sec-0028"> <h5 class="title">2. Placebo</h5> </section> </section> <section id="CD006918-sec-0029"> <h4 class="title">Types of outcome measures</h4> <p>We grouped outcomes into short term (up to 12 weeks), medium term (13 to 26 weeks), and long term (over 26 weeks). </p> <section id="CD006918-sec-0030"> <h5 class="title">Primary outcomes</h5> <section id="CD006918-sec-0031"> <h6 class="title">1. Mental state</h6> <p>1.1 Clinical response: no clinically significant response in psychotic symptoms, as defined by each of the studies (short term) </p> </section> <section id="CD006918-sec-0032"> <h6 class="title">2. Service utilisation</h6> <p>2.1 Hospital admission and/or re‐admission</p> </section> </section> <section id="CD006918-sec-0033"> <h5 class="title">Secondary outcomes</h5> <section id="CD006918-sec-0034"> <h6 class="title">1. Leaving the study early</h6> </section> <section id="CD006918-sec-0035"> <h6 class="title">2. Global state</h6> <p>2.1 Average score/change in global state<br/> 2.2 No clinically significant response on global state, as defined by each of the studies </p> </section> <section id="CD006918-sec-0036"> <h6 class="title">3. Mental state</h6> <p>3.1 Average score/change on psychotic symptoms<br/> 3.2 No clinically significant response on positive symptoms, as defined by each of the studies<br/> 3.3 Average score/change in positive symptoms<br/> 3.4 No clinically significant response on negative symptoms, as defined by each of the studies<br/> 3.5 Average score/change in negative symptoms<br/> 3.6 Use of additional medication (other than anticholinergics) for psychiatric symptoms </p> </section> <section id="CD006918-sec-0037"> <h6 class="title">4. Extrapyramidal adverse effects</h6> <p>4.1 Use of antiparkinson drugs<br/> 4.2 No clinically significant extrapyramidal adverse effects, as defined by each of the studies<br/> 4.3 Average score/change in extrapyramidal adverse effects </p> </section> <section id="CD006918-sec-0038"> <h6 class="title">5. Other adverse effects</h6> <p>5.1 General and specific (including deaths by suicide or natural causes)</p> </section> <section id="CD006918-sec-0039"> <h6 class="title">6. Service utilisation outcomes</h6> <p>6.1 Days in hospital</p> </section> <section id="CD006918-sec-0040"> <h6 class="title">7. Economic outcomes</h6> </section> <section id="CD006918-sec-0041"> <h6 class="title">8. Quality of life/satisfaction with care for either recipients of care or carers</h6> <p>8.1 Significant change in quality of life/satisfaction, as defined by each of the studies<br/> 8.2 Average score/change in quality of life/satisfaction </p> </section> <section id="CD006918-sec-0042"> <h6 class="title">9. 'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings and used <a href="http://ims.cochrane.org/gradepro" target="_blank">GRADEpro</a> to import data from <a href="http://www.ims.cochrane.org/revman" target="_blank">RevMan 5.1</a> to create 'Summary of findings' tables (<a href="./references#CD006918-bbs2-0179" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83. ">Schünemann 2008</a>). These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient‐care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table: </p> <p> <ol id="CD006918-list-0001"> <li> <p>Mental state ‐ no clinically significant response</p> </li> <li> <p>Leaving the study early ‐ for any reason</p> </li> <li> <p>Global state ‐ no significant clinical improvement</p> </li> <li> <p>Adverse events ‐ extrapyramidal effects</p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD006918-sec-0043"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006918-sec-0044"> <h4 class="title">Electronic searches</h4> <section id="CD006918-sec-0045"> <h5 class="title">1. Cochrane Schizophrenia Group Trials Register</h5> <p>On 19th October 2015, the Trials Search Co‐ordinator searched the Cochrane Schizophrenia Group Trials Register using the following search strategy: </p> <p>((risperidone* or Risperdal*) AND placebo*):ti,ab of REFERENCES or ((risperidone* or Risperdal*) AND placebo*):sin of STUDIES </p> <p>The Cochrane Schizophrenia Group Trials Register is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, EMBASE, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group Module</a>). There are no language, date, document type, or publication status limitations for inclusion of records into the register. </p> <p>For details of the previous search, please see <a href="./appendices#CD006918-sec-0319">Appendix 1</a>. </p> </section> </section> <section id="CD006918-sec-0046"> <h4 class="title">Searching other resources</h4> <section id="CD006918-sec-0047"> <h5 class="title">1. Reference lists</h5> <p>We searched all references of the reports of included trials for further relevant studies. </p> </section> <section id="CD006918-sec-0048"> <h5 class="title">2. Authors of studies</h5> <p>When necessary, we contacted authors of studies to clarify data and request additional studies, but received no response. We also contacted authors for information on any published or unpublished additional studies that they were aware of, but again, received no response. </p> </section> <section id="CD006918-sec-0049"> <h5 class="title">3. Pharmaceutical companies</h5> <p>We contacted relevant pharmaceutical companies for additional studies and to clarify study data. However, we did not receive any further information. </p> </section> </section> </section> <section id="CD006918-sec-0050"> <h3 class="title" id="CD006918-sec-0050">Data collection and analysis</h3> <p>We have updated some text of the methods to reflect changes and updates in Cochrane methodology; please see <a href="./appendices#CD006918-sec-0320">Appendix 2</a> for details of methods used in original version. </p> <section id="CD006918-sec-0051"> <h4 class="title">Selection of studies</h4> <p>Two review authors (RR, MJ) independently inspected all reports of studies identified for the original search. Any disagreements were resolved by consensus; where doubt remained, we acquired the full article. Review authors (RR, BL and JX) independently decided whether these studies met the review criteria. We did not intend to blind the names of authors, institutions, and journal of publication. Again, any disagreements were resolved by consensus. When this was not possible, we sought further information and, in the interim, added these trials to the <a href="./references#CD006918-bbs1-0003" title="">Studies awaiting classification</a> list. </p> <p>SS screended results from 2013 search and review authors SZ and BL independently inspected citations from the subsequent updated search (19th October 2015) to identify relevant abstracts. We obtained and inspected full reports of the abstracts meeting the review criteria. </p> </section> <section id="CD006918-sec-0052"> <h4 class="title">Data extraction and management</h4> <section id="CD006918-sec-0053"> <h5 class="title">1. Extraction</h5> <p>Review authors RR, MJ (original search), SS (2013 search), SZ, BL (2015 search) independently extracted data from all included studies. In addition, to ensure reliability, JX independently extracted data from a random sample of these studies comprising 10% of the total. Again, we discussed any disagreements and documented decisions. The need did not arise, but we had planned to extract data presented only in graphs and figures whenever possible, while only including the data if two review authors independently reached the same result. We also attempted to contact authors through an open‐ended request in order to obtain missing information or for clarification whenever necessary. </p> </section> <section id="CD006918-sec-0054"> <h5 class="title">2. Management</h5> <section id="CD006918-sec-0055"> <h6 class="title">2.1 Forms</h6> <p>We extracted data on to standard, simple forms.</p> </section> <section id="CD006918-sec-0056"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:<br/> a. the psychometric properties of the measuring instrument have been described in a peer‐reviewed journal (<a href="./references#CD006918-bbs2-0174" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and<br/> b. the measuring instrument was not written or modified by one of the trialists for that particular trial. </p> </section> <section id="CD006918-sec-0057"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>Both endpoint and change data have advantages. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and hard‐to‐measure conditions such as schizophrenia. We decided to primarily use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis, as we used mean differences (MD) rather than standardised mean differences (SMD) throughout (<a href="./references#CD006918-bbs2-0150" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available from www.cochrane‐handbook.org: The Cochrane Collaboration, 2011. ">Higgins 2011</a>, Chapter 9.4.5.2). </p> </section> <section id="CD006918-sec-0058"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we aimed to apply the following standards to all data before inclusion: a) standard deviations and means are reported in the paper or obtainable from the authors; b) when a scale starts from the finite number 0, the standard deviation, when multiplied by 2, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<a href="./references#CD006918-bbs2-0121" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996</a>)); c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases, skew is present if 2 SD &gt; (S ‐ S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have a finite start and endpoint, and these rules can be applied. We entered skewed endpoint data from studies of fewer than 200 participants in 'other tables' within the <a href="./references#CD006918-sec-0317" title="">Data and analyses</a> section rather than into a statistical analysis. Skewed data pose less of a problem when looking at mean if the sample size is large; we entered such data from studies with over 200 participants into syntheses. When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not, we entered skewed change data into analyses. </p> </section> <section id="CD006918-sec-0059"> <h6 class="title">2.5 Common measure</h6> <p>Had we identified such data, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week, or per month) to a common metric (for example mean days per month) to facilitate comparison between trials. However, we did not identify such data. </p> </section> <section id="CD006918-sec-0060"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cutoff points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale, <a href="./references#CD006918-bbs2-0177" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>, or the PANSS, <a href="./references#CD006918-bbs2-0159" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>, this could be considered as a clinically significant response (<a href="./references#CD006918-bbs2-0167" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. ">Leucht 2005a</a>; <a href="./references#CD006918-bbs2-0168" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. ">Leucht 2005b</a>). If data based on these thresholds were not available, we used the primary cutoff the original authors presented. Some included studies provided a definition of response as a reduction in PANSS or Clinical Global Impression scores, in which case we employed the dichotomous data provided from the primary study report. </p> </section> <section id="CD006918-sec-0061"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for risperidone. </p> </section> </section> </section> <section id="CD006918-sec-0062"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For the update, two review authors (SZ, BL) independently used the criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i><a href="./references#CD006918-bbs2-0150" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available from www.cochrane‐handbook.org: The Cochrane Collaboration, 2011. ">Higgins 2011</a>to assess trial quality (<a href="./references#CD006918-bbs2-0150" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available from www.cochrane‐handbook.org: The Cochrane Collaboration, 2011. ">Higgins 2011</a>). This new set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data, and selective reporting. </p> <p>Where details of randomisation and other characteristics of trials were inadequate, we contacted authors of the studies to obtain additional information. </p> <p>We have noted the level of risk of bias in both the text of the review and in Summary of findings table 1 and <a href="./full#CD006918-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD006918-sec-0063"> <h4 class="title">Measures of treatment effect</h4> <section id="CD006918-sec-0064"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive than odds ratios and that clinicians tend to interpret odds ratios as RR (<a href="./references#CD006918-bbs2-0131" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>; <a href="./references#CD006918-bbs2-0137" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). The number needed to treat to harm statistic with its CIs is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta‐analyses and in its interpretation (<a href="./references#CD006918-bbs2-0153" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27‐30. ">Hutton 2009</a>). For binary data presented in the 'Summary of findings' table/s, where possible, we calculated illustrative comparative risks. </p> </section> <section id="CD006918-sec-0065"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes, we estimated MD between groups. We preferred not to calculate effect size measures (SMD). However, if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and we calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD006918-sec-0066"> <h4 class="title">Unit of analysis issues</h4> <p>To facilitate comparison between trials, we intended to convert variables (such as days in hospital) that can be reported in different metrics (mean days per year, per week, or per month) to a common metric (for example mean days per month), but no studies reported data for these types of outcomes. </p> </section> <section id="CD006918-sec-0067"> <h4 class="title">Dealing with missing data</h4> <section id="CD006918-sec-0068"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data loses credibility (<a href="./references#CD006918-bbs2-0183" title="XiaJ , AdamsC , BhagatN , BhagatV , BhoopathyP , El‐SayehH , et al. Losing participants before the trial ends erodes credibility of findings. Psychiatric Bulletin2009;33:254‐7. ">Xia 2009</a>). For outcomes where more than 50% of data were unaccounted for, we intended to not reproduce these data or use them within analyses. If more than 50% of data in one arm of a study were lost, but the total loss was less than 50%, we intended to mark data with (*) to indicate that such a result may well be prone to bias. </p> </section> <section id="CD006918-sec-0069"> <h5 class="title">2. Binary</h5> <p>In cases where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented data on a 'once‐randomised‐always‐analyse' basis wherever possible (an intention‐to‐treat (ITT) analysis). For every outcome with the exception of the outcome of death, we had planned to assume those participants leaving the study early to have the same rates of negative outcome as those who completed. However, doing this drastically changed the significance of many outcomes and sometimes the direction of significant results, so we only presented data that was already available from the studies to reduce the risk of making incorrect assumptions. </p> </section> <section id="CD006918-sec-0070"> <h5 class="title">3. Continuous</h5> <section id="CD006918-sec-0071"> <h6 class="title">3.1 Attrition</h6> <p>In cases where attrition for a continuous outcome was between 0% and 50% and completer‐only data were reported, we reproduced these. </p> </section> <section id="CD006918-sec-0072"> <h6 class="title">3.2 Standard deviations</h6> <p>We didn't need to calculate any standard deviations (SD) in this review, but our protocol stated that we would first try to obtain missing values from the authors. If not available, where measures of variance for continuous data were missing but an exact standard error (SE) and CI were available for group means, and either the P value or t value was available for differences in means, we calculated SDs according to the rules described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006918-bbs2-0150" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available from www.cochrane‐handbook.org: The Cochrane Collaboration, 2011. ">Higgins 2011</a>). When only the SE was reported, we would calculate SDs using the formula SD = SE * square root (n). Sections 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i><a href="./references#CD006918-bbs2-0150" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available from www.cochrane‐handbook.org: The Cochrane Collaboration, 2011. ">Higgins 2011</a>present detailed formulae for estimating SDs from P values, t or F values, CIs, or other statistics (<a href="./references#CD006918-bbs2-0150" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available from www.cochrane‐handbook.org: The Cochrane Collaboration, 2011. ">Higgins 2011</a>). If these formulae did not apply, we would calculate the SDs according to a validated imputation method that is based on the SDs of the other included studies (<a href="./references#CD006918-bbs2-0143" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. We would nevertheless examine the validity of the imputations in a sensitivity analysis excluding imputed values. </p> </section> <section id="CD006918-sec-0073"> <h6 class="title">3.3 Last observation carried forward</h6> <p>We anticipated that some studies would employ the method of last observation carried forward (LOCF). As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results. Therefore, where a trial used LOCF data, if less than 50% of the data were assumed, we reproduced these data and indicated that they were the product of LOCF assumptions. </p> </section> </section> </section> <section id="CD006918-sec-0074"> <h4 class="title">Assessment of heterogeneity</h4> <p>Firstly, we considered all the included studies within any comparison to judge clinical heterogeneity. We then visually inspected the graphs in order to investigate the possibility of statistical heterogeneity; to supplement this we used, primarily, the I<sup>2</sup> statistic, which provides an estimate of the percentage of variability due to heterogeneity rather than due to chance alone. Where the I<sup>2</sup> estimate was greater than or equal to 75%, we interpreted this as indicating the presence of high levels of heterogeneity (<a href="./references#CD006918-bbs2-0148" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). If inconsistency became high, we did not summate data, but presented it separately, and we investigated the reasons for heterogeneity. </p> </section> <section id="CD006918-sec-0075"> <h4 class="title">Assessment of reporting biases</h4> <p>In order to investigate the likelihood of overt publication bias, we entered all data from all identified and selected trials into a funnel graph (trial effect against trial size) (<a href="./references#CD006918-bbs2-0142" title="EggerM , Davey‐SmithG , SchneiderM , MinderCSO . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;13:629‐34. ">Egger 1997</a>). </p> </section> <section id="CD006918-sec-0076"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. We used the random‐effects model for all analyses due to the potential for heterogeneity between studies. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us, and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. However, there is a disadvantage to the random‐effects model. It puts added weight on to small studies, which are often the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. </p> </section> <section id="CD006918-sec-0077"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If data were clearly heterogeneous, we checked that they had been extracted and entered correctly, and that we had made no unit of analysis errors. If the high levels of heterogeneity remained, we did not undertake a meta‐analysis at this point, because if there is considerable variation in results, and particularly if there is inconsistency in the direction of effect, it may be misleading to quote an average value for the intervention effect. We prespecified no characteristics of studies that may be associated with heterogeneity except quality of trial method. </p> </section> <section id="CD006918-sec-0078"> <h4 class="title">Sensitivity analysis</h4> <p>If studies had high attrition rates, we analysed the effect of including these studies in a sensitivity analysis, but we did not include any figures with more than 50% attrition in the analysis of efficacy. Where a trial was described as 'double‐blind', but it was implied that the study was randomised, we had intended to include such studies in the sensitivity analysis, but we did not come across any such studies. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006918-sec-0079" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006918-sec-0079"></div> <section id="CD006918-sec-0080"> <h3 class="title">Description of studies</h3> <p>For a substantial description of each study, please refer to the relevant tables:<a href="./references#CD006918-sec-0364" title="">Characteristics of included studies</a>, <a href="./references#CD006918-sec-0365" title="">Characteristics of excluded studies</a>, <a href="./references#CD006918-sec-0367" title="">Characteristics of ongoing studies</a>. </p> <section id="CD006918-sec-0081"> <h4 class="title">Results of the search</h4> <p>The initial search resulted in 815 citations. We were able to include 42 references, relating to only 10 studies from which we could extract useable data. We used information regarding unpublished data from trials on risperidone available to the Cochrane Schizophrenia Group from drug companies. The update searches run in 2013 and 2015 yielded 94 citations, of which 5 new studies were included. </p> <p>In total up to the current update, 909 citations were identified from the search process in total. After removing duplicates, 763 unique records were screened by viewing titles and abstracts. A total number of 116 studies with 406 full‐text articles were screened for eligibility. Finally, 86 studies with 337 references were excluded, 14 studies with 24 references are awaiting assessment due to lack of full‐texts and one study was onging trial, which resulted in 15 studies with 56 references being included in the data and analysis (see <a href="#CD006918-fig-0002">Figure 2</a> for study flow diagram). </p> <div class="figure" id="CD006918-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006918-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD006918-sec-0082"> <h4 class="title">Included studies</h4> <section id="CD006918-sec-0083"> <h5 class="title">1. Length of trials</h5> <p>Fourteen studies reported data on short‐term follow‐up, and only 1 study reported medium‐term outcomes (<a href="./references#CD006918-bbs2-0001" title="BachmannM , RamseyM , BuchananRW , ConleyRC , WeinerE . Clozapine treatment of schizophrenic patients. www.clinicaltrials.gov (accessed 9 October 2013). [NCT00056498] ">Bachmann 2003</a>), but even that was only at 16 weeks. Two studies were of 4 weeks duration (<a href="./references#CD006918-bbs2-0011" title="PotkinSG , GutierrezR . Safety and efficacy of once‐daily risperidone in the treatment of schizophrenia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17‐22; San Diego, California, USA. 1997. ">Potkin 1997</a>; <a href="./references#CD006918-bbs2-0012" title="PotkinSG , KujawaM , CarsonWH , SahaAR , AliM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2003;60(1):300. PotkinSG , SahaAR , KujawaMJ , CarsonWH , AliM , StockE , et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry2003;60(7):681‐90. SahaA , CarsonW , AliM , DunbarG , IngenitoG . Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001. YeungP , KujawaM , CarsonWH , SahaA , AlidM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2002;53(3 Suppl 1):185‐6. YeungP , McQuadeRD , CarsonWH , SahaA , AliMW , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia. European Psychiatry2002;17(Suppl 1):102s. YeungPP , CarsonWH , SahaA , McQuadeRD , AliM , StringfellowJC , et al. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: results of a placebo‐controlled trial with risperidone. European Neuropsychopharmacology2001;11(3):259. ">Potkin 2003</a>), 6 studies were 6‐weeks long (<a href="./references#CD006918-bbs2-0002" title="BorisonR . Risperidone versus haloperidol versus placebo in the treatment of schizophrenia. Clinical report1991. ">Borison 1992</a>; <a href="./references#CD006918-bbs2-0006" title="GeffenY , AnandR , KeefeR , DavidsonM . Results of phase 2b eagle trial; a double blind placebo control study evaluating the efficacy and safety of bl‐1020, a gaba enhanced antipsychotic for the treatment of schizophrenia. Schizophrenia Research2010;117(2‐3):212. ">Geffen 2010</a>; <a href="./references#CD006918-bbs2-0007" title="HeisterbergJ , BarbatoLM , YeungPP , ShapiraNA . Lipid profile among patients with schizophrenia randomized to bifeprunox, placebo, or risperidone: a comparison of results. Schizophrenia Bulletin2007;33(2):432‐3. YeungPP , BarbatoLM , HeisterbergJ , ShapiraNA . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Schizophrenia Bulletin2007;33(2):466‐7. YeungPP , ShapiraNA , HeisterbergJ . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28‐Apr 1, Colorado Springs, Colorado, USA. 2007. ">Heisterberg 2007</a>; <a href="./references#CD006918-bbs2-0013" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , McLemoreJ , GharabawiG . Atypical antipsychotics in patients with schizophrenia and comorbid substance abuse. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005:Nr279. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , et al. Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S503. NCT00061802 . A randomized, double blind study to evaluate the efficacy and safety of two atypical antipsychotics vs placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder. clinicaltrials.gov/show/NCT00061802(2003). PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. RupnowM , GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , GharabawiG , et al. Polypharmacy in schizophrenia: data from a randomized, double‐blind study. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005. StahlS , RupnowM , GreenspanA , Kosik‐GonzalezC , ZhuY , GharabawiG . Use and cost of polypharmacy in schizophrenia: data from a randomized, double‐blind study of risperidone and quetiapine. Neuropsychopharmacology2004;29(Suppl 1):S227. ">Potkin 2006</a>; <a href="./references#CD006918-bbs2-0014" title="PotkinS , FlemingK , BinnemanB , KellerDS , AlphsL , PanagidesJ . Asenapine improves cognitive function in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19‐24; San Diego, CA2007. PotkinS , FlemingK , BinnemanB , KellerS . Asenapine cognitive function effects in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Schizophrenia Bulletin2007;33(2):454. PotkinSG , CohenM , JinaAS , NettlerS , AlphsL , PanagidesJ . Asenapine efficacy during acute episodes of schizophrenia: a randomized placebo and risperidone controlled trial. Proceedings of the 44th American College of Neuropsychopharmacology; 2005 December 11‐15, Waikoloa, Hawaii2005. PotkinSG , CohenM , PanagidesJ . Efficacy and tolerability of asenapine in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Journal of Clinical Psychiatry2007;68(10):1492‐500. PotkinSG , CohenM , PanagidesJ , JinaA . Asenapine safety and tolerability in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. European Neuropsychopharmacology2006;16(Suppl 4):S401. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy in acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S275. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy, safety, and tolerability in the treatment of acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. Biological Psychiatry2006;59(8 Suppl):154S. ">Potkin 2007</a>; <a href="./references#CD006918-bbs2-0015" title="AkdedeBB , Anil YacioluAE , AlptekinK , TurgutTI , TumukluM , YaziciMK , et al. A double‐blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Journal of Clinical Psychiatry2006;67(12):1912‐9. YagciogluAE , Kivircik AkdedeBB , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry2005;66(1):63‐72. ">Yagcioglu 2005</a>), 3 studies were 8 weeks from start to finish (<a href="./references#CD006918-bbs2-0003" title="ChouinardG . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. [MEDLINE: 7537286] ChouinardG , AlbrightPS . Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology1997;17(4):298‐307. [MEDLINE: 9241010] ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. 1993:22. [MEDLINE: 94350925] ChouinardG , ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15(Suppl 1 Pt B):266. [MEDLINE: 94350925] ChouinardG , ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biological Psychiatry1992;31:158. [MEDLINE: 94350925] ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. [MEDLINE: 93253120] ChouinardG , VainerJL , BeauclairL . Dose regimens of neuroleptics in negative symptoms. 19th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1994 Jun 27‐Jul 1; Washington DC, USA1994;10(3 Suppl 1):S363. [MEDLINE: 94350925] ">Chouinard 1992</a>; <a href="./references#CD006918-bbs2-0008" title="HonerW . International study of improving treatment for the most severely ill with schizophrenia. www.clinicaltrials.gov (accessed 9 October 2013). [NCT00272584] ">Honer 2006</a>; <a href="./references#CD006918-bbs2-0009" title="EreshefskyL , AndersonC , TrueJ , SakladSR , ReisenmanC , ToneyG , et al. Plasma concentration of oral risperidone and active metabolite in schizophrenics. Pharmacotherapy1993;13(3):292. [LMD96402] LindenmayerJP , The Risperidone Study Group. Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia. 146th Annual Meeting of the American Psychiatric Association; 1993 May 22‐27; San Francisco, California, USA. 1993. [MEDLINE: 94350925] MarderS . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Clinical Research Report RIS‐INT‐31991. [MEDLINE: 1375802] MarderSR . Risperidone: clinical development: North American results. Clinical Neuropharmacology1992;15(Suppl 1 Pt A):92A‐3A. [MEDLINE: 92361850] MarderSR . Risperidone: efficacy. Journal of Clinical Psychiatry1994;12:49‐52. [MEDLINE: 94350925] MarderSR , DavisJM , ChouinardG . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychological Medicine [临床精神医学杂志]1997;58(12):538‐46. MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151(6):825‐35. [EMBASE 1994202181] McEvoyJP . Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry1994;55(5 Suppl):18‐21. [EMBASE 1994182002] MeibachR . Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. 1st International Risperidone Investigators' Meeting; 1992 Mar 9‐10; Paris, France. USA, 1992:28‐9. [LMD94893] MeibachRC , The Risperidone Study Group. A fixed dose, parallel group study of risperidone vs. haloperidol vs. placebo. Schizophrenia Research1993;9(2,3):245. [MEDLINE: 94350925] NCT00249132 . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. clinicaltrials.gov/show/NCT00249132(2005). SchoolerNR . Negative symptoms in schizophrenia: assessment of the effect of risperidone. Journal of Clinical Psychiatry1994;55(Suppl 5):22‐8. [MEDLINE: 94350925] SimpsonGM , LindenmayerJP . Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology1997;17(3):194‐201. [MEDLINE: 97313564; PsycINFO 1997‐06350‐009] ">Marder 1994a</a>), 2 studies were 9 weeks from start to finish (<a href="./references#CD006918-bbs2-0004" title="DowningA M , KinonB J , MillenB A , ZhangL , LiuL , MorozovaM A , et al. A double‐blind, placebo‐controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry2014;14:351. ">Downing 2014</a>; <a href="./references#CD006918-bbs2-0005" title="DurgamS , StaraceA , LiD , MiglioreR , RuthA , NemethG , et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res2014;152:450‐7. ">Durgam 2014</a>) and 1 study was 12 weeks in duration (<a href="./references#CD006918-bbs2-0010" title="BaiYM , YuSC , LinCC . Risperidone for severe tardive dyskinesia: a 12‐week randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64(11):1342‐8. PaiY‐M , YuS‐C , LinC‐C . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. PaiY‐M , YuS‐C , LinC‐C . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Pai 2002</a>). </p> </section> <section id="CD006918-sec-0084"> <h5 class="title">2. Participants</h5> <p>Amongst our included studies, two included participants with no clear operational diagnostic criteria and simply stated "schizophrenia" (<a href="./references#CD006918-bbs2-0011" title="PotkinSG , GutierrezR . Safety and efficacy of once‐daily risperidone in the treatment of schizophrenia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17‐22; San Diego, California, USA. 1997. ">Potkin 1997</a>; <a href="./references#CD006918-bbs2-0014" title="PotkinS , FlemingK , BinnemanB , KellerDS , AlphsL , PanagidesJ . Asenapine improves cognitive function in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19‐24; San Diego, CA2007. PotkinS , FlemingK , BinnemanB , KellerS . Asenapine cognitive function effects in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Schizophrenia Bulletin2007;33(2):454. PotkinSG , CohenM , JinaAS , NettlerS , AlphsL , PanagidesJ . Asenapine efficacy during acute episodes of schizophrenia: a randomized placebo and risperidone controlled trial. Proceedings of the 44th American College of Neuropsychopharmacology; 2005 December 11‐15, Waikoloa, Hawaii2005. PotkinSG , CohenM , PanagidesJ . Efficacy and tolerability of asenapine in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Journal of Clinical Psychiatry2007;68(10):1492‐500. PotkinSG , CohenM , PanagidesJ , JinaA . Asenapine safety and tolerability in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. European Neuropsychopharmacology2006;16(Suppl 4):S401. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy in acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S275. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy, safety, and tolerability in the treatment of acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. Biological Psychiatry2006;59(8 Suppl):154S. ">Potkin 2007</a>). Nine studies included people with a sole diagnosis of schizophrenia as per Diagnostic Statistical Manual of Mental Disorders (DSM) criteria (<a href="./references#CD006918-bbs2-0002" title="BorisonR . Risperidone versus haloperidol versus placebo in the treatment of schizophrenia. Clinical report1991. ">Borison 1992</a>; <a href="./references#CD006918-bbs2-0003" title="ChouinardG . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. [MEDLINE: 7537286] ChouinardG , AlbrightPS . Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology1997;17(4):298‐307. [MEDLINE: 9241010] ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. 1993:22. [MEDLINE: 94350925] ChouinardG , ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15(Suppl 1 Pt B):266. [MEDLINE: 94350925] ChouinardG , ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biological Psychiatry1992;31:158. [MEDLINE: 94350925] ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. [MEDLINE: 93253120] ChouinardG , VainerJL , BeauclairL . Dose regimens of neuroleptics in negative symptoms. 19th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1994 Jun 27‐Jul 1; Washington DC, USA1994;10(3 Suppl 1):S363. [MEDLINE: 94350925] ">Chouinard 1992</a>; <a href="./references#CD006918-bbs2-0004" title="DowningA M , KinonB J , MillenB A , ZhangL , LiuL , MorozovaM A , et al. A double‐blind, placebo‐controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry2014;14:351. ">Downing 2014</a>; <a href="./references#CD006918-bbs2-0005" title="DurgamS , StaraceA , LiD , MiglioreR , RuthA , NemethG , et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res2014;152:450‐7. ">Durgam 2014</a>; <a href="./references#CD006918-bbs2-0006" title="GeffenY , AnandR , KeefeR , DavidsonM . Results of phase 2b eagle trial; a double blind placebo control study evaluating the efficacy and safety of bl‐1020, a gaba enhanced antipsychotic for the treatment of schizophrenia. Schizophrenia Research2010;117(2‐3):212. ">Geffen 2010</a>; <a href="./references#CD006918-bbs2-0007" title="HeisterbergJ , BarbatoLM , YeungPP , ShapiraNA . Lipid profile among patients with schizophrenia randomized to bifeprunox, placebo, or risperidone: a comparison of results. Schizophrenia Bulletin2007;33(2):432‐3. YeungPP , BarbatoLM , HeisterbergJ , ShapiraNA . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Schizophrenia Bulletin2007;33(2):466‐7. YeungPP , ShapiraNA , HeisterbergJ . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28‐Apr 1, Colorado Springs, Colorado, USA. 2007. ">Heisterberg 2007</a>; <a href="./references#CD006918-bbs2-0009" title="EreshefskyL , AndersonC , TrueJ , SakladSR , ReisenmanC , ToneyG , et al. Plasma concentration of oral risperidone and active metabolite in schizophrenics. Pharmacotherapy1993;13(3):292. [LMD96402] LindenmayerJP , The Risperidone Study Group. Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia. 146th Annual Meeting of the American Psychiatric Association; 1993 May 22‐27; San Francisco, California, USA. 1993. [MEDLINE: 94350925] MarderS . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Clinical Research Report RIS‐INT‐31991. [MEDLINE: 1375802] MarderSR . Risperidone: clinical development: North American results. Clinical Neuropharmacology1992;15(Suppl 1 Pt A):92A‐3A. [MEDLINE: 92361850] MarderSR . Risperidone: efficacy. Journal of Clinical Psychiatry1994;12:49‐52. [MEDLINE: 94350925] MarderSR , DavisJM , ChouinardG . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychological Medicine [临床精神医学杂志]1997;58(12):538‐46. MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151(6):825‐35. [EMBASE 1994202181] McEvoyJP . Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry1994;55(5 Suppl):18‐21. [EMBASE 1994182002] MeibachR . Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. 1st International Risperidone Investigators' Meeting; 1992 Mar 9‐10; Paris, France. USA, 1992:28‐9. [LMD94893] MeibachRC , The Risperidone Study Group. A fixed dose, parallel group study of risperidone vs. haloperidol vs. placebo. Schizophrenia Research1993;9(2,3):245. [MEDLINE: 94350925] NCT00249132 . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. clinicaltrials.gov/show/NCT00249132(2005). SchoolerNR . Negative symptoms in schizophrenia: assessment of the effect of risperidone. Journal of Clinical Psychiatry1994;55(Suppl 5):22‐8. [MEDLINE: 94350925] SimpsonGM , LindenmayerJP . Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology1997;17(3):194‐201. [MEDLINE: 97313564; PsycINFO 1997‐06350‐009] ">Marder 1994a</a>; <a href="./references#CD006918-bbs2-0010" title="BaiYM , YuSC , LinCC . Risperidone for severe tardive dyskinesia: a 12‐week randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64(11):1342‐8. PaiY‐M , YuS‐C , LinC‐C . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. PaiY‐M , YuS‐C , LinC‐C . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Pai 2002</a>; <a href="./references#CD006918-bbs2-0015" title="AkdedeBB , Anil YacioluAE , AlptekinK , TurgutTI , TumukluM , YaziciMK , et al. A double‐blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Journal of Clinical Psychiatry2006;67(12):1912‐9. YagciogluAE , Kivircik AkdedeBB , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry2005;66(1):63‐72. ">Yagcioglu 2005</a>), and the remaining four studies included participants with a diagnosis of schizophrenia or schizoaffective disorder as per DSM criteria (<a href="./references#CD006918-bbs2-0001" title="BachmannM , RamseyM , BuchananRW , ConleyRC , WeinerE . Clozapine treatment of schizophrenic patients. www.clinicaltrials.gov (accessed 9 October 2013). [NCT00056498] ">Bachmann 2003</a>; <a href="./references#CD006918-bbs2-0008" title="HonerW . International study of improving treatment for the most severely ill with schizophrenia. www.clinicaltrials.gov (accessed 9 October 2013). [NCT00272584] ">Honer 2006</a>; <a href="./references#CD006918-bbs2-0012" title="PotkinSG , KujawaM , CarsonWH , SahaAR , AliM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2003;60(1):300. PotkinSG , SahaAR , KujawaMJ , CarsonWH , AliM , StockE , et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry2003;60(7):681‐90. SahaA , CarsonW , AliM , DunbarG , IngenitoG . Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001. YeungP , KujawaM , CarsonWH , SahaA , AlidM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2002;53(3 Suppl 1):185‐6. YeungP , McQuadeRD , CarsonWH , SahaA , AliMW , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia. European Psychiatry2002;17(Suppl 1):102s. YeungPP , CarsonWH , SahaA , McQuadeRD , AliM , StringfellowJC , et al. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: results of a placebo‐controlled trial with risperidone. European Neuropsychopharmacology2001;11(3):259. ">Potkin 2003</a>; <a href="./references#CD006918-bbs2-0013" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , McLemoreJ , GharabawiG . Atypical antipsychotics in patients with schizophrenia and comorbid substance abuse. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005:Nr279. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , et al. Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S503. NCT00061802 . A randomized, double blind study to evaluate the efficacy and safety of two atypical antipsychotics vs placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder. clinicaltrials.gov/show/NCT00061802(2003). PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. RupnowM , GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , GharabawiG , et al. Polypharmacy in schizophrenia: data from a randomized, double‐blind study. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005. StahlS , RupnowM , GreenspanA , Kosik‐GonzalezC , ZhuY , GharabawiG . Use and cost of polypharmacy in schizophrenia: data from a randomized, double‐blind study of risperidone and quetiapine. Neuropsychopharmacology2004;29(Suppl 1):S227. ">Potkin 2006</a>). </p> <p><a href="./references#CD006918-bbs2-0014" title="PotkinS , FlemingK , BinnemanB , KellerDS , AlphsL , PanagidesJ . Asenapine improves cognitive function in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19‐24; San Diego, CA2007. PotkinS , FlemingK , BinnemanB , KellerS . Asenapine cognitive function effects in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Schizophrenia Bulletin2007;33(2):454. PotkinSG , CohenM , JinaAS , NettlerS , AlphsL , PanagidesJ . Asenapine efficacy during acute episodes of schizophrenia: a randomized placebo and risperidone controlled trial. Proceedings of the 44th American College of Neuropsychopharmacology; 2005 December 11‐15, Waikoloa, Hawaii2005. PotkinSG , CohenM , PanagidesJ . Efficacy and tolerability of asenapine in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Journal of Clinical Psychiatry2007;68(10):1492‐500. PotkinSG , CohenM , PanagidesJ , JinaA . Asenapine safety and tolerability in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. European Neuropsychopharmacology2006;16(Suppl 4):S401. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy in acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S275. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy, safety, and tolerability in the treatment of acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. Biological Psychiatry2006;59(8 Suppl):154S. ">Potkin 2007</a> did not report the sex of participants in the study. All other studies included both men and women, but the majority of participants were male. Most participants were aged between late 30s and early 40s. </p> <p>Two studies did not have definitive exclusion criteria (<a href="./references#CD006918-bbs2-0007" title="HeisterbergJ , BarbatoLM , YeungPP , ShapiraNA . Lipid profile among patients with schizophrenia randomized to bifeprunox, placebo, or risperidone: a comparison of results. Schizophrenia Bulletin2007;33(2):432‐3. YeungPP , BarbatoLM , HeisterbergJ , ShapiraNA . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Schizophrenia Bulletin2007;33(2):466‐7. YeungPP , ShapiraNA , HeisterbergJ . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28‐Apr 1, Colorado Springs, Colorado, USA. 2007. ">Heisterberg 2007</a>; <a href="./references#CD006918-bbs2-0011" title="PotkinSG , GutierrezR . Safety and efficacy of once‐daily risperidone in the treatment of schizophrenia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17‐22; San Diego, California, USA. 1997. ">Potkin 1997</a>). The remaining studies excluded people with alcohol and substance misuse, as well as pregnant or breastfeeding women. <a href="./references#CD006918-bbs2-0015" title="AkdedeBB , Anil YacioluAE , AlptekinK , TurgutTI , TumukluM , YaziciMK , et al. A double‐blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Journal of Clinical Psychiatry2006;67(12):1912‐9. YagciogluAE , Kivircik AkdedeBB , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry2005;66(1):63‐72. ">Yagcioglu 2005</a> excluded people who were intolerant to risperidone in the past, <a href="./references#CD006918-bbs2-0012" title="PotkinSG , KujawaM , CarsonWH , SahaAR , AliM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2003;60(1):300. PotkinSG , SahaAR , KujawaMJ , CarsonWH , AliM , StockE , et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry2003;60(7):681‐90. SahaA , CarsonW , AliM , DunbarG , IngenitoG . Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001. YeungP , KujawaM , CarsonWH , SahaA , AlidM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2002;53(3 Suppl 1):185‐6. YeungP , McQuadeRD , CarsonWH , SahaA , AliMW , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia. European Psychiatry2002;17(Suppl 1):102s. YeungPP , CarsonWH , SahaA , McQuadeRD , AliM , StringfellowJC , et al. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: results of a placebo‐controlled trial with risperidone. European Neuropsychopharmacology2001;11(3):259. ">Potkin 2003</a> excluded people being treated with risperidone at baseline, and <a href="./references#CD006918-bbs2-0013" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , McLemoreJ , GharabawiG . Atypical antipsychotics in patients with schizophrenia and comorbid substance abuse. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005:Nr279. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , et al. Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S503. NCT00061802 . A randomized, double blind study to evaluate the efficacy and safety of two atypical antipsychotics vs placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder. clinicaltrials.gov/show/NCT00061802(2003). PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. RupnowM , GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , GharabawiG , et al. Polypharmacy in schizophrenia: data from a randomized, double‐blind study. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005. StahlS , RupnowM , GreenspanA , Kosik‐GonzalezC , ZhuY , GharabawiG . Use and cost of polypharmacy in schizophrenia: data from a randomized, double‐blind study of risperidone and quetiapine. Neuropsychopharmacology2004;29(Suppl 1):S227. ">Potkin 2006</a> excluded people who had received risperidone within the last seven days. <a href="./references#CD006918-bbs2-0009" title="EreshefskyL , AndersonC , TrueJ , SakladSR , ReisenmanC , ToneyG , et al. Plasma concentration of oral risperidone and active metabolite in schizophrenics. Pharmacotherapy1993;13(3):292. [LMD96402] LindenmayerJP , The Risperidone Study Group. Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia. 146th Annual Meeting of the American Psychiatric Association; 1993 May 22‐27; San Francisco, California, USA. 1993. [MEDLINE: 94350925] MarderS . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Clinical Research Report RIS‐INT‐31991. [MEDLINE: 1375802] MarderSR . Risperidone: clinical development: North American results. Clinical Neuropharmacology1992;15(Suppl 1 Pt A):92A‐3A. [MEDLINE: 92361850] MarderSR . Risperidone: efficacy. Journal of Clinical Psychiatry1994;12:49‐52. [MEDLINE: 94350925] MarderSR , DavisJM , ChouinardG . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychological Medicine [临床精神医学杂志]1997;58(12):538‐46. MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151(6):825‐35. [EMBASE 1994202181] McEvoyJP . Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry1994;55(5 Suppl):18‐21. [EMBASE 1994182002] MeibachR . Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. 1st International Risperidone Investigators' Meeting; 1992 Mar 9‐10; Paris, France. USA, 1992:28‐9. [LMD94893] MeibachRC , The Risperidone Study Group. A fixed dose, parallel group study of risperidone vs. haloperidol vs. placebo. Schizophrenia Research1993;9(2,3):245. [MEDLINE: 94350925] NCT00249132 . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. clinicaltrials.gov/show/NCT00249132(2005). SchoolerNR . Negative symptoms in schizophrenia: assessment of the effect of risperidone. Journal of Clinical Psychiatry1994;55(Suppl 5):22‐8. [MEDLINE: 94350925] SimpsonGM , LindenmayerJP . Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology1997;17(3):194‐201. [MEDLINE: 97313564; PsycINFO 1997‐06350‐009] ">Marder 1994a</a> excluded people with schizoaffective disorder, and <a href="./references#CD006918-bbs2-0013" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , McLemoreJ , GharabawiG . Atypical antipsychotics in patients with schizophrenia and comorbid substance abuse. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005:Nr279. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , et al. Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S503. NCT00061802 . A randomized, double blind study to evaluate the efficacy and safety of two atypical antipsychotics vs placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder. clinicaltrials.gov/show/NCT00061802(2003). PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. RupnowM , GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , GharabawiG , et al. Polypharmacy in schizophrenia: data from a randomized, double‐blind study. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005. StahlS , RupnowM , GreenspanA , Kosik‐GonzalezC , ZhuY , GharabawiG . Use and cost of polypharmacy in schizophrenia: data from a randomized, double‐blind study of risperidone and quetiapine. Neuropsychopharmacology2004;29(Suppl 1):S227. ">Potkin 2006</a> excluded people with borderline personality disorder. <a href="./references#CD006918-bbs2-0014" title="PotkinS , FlemingK , BinnemanB , KellerDS , AlphsL , PanagidesJ . Asenapine improves cognitive function in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19‐24; San Diego, CA2007. PotkinS , FlemingK , BinnemanB , KellerS . Asenapine cognitive function effects in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Schizophrenia Bulletin2007;33(2):454. PotkinSG , CohenM , JinaAS , NettlerS , AlphsL , PanagidesJ . Asenapine efficacy during acute episodes of schizophrenia: a randomized placebo and risperidone controlled trial. Proceedings of the 44th American College of Neuropsychopharmacology; 2005 December 11‐15, Waikoloa, Hawaii2005. PotkinSG , CohenM , PanagidesJ . Efficacy and tolerability of asenapine in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Journal of Clinical Psychiatry2007;68(10):1492‐500. PotkinSG , CohenM , PanagidesJ , JinaA . Asenapine safety and tolerability in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. European Neuropsychopharmacology2006;16(Suppl 4):S401. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy in acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S275. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy, safety, and tolerability in the treatment of acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. Biological Psychiatry2006;59(8 Suppl):154S. ">Potkin 2007</a> excluded people who had made a recent suicide attempt and who had serious suicidal thoughts. </p> </section> <section id="CD006918-sec-0085"> <h5 class="title">3. Setting</h5> <p>Eight of the included studies took place in the inpatient setting (<a href="./references#CD006918-bbs2-0002" title="BorisonR . Risperidone versus haloperidol versus placebo in the treatment of schizophrenia. Clinical report1991. ">Borison 1992</a>; <a href="./references#CD006918-bbs2-0003" title="ChouinardG . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. [MEDLINE: 7537286] ChouinardG , AlbrightPS . Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology1997;17(4):298‐307. [MEDLINE: 9241010] ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. 1993:22. [MEDLINE: 94350925] ChouinardG , ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15(Suppl 1 Pt B):266. [MEDLINE: 94350925] ChouinardG , ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biological Psychiatry1992;31:158. [MEDLINE: 94350925] ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. [MEDLINE: 93253120] ChouinardG , VainerJL , BeauclairL . Dose regimens of neuroleptics in negative symptoms. 19th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1994 Jun 27‐Jul 1; Washington DC, USA1994;10(3 Suppl 1):S363. [MEDLINE: 94350925] ">Chouinard 1992</a>; <a href="./references#CD006918-bbs2-0004" title="DowningA M , KinonB J , MillenB A , ZhangL , LiuL , MorozovaM A , et al. A double‐blind, placebo‐controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry2014;14:351. ">Downing 2014</a>; <a href="./references#CD006918-bbs2-0005" title="DurgamS , StaraceA , LiD , MiglioreR , RuthA , NemethG , et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res2014;152:450‐7. ">Durgam 2014</a>; <a href="./references#CD006918-bbs2-0006" title="GeffenY , AnandR , KeefeR , DavidsonM . Results of phase 2b eagle trial; a double blind placebo control study evaluating the efficacy and safety of bl‐1020, a gaba enhanced antipsychotic for the treatment of schizophrenia. Schizophrenia Research2010;117(2‐3):212. ">Geffen 2010</a>; <a href="./references#CD006918-bbs2-0009" title="EreshefskyL , AndersonC , TrueJ , SakladSR , ReisenmanC , ToneyG , et al. Plasma concentration of oral risperidone and active metabolite in schizophrenics. Pharmacotherapy1993;13(3):292. [LMD96402] LindenmayerJP , The Risperidone Study Group. Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia. 146th Annual Meeting of the American Psychiatric Association; 1993 May 22‐27; San Francisco, California, USA. 1993. [MEDLINE: 94350925] MarderS . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Clinical Research Report RIS‐INT‐31991. [MEDLINE: 1375802] MarderSR . Risperidone: clinical development: North American results. Clinical Neuropharmacology1992;15(Suppl 1 Pt A):92A‐3A. [MEDLINE: 92361850] MarderSR . Risperidone: efficacy. Journal of Clinical Psychiatry1994;12:49‐52. [MEDLINE: 94350925] MarderSR , DavisJM , ChouinardG . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychological Medicine [临床精神医学杂志]1997;58(12):538‐46. MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151(6):825‐35. [EMBASE 1994202181] McEvoyJP . Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry1994;55(5 Suppl):18‐21. [EMBASE 1994182002] MeibachR . Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. 1st International Risperidone Investigators' Meeting; 1992 Mar 9‐10; Paris, France. USA, 1992:28‐9. [LMD94893] MeibachRC , The Risperidone Study Group. A fixed dose, parallel group study of risperidone vs. haloperidol vs. placebo. Schizophrenia Research1993;9(2,3):245. [MEDLINE: 94350925] NCT00249132 . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. clinicaltrials.gov/show/NCT00249132(2005). SchoolerNR . Negative symptoms in schizophrenia: assessment of the effect of risperidone. Journal of Clinical Psychiatry1994;55(Suppl 5):22‐8. [MEDLINE: 94350925] SimpsonGM , LindenmayerJP . Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology1997;17(3):194‐201. [MEDLINE: 97313564; PsycINFO 1997‐06350‐009] ">Marder 1994a</a>; <a href="./references#CD006918-bbs2-0012" title="PotkinSG , KujawaM , CarsonWH , SahaAR , AliM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2003;60(1):300. PotkinSG , SahaAR , KujawaMJ , CarsonWH , AliM , StockE , et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry2003;60(7):681‐90. SahaA , CarsonW , AliM , DunbarG , IngenitoG . Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001. YeungP , KujawaM , CarsonWH , SahaA , AlidM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2002;53(3 Suppl 1):185‐6. YeungP , McQuadeRD , CarsonWH , SahaA , AliMW , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia. European Psychiatry2002;17(Suppl 1):102s. YeungPP , CarsonWH , SahaA , McQuadeRD , AliM , StringfellowJC , et al. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: results of a placebo‐controlled trial with risperidone. European Neuropsychopharmacology2001;11(3):259. ">Potkin 2003</a>; <a href="./references#CD006918-bbs2-0013" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , McLemoreJ , GharabawiG . Atypical antipsychotics in patients with schizophrenia and comorbid substance abuse. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005:Nr279. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , et al. Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S503. NCT00061802 . A randomized, double blind study to evaluate the efficacy and safety of two atypical antipsychotics vs placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder. clinicaltrials.gov/show/NCT00061802(2003). PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. RupnowM , GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , GharabawiG , et al. Polypharmacy in schizophrenia: data from a randomized, double‐blind study. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005. StahlS , RupnowM , GreenspanA , Kosik‐GonzalezC , ZhuY , GharabawiG . Use and cost of polypharmacy in schizophrenia: data from a randomized, double‐blind study of risperidone and quetiapine. Neuropsychopharmacology2004;29(Suppl 1):S227. ">Potkin 2006</a>). Three studies involved both inpatients and outpatients (<a href="./references#CD006918-bbs2-0001" title="BachmannM , RamseyM , BuchananRW , ConleyRC , WeinerE . Clozapine treatment of schizophrenic patients. www.clinicaltrials.gov (accessed 9 October 2013). [NCT00056498] ">Bachmann 2003</a>; <a href="./references#CD006918-bbs2-0008" title="HonerW . International study of improving treatment for the most severely ill with schizophrenia. www.clinicaltrials.gov (accessed 9 October 2013). [NCT00272584] ">Honer 2006</a>; <a href="./references#CD006918-bbs2-0015" title="AkdedeBB , Anil YacioluAE , AlptekinK , TurgutTI , TumukluM , YaziciMK , et al. A double‐blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Journal of Clinical Psychiatry2006;67(12):1912‐9. YagciogluAE , Kivircik AkdedeBB , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry2005;66(1):63‐72. ">Yagcioglu 2005</a>). We could not find any explicit information on setting for the remaining four studies (<a href="./references#CD006918-bbs2-0007" title="HeisterbergJ , BarbatoLM , YeungPP , ShapiraNA . Lipid profile among patients with schizophrenia randomized to bifeprunox, placebo, or risperidone: a comparison of results. Schizophrenia Bulletin2007;33(2):432‐3. YeungPP , BarbatoLM , HeisterbergJ , ShapiraNA . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Schizophrenia Bulletin2007;33(2):466‐7. YeungPP , ShapiraNA , HeisterbergJ . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28‐Apr 1, Colorado Springs, Colorado, USA. 2007. ">Heisterberg 2007</a>; <a href="./references#CD006918-bbs2-0010" title="BaiYM , YuSC , LinCC . Risperidone for severe tardive dyskinesia: a 12‐week randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64(11):1342‐8. PaiY‐M , YuS‐C , LinC‐C . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. PaiY‐M , YuS‐C , LinC‐C . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Pai 2002</a>; <a href="./references#CD006918-bbs2-0011" title="PotkinSG , GutierrezR . Safety and efficacy of once‐daily risperidone in the treatment of schizophrenia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17‐22; San Diego, California, USA. 1997. ">Potkin 1997</a>; <a href="./references#CD006918-bbs2-0014" title="PotkinS , FlemingK , BinnemanB , KellerDS , AlphsL , PanagidesJ . Asenapine improves cognitive function in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19‐24; San Diego, CA2007. PotkinS , FlemingK , BinnemanB , KellerS . Asenapine cognitive function effects in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Schizophrenia Bulletin2007;33(2):454. PotkinSG , CohenM , JinaAS , NettlerS , AlphsL , PanagidesJ . Asenapine efficacy during acute episodes of schizophrenia: a randomized placebo and risperidone controlled trial. Proceedings of the 44th American College of Neuropsychopharmacology; 2005 December 11‐15, Waikoloa, Hawaii2005. PotkinSG , CohenM , PanagidesJ . Efficacy and tolerability of asenapine in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Journal of Clinical Psychiatry2007;68(10):1492‐500. PotkinSG , CohenM , PanagidesJ , JinaA . Asenapine safety and tolerability in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. European Neuropsychopharmacology2006;16(Suppl 4):S401. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy in acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S275. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy, safety, and tolerability in the treatment of acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. Biological Psychiatry2006;59(8 Suppl):154S. ">Potkin 2007</a>). </p> <p>Studies were conducted in the USA (<a href="./references#CD006918-bbs2-0001" title="BachmannM , RamseyM , BuchananRW , ConleyRC , WeinerE . Clozapine treatment of schizophrenic patients. www.clinicaltrials.gov (accessed 9 October 2013). [NCT00056498] ">Bachmann 2003</a>; <a href="./references#CD006918-bbs2-0002" title="BorisonR . Risperidone versus haloperidol versus placebo in the treatment of schizophrenia. Clinical report1991. ">Borison 1992</a>; <a href="./references#CD006918-bbs2-0006" title="GeffenY , AnandR , KeefeR , DavidsonM . Results of phase 2b eagle trial; a double blind placebo control study evaluating the efficacy and safety of bl‐1020, a gaba enhanced antipsychotic for the treatment of schizophrenia. Schizophrenia Research2010;117(2‐3):212. ">Geffen 2010</a>; <a href="./references#CD006918-bbs2-0009" title="EreshefskyL , AndersonC , TrueJ , SakladSR , ReisenmanC , ToneyG , et al. Plasma concentration of oral risperidone and active metabolite in schizophrenics. Pharmacotherapy1993;13(3):292. [LMD96402] LindenmayerJP , The Risperidone Study Group. Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia. 146th Annual Meeting of the American Psychiatric Association; 1993 May 22‐27; San Francisco, California, USA. 1993. [MEDLINE: 94350925] MarderS . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Clinical Research Report RIS‐INT‐31991. [MEDLINE: 1375802] MarderSR . Risperidone: clinical development: North American results. Clinical Neuropharmacology1992;15(Suppl 1 Pt A):92A‐3A. [MEDLINE: 92361850] MarderSR . Risperidone: efficacy. Journal of Clinical Psychiatry1994;12:49‐52. [MEDLINE: 94350925] MarderSR , DavisJM , ChouinardG . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychological Medicine [临床精神医学杂志]1997;58(12):538‐46. MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151(6):825‐35. [EMBASE 1994202181] McEvoyJP . Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry1994;55(5 Suppl):18‐21. [EMBASE 1994182002] MeibachR . Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. 1st International Risperidone Investigators' Meeting; 1992 Mar 9‐10; Paris, France. USA, 1992:28‐9. [LMD94893] MeibachRC , The Risperidone Study Group. A fixed dose, parallel group study of risperidone vs. haloperidol vs. placebo. Schizophrenia Research1993;9(2,3):245. [MEDLINE: 94350925] NCT00249132 . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. clinicaltrials.gov/show/NCT00249132(2005). SchoolerNR . Negative symptoms in schizophrenia: assessment of the effect of risperidone. Journal of Clinical Psychiatry1994;55(Suppl 5):22‐8. [MEDLINE: 94350925] SimpsonGM , LindenmayerJP . Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology1997;17(3):194‐201. [MEDLINE: 97313564; PsycINFO 1997‐06350‐009] ">Marder 1994a</a>; <a href="./references#CD006918-bbs2-0011" title="PotkinSG , GutierrezR . Safety and efficacy of once‐daily risperidone in the treatment of schizophrenia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17‐22; San Diego, California, USA. 1997. ">Potkin 1997</a>; <a href="./references#CD006918-bbs2-0012" title="PotkinSG , KujawaM , CarsonWH , SahaAR , AliM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2003;60(1):300. PotkinSG , SahaAR , KujawaMJ , CarsonWH , AliM , StockE , et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry2003;60(7):681‐90. SahaA , CarsonW , AliM , DunbarG , IngenitoG . Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001. YeungP , KujawaM , CarsonWH , SahaA , AlidM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2002;53(3 Suppl 1):185‐6. YeungP , McQuadeRD , CarsonWH , SahaA , AliMW , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia. European Psychiatry2002;17(Suppl 1):102s. YeungPP , CarsonWH , SahaA , McQuadeRD , AliM , StringfellowJC , et al. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: results of a placebo‐controlled trial with risperidone. European Neuropsychopharmacology2001;11(3):259. ">Potkin 2003</a>; <a href="./references#CD006918-bbs2-0013" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , McLemoreJ , GharabawiG . Atypical antipsychotics in patients with schizophrenia and comorbid substance abuse. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005:Nr279. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , et al. Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S503. NCT00061802 . A randomized, double blind study to evaluate the efficacy and safety of two atypical antipsychotics vs placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder. clinicaltrials.gov/show/NCT00061802(2003). PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. RupnowM , GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , GharabawiG , et al. Polypharmacy in schizophrenia: data from a randomized, double‐blind study. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005. StahlS , RupnowM , GreenspanA , Kosik‐GonzalezC , ZhuY , GharabawiG . Use and cost of polypharmacy in schizophrenia: data from a randomized, double‐blind study of risperidone and quetiapine. Neuropsychopharmacology2004;29(Suppl 1):S227. ">Potkin 2006</a>; <a href="./references#CD006918-bbs2-0014" title="PotkinS , FlemingK , BinnemanB , KellerDS , AlphsL , PanagidesJ . Asenapine improves cognitive function in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19‐24; San Diego, CA2007. PotkinS , FlemingK , BinnemanB , KellerS . Asenapine cognitive function effects in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Schizophrenia Bulletin2007;33(2):454. PotkinSG , CohenM , JinaAS , NettlerS , AlphsL , PanagidesJ . Asenapine efficacy during acute episodes of schizophrenia: a randomized placebo and risperidone controlled trial. Proceedings of the 44th American College of Neuropsychopharmacology; 2005 December 11‐15, Waikoloa, Hawaii2005. PotkinSG , CohenM , PanagidesJ . Efficacy and tolerability of asenapine in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Journal of Clinical Psychiatry2007;68(10):1492‐500. PotkinSG , CohenM , PanagidesJ , JinaA . Asenapine safety and tolerability in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. European Neuropsychopharmacology2006;16(Suppl 4):S401. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy in acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S275. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy, safety, and tolerability in the treatment of acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. Biological Psychiatry2006;59(8 Suppl):154S. ">Potkin 2007</a>), Canada (<a href="./references#CD006918-bbs2-0003" title="ChouinardG . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. [MEDLINE: 7537286] ChouinardG , AlbrightPS . Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology1997;17(4):298‐307. [MEDLINE: 9241010] ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. 1993:22. [MEDLINE: 94350925] ChouinardG , ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15(Suppl 1 Pt B):266. [MEDLINE: 94350925] ChouinardG , ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biological Psychiatry1992;31:158. [MEDLINE: 94350925] ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. [MEDLINE: 93253120] ChouinardG , VainerJL , BeauclairL . Dose regimens of neuroleptics in negative symptoms. 19th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1994 Jun 27‐Jul 1; Washington DC, USA1994;10(3 Suppl 1):S363. [MEDLINE: 94350925] ">Chouinard 1992</a>; <a href="./references#CD006918-bbs2-0008" title="HonerW . International study of improving treatment for the most severely ill with schizophrenia. www.clinicaltrials.gov (accessed 9 October 2013). [NCT00272584] ">Honer 2006</a>), India (<a href="./references#CD006918-bbs2-0006" title="GeffenY , AnandR , KeefeR , DavidsonM . Results of phase 2b eagle trial; a double blind placebo control study evaluating the efficacy and safety of bl‐1020, a gaba enhanced antipsychotic for the treatment of schizophrenia. Schizophrenia Research2010;117(2‐3):212. ">Geffen 2010</a>), Romania (<a href="./references#CD006918-bbs2-0006" title="GeffenY , AnandR , KeefeR , DavidsonM . Results of phase 2b eagle trial; a double blind placebo control study evaluating the efficacy and safety of bl‐1020, a gaba enhanced antipsychotic for the treatment of schizophrenia. Schizophrenia Research2010;117(2‐3):212. ">Geffen 2010</a>), Denmark (<a href="./references#CD006918-bbs2-0007" title="HeisterbergJ , BarbatoLM , YeungPP , ShapiraNA . Lipid profile among patients with schizophrenia randomized to bifeprunox, placebo, or risperidone: a comparison of results. Schizophrenia Bulletin2007;33(2):432‐3. YeungPP , BarbatoLM , HeisterbergJ , ShapiraNA . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Schizophrenia Bulletin2007;33(2):466‐7. YeungPP , ShapiraNA , HeisterbergJ . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28‐Apr 1, Colorado Springs, Colorado, USA. 2007. ">Heisterberg 2007</a>), and Turkey (<a href="./references#CD006918-bbs2-0015" title="AkdedeBB , Anil YacioluAE , AlptekinK , TurgutTI , TumukluM , YaziciMK , et al. A double‐blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Journal of Clinical Psychiatry2006;67(12):1912‐9. YagciogluAE , Kivircik AkdedeBB , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry2005;66(1):63‐72. ">Yagcioglu 2005</a>). One studies recruited participants internationally from 65 study centres in the United States, India, Russia, Ukraine, and Malaysia. </p> </section> <section id="CD006918-sec-0086"> <h5 class="title">4. Study size</h5> <p>The largest study was <a href="./references#CD006918-bbs2-0004" title="DowningA M , KinonB J , MillenB A , ZhangL , LiuL , MorozovaM A , et al. A double‐blind, placebo‐controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry2014;14:351. ">Downing 2014</a>, which randmised 1009 people to four groups, among which, 437 participants were assigned to either resperidone or placebo group. <a href="./references#CD006918-bbs2-0007" title="HeisterbergJ , BarbatoLM , YeungPP , ShapiraNA . Lipid profile among patients with schizophrenia randomized to bifeprunox, placebo, or risperidone: a comparison of results. Schizophrenia Bulletin2007;33(2):432‐3. YeungPP , BarbatoLM , HeisterbergJ , ShapiraNA . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Schizophrenia Bulletin2007;33(2):466‐7. YeungPP , ShapiraNA , HeisterbergJ . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28‐Apr 1, Colorado Springs, Colorado, USA. 2007. ">Heisterberg 2007</a> randomised 303 people to receive either risperidone or placebo. <a href="./references#CD006918-bbs2-0005" title="DurgamS , StaraceA , LiD , MiglioreR , RuthA , NemethG , et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res2014;152:450‐7. ">Durgam 2014</a> randomised 729 people to five groups, however, only 291 participants were assigned to either resperidone or placebo group. Where a study randomised different doses of risperidone in different arms, as well as having a separate placebo arm, we tried to take data from the risperidone arm that best fitted with the average doses across studies. For example, as the mean dose of risperidone for all the other trials was 5.5 mg per day, we took the 6 mg arm from the <a href="./references#CD006918-bbs2-0009" title="EreshefskyL , AndersonC , TrueJ , SakladSR , ReisenmanC , ToneyG , et al. Plasma concentration of oral risperidone and active metabolite in schizophrenics. Pharmacotherapy1993;13(3):292. [LMD96402] LindenmayerJP , The Risperidone Study Group. Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia. 146th Annual Meeting of the American Psychiatric Association; 1993 May 22‐27; San Francisco, California, USA. 1993. [MEDLINE: 94350925] MarderS . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Clinical Research Report RIS‐INT‐31991. [MEDLINE: 1375802] MarderSR . Risperidone: clinical development: North American results. Clinical Neuropharmacology1992;15(Suppl 1 Pt A):92A‐3A. [MEDLINE: 92361850] MarderSR . Risperidone: efficacy. Journal of Clinical Psychiatry1994;12:49‐52. [MEDLINE: 94350925] MarderSR , DavisJM , ChouinardG . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychological Medicine [临床精神医学杂志]1997;58(12):538‐46. MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151(6):825‐35. [EMBASE 1994202181] McEvoyJP . Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry1994;55(5 Suppl):18‐21. [EMBASE 1994182002] MeibachR . Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. 1st International Risperidone Investigators' Meeting; 1992 Mar 9‐10; Paris, France. USA, 1992:28‐9. [LMD94893] MeibachRC , The Risperidone Study Group. A fixed dose, parallel group study of risperidone vs. haloperidol vs. placebo. Schizophrenia Research1993;9(2,3):245. [MEDLINE: 94350925] NCT00249132 . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. clinicaltrials.gov/show/NCT00249132(2005). SchoolerNR . Negative symptoms in schizophrenia: assessment of the effect of risperidone. Journal of Clinical Psychiatry1994;55(Suppl 5):22‐8. [MEDLINE: 94350925] SimpsonGM , LindenmayerJP . Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology1997;17(3):194‐201. [MEDLINE: 97313564; PsycINFO 1997‐06350‐009] ">Marder 1994a</a> and <a href="./references#CD006918-bbs2-0003" title="ChouinardG . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. [MEDLINE: 7537286] ChouinardG , AlbrightPS . Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology1997;17(4):298‐307. [MEDLINE: 9241010] ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. 1993:22. [MEDLINE: 94350925] ChouinardG , ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15(Suppl 1 Pt B):266. [MEDLINE: 94350925] ChouinardG , ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biological Psychiatry1992;31:158. [MEDLINE: 94350925] ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. [MEDLINE: 93253120] ChouinardG , VainerJL , BeauclairL . Dose regimens of neuroleptics in negative symptoms. 19th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1994 Jun 27‐Jul 1; Washington DC, USA1994;10(3 Suppl 1):S363. [MEDLINE: 94350925] ">Chouinard 1992</a> trials for efficacy measures in the meta‐analysis. In <a href="./references#CD006918-bbs2-0011" title="PotkinSG , GutierrezR . Safety and efficacy of once‐daily risperidone in the treatment of schizophrenia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17‐22; San Diego, California, USA. 1997. ">Potkin 1997</a>, which had two risperidone arms of 4 mg and 8 mg, we took the 4 mg arm for efficacy measures in the meta‐analysis, as this was closer than the 8 mg arm to the mean of 5.5 mg. <a href="./references#CD006918-bbs2-0013" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , McLemoreJ , GharabawiG . Atypical antipsychotics in patients with schizophrenia and comorbid substance abuse. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005:Nr279. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , et al. Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S503. NCT00061802 . A randomized, double blind study to evaluate the efficacy and safety of two atypical antipsychotics vs placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder. clinicaltrials.gov/show/NCT00061802(2003). PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. RupnowM , GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , GharabawiG , et al. Polypharmacy in schizophrenia: data from a randomized, double‐blind study. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005. StahlS , RupnowM , GreenspanA , Kosik‐GonzalezC , ZhuY , GharabawiG . Use and cost of polypharmacy in schizophrenia: data from a randomized, double‐blind study of risperidone and quetiapine. Neuropsychopharmacology2004;29(Suppl 1):S227. ">Potkin 2006</a> randomised 226 people, <a href="./references#CD006918-bbs2-0012" title="PotkinSG , KujawaM , CarsonWH , SahaAR , AliM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2003;60(1):300. PotkinSG , SahaAR , KujawaMJ , CarsonWH , AliM , StockE , et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry2003;60(7):681‐90. SahaA , CarsonW , AliM , DunbarG , IngenitoG . Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001. YeungP , KujawaM , CarsonWH , SahaA , AlidM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2002;53(3 Suppl 1):185‐6. YeungP , McQuadeRD , CarsonWH , SahaA , AliMW , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia. European Psychiatry2002;17(Suppl 1):102s. YeungPP , CarsonWH , SahaA , McQuadeRD , AliM , StringfellowJC , et al. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: results of a placebo‐controlled trial with risperidone. European Neuropsychopharmacology2001;11(3):259. ">Potkin 2003</a> 202, <a href="./references#CD006918-bbs2-0009" title="EreshefskyL , AndersonC , TrueJ , SakladSR , ReisenmanC , ToneyG , et al. Plasma concentration of oral risperidone and active metabolite in schizophrenics. Pharmacotherapy1993;13(3):292. [LMD96402] LindenmayerJP , The Risperidone Study Group. Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia. 146th Annual Meeting of the American Psychiatric Association; 1993 May 22‐27; San Francisco, California, USA. 1993. [MEDLINE: 94350925] MarderS . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Clinical Research Report RIS‐INT‐31991. [MEDLINE: 1375802] MarderSR . Risperidone: clinical development: North American results. Clinical Neuropharmacology1992;15(Suppl 1 Pt A):92A‐3A. [MEDLINE: 92361850] MarderSR . Risperidone: efficacy. Journal of Clinical Psychiatry1994;12:49‐52. [MEDLINE: 94350925] MarderSR , DavisJM , ChouinardG . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychological Medicine [临床精神医学杂志]1997;58(12):538‐46. MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151(6):825‐35. [EMBASE 1994202181] McEvoyJP . Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry1994;55(5 Suppl):18‐21. [EMBASE 1994182002] MeibachR . Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. 1st International Risperidone Investigators' Meeting; 1992 Mar 9‐10; Paris, France. USA, 1992:28‐9. [LMD94893] MeibachRC , The Risperidone Study Group. A fixed dose, parallel group study of risperidone vs. haloperidol vs. placebo. Schizophrenia Research1993;9(2,3):245. [MEDLINE: 94350925] NCT00249132 . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. clinicaltrials.gov/show/NCT00249132(2005). SchoolerNR . Negative symptoms in schizophrenia: assessment of the effect of risperidone. Journal of Clinical Psychiatry1994;55(Suppl 5):22‐8. [MEDLINE: 94350925] SimpsonGM , LindenmayerJP . Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology1997;17(3):194‐201. [MEDLINE: 97313564; PsycINFO 1997‐06350‐009] ">Marder 1994a</a> 130, <a href="./references#CD006918-bbs2-0003" title="ChouinardG . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. [MEDLINE: 7537286] ChouinardG , AlbrightPS . Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology1997;17(4):298‐307. [MEDLINE: 9241010] ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. 1993:22. [MEDLINE: 94350925] ChouinardG , ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15(Suppl 1 Pt B):266. [MEDLINE: 94350925] ChouinardG , ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biological Psychiatry1992;31:158. [MEDLINE: 94350925] ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. [MEDLINE: 93253120] ChouinardG , VainerJL , BeauclairL . Dose regimens of neuroleptics in negative symptoms. 19th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1994 Jun 27‐Jul 1; Washington DC, USA1994;10(3 Suppl 1):S363. [MEDLINE: 94350925] ">Chouinard 1992</a> 44, and <a href="./references#CD006918-bbs2-0011" title="PotkinSG , GutierrezR . Safety and efficacy of once‐daily risperidone in the treatment of schizophrenia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17‐22; San Diego, California, USA. 1997. ">Potkin 1997</a> 168. The rest of the studies ranged between 24 and 121 participants. </p> </section> <section id="CD006918-sec-0087"> <h5 class="title">5. Interventions</h5> <section id="CD006918-sec-0088"> <h6 class="title">5.1 Risperidone</h6> <p>The dose of risperidone administered by the trialists varied from 2 mg up to 10 mg per day. </p> </section> <section id="CD006918-sec-0089"> <h6 class="title">5.2 Placebo</h6> <p>All studies had a placebo arm, and most had another arm with an active treatment in addition to risperidone. <a href="./references#CD006918-bbs2-0002" title="BorisonR . Risperidone versus haloperidol versus placebo in the treatment of schizophrenia. Clinical report1991. ">Borison 1992</a>, <a href="./references#CD006918-bbs2-0009" title="EreshefskyL , AndersonC , TrueJ , SakladSR , ReisenmanC , ToneyG , et al. Plasma concentration of oral risperidone and active metabolite in schizophrenics. Pharmacotherapy1993;13(3):292. [LMD96402] LindenmayerJP , The Risperidone Study Group. Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia. 146th Annual Meeting of the American Psychiatric Association; 1993 May 22‐27; San Francisco, California, USA. 1993. [MEDLINE: 94350925] MarderS . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Clinical Research Report RIS‐INT‐31991. [MEDLINE: 1375802] MarderSR . Risperidone: clinical development: North American results. Clinical Neuropharmacology1992;15(Suppl 1 Pt A):92A‐3A. [MEDLINE: 92361850] MarderSR . Risperidone: efficacy. Journal of Clinical Psychiatry1994;12:49‐52. [MEDLINE: 94350925] MarderSR , DavisJM , ChouinardG . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychological Medicine [临床精神医学杂志]1997;58(12):538‐46. MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151(6):825‐35. [EMBASE 1994202181] McEvoyJP . Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry1994;55(5 Suppl):18‐21. [EMBASE 1994182002] MeibachR . Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. 1st International Risperidone Investigators' Meeting; 1992 Mar 9‐10; Paris, France. USA, 1992:28‐9. [LMD94893] MeibachRC , The Risperidone Study Group. A fixed dose, parallel group study of risperidone vs. haloperidol vs. placebo. Schizophrenia Research1993;9(2,3):245. [MEDLINE: 94350925] NCT00249132 . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. clinicaltrials.gov/show/NCT00249132(2005). SchoolerNR . Negative symptoms in schizophrenia: assessment of the effect of risperidone. Journal of Clinical Psychiatry1994;55(Suppl 5):22‐8. [MEDLINE: 94350925] SimpsonGM , LindenmayerJP . Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology1997;17(3):194‐201. [MEDLINE: 97313564; PsycINFO 1997‐06350‐009] ">Marder 1994a</a>, and <a href="./references#CD006918-bbs2-0003" title="ChouinardG . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. [MEDLINE: 7537286] ChouinardG , AlbrightPS . Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology1997;17(4):298‐307. [MEDLINE: 9241010] ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. 1993:22. [MEDLINE: 94350925] ChouinardG , ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15(Suppl 1 Pt B):266. [MEDLINE: 94350925] ChouinardG , ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biological Psychiatry1992;31:158. [MEDLINE: 94350925] ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. [MEDLINE: 93253120] ChouinardG , VainerJL , BeauclairL . Dose regimens of neuroleptics in negative symptoms. 19th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1994 Jun 27‐Jul 1; Washington DC, USA1994;10(3 Suppl 1):S363. [MEDLINE: 94350925] ">Chouinard 1992</a> had an arm for haloperidol. <a href="./references#CD006918-bbs2-0004" title="DowningA M , KinonB J , MillenB A , ZhangL , LiuL , MorozovaM A , et al. A double‐blind, placebo‐controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry2014;14:351. ">Downing 2014</a> had two arms for LY2140023 with low dosage or high dosage. <a href="./references#CD006918-bbs2-0005" title="DurgamS , StaraceA , LiD , MiglioreR , RuthA , NemethG , et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res2014;152:450‐7. ">Durgam 2014</a> had three arms of cariprazine with low, medium or high dosage. <a href="./references#CD006918-bbs2-0006" title="GeffenY , AnandR , KeefeR , DavidsonM . Results of phase 2b eagle trial; a double blind placebo control study evaluating the efficacy and safety of bl‐1020, a gaba enhanced antipsychotic for the treatment of schizophrenia. Schizophrenia Research2010;117(2‐3):212. ">Geffen 2010</a> had two additional arms for a low dose and a high dose of BL‐1020. <a href="./references#CD006918-bbs2-0009" title="EreshefskyL , AndersonC , TrueJ , SakladSR , ReisenmanC , ToneyG , et al. Plasma concentration of oral risperidone and active metabolite in schizophrenics. Pharmacotherapy1993;13(3):292. [LMD96402] LindenmayerJP , The Risperidone Study Group. Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia. 146th Annual Meeting of the American Psychiatric Association; 1993 May 22‐27; San Francisco, California, USA. 1993. [MEDLINE: 94350925] MarderS . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Clinical Research Report RIS‐INT‐31991. [MEDLINE: 1375802] MarderSR . Risperidone: clinical development: North American results. Clinical Neuropharmacology1992;15(Suppl 1 Pt A):92A‐3A. [MEDLINE: 92361850] MarderSR . Risperidone: efficacy. Journal of Clinical Psychiatry1994;12:49‐52. [MEDLINE: 94350925] MarderSR , DavisJM , ChouinardG . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychological Medicine [临床精神医学杂志]1997;58(12):538‐46. MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151(6):825‐35. [EMBASE 1994202181] McEvoyJP . Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry1994;55(5 Suppl):18‐21. [EMBASE 1994182002] MeibachR . Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. 1st International Risperidone Investigators' Meeting; 1992 Mar 9‐10; Paris, France. USA, 1992:28‐9. [LMD94893] MeibachRC , The Risperidone Study Group. A fixed dose, parallel group study of risperidone vs. haloperidol vs. placebo. Schizophrenia Research1993;9(2,3):245. [MEDLINE: 94350925] NCT00249132 . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. clinicaltrials.gov/show/NCT00249132(2005). SchoolerNR . Negative symptoms in schizophrenia: assessment of the effect of risperidone. Journal of Clinical Psychiatry1994;55(Suppl 5):22‐8. [MEDLINE: 94350925] SimpsonGM , LindenmayerJP . Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology1997;17(3):194‐201. [MEDLINE: 97313564; PsycINFO 1997‐06350‐009] ">Marder 1994a</a> and <a href="./references#CD006918-bbs2-0003" title="ChouinardG . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. [MEDLINE: 7537286] ChouinardG , AlbrightPS . Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology1997;17(4):298‐307. [MEDLINE: 9241010] ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. 1993:22. [MEDLINE: 94350925] ChouinardG , ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15(Suppl 1 Pt B):266. [MEDLINE: 94350925] ChouinardG , ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biological Psychiatry1992;31:158. [MEDLINE: 94350925] ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. [MEDLINE: 93253120] ChouinardG , VainerJL , BeauclairL . Dose regimens of neuroleptics in negative symptoms. 19th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1994 Jun 27‐Jul 1; Washington DC, USA1994;10(3 Suppl 1):S363. [MEDLINE: 94350925] ">Chouinard 1992</a> also had four different risperidone arms with daily doses of 2 mg, 6 mg, 10 mg, and 16 mg. We used the 6 mg arm from the <a href="./references#CD006918-bbs2-0009" title="EreshefskyL , AndersonC , TrueJ , SakladSR , ReisenmanC , ToneyG , et al. Plasma concentration of oral risperidone and active metabolite in schizophrenics. Pharmacotherapy1993;13(3):292. [LMD96402] LindenmayerJP , The Risperidone Study Group. Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia. 146th Annual Meeting of the American Psychiatric Association; 1993 May 22‐27; San Francisco, California, USA. 1993. [MEDLINE: 94350925] MarderS . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Clinical Research Report RIS‐INT‐31991. [MEDLINE: 1375802] MarderSR . Risperidone: clinical development: North American results. Clinical Neuropharmacology1992;15(Suppl 1 Pt A):92A‐3A. [MEDLINE: 92361850] MarderSR . Risperidone: efficacy. Journal of Clinical Psychiatry1994;12:49‐52. [MEDLINE: 94350925] MarderSR , DavisJM , ChouinardG . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychological Medicine [临床精神医学杂志]1997;58(12):538‐46. MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151(6):825‐35. [EMBASE 1994202181] McEvoyJP . Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry1994;55(5 Suppl):18‐21. [EMBASE 1994182002] MeibachR . Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. 1st International Risperidone Investigators' Meeting; 1992 Mar 9‐10; Paris, France. USA, 1992:28‐9. [LMD94893] MeibachRC , The Risperidone Study Group. A fixed dose, parallel group study of risperidone vs. haloperidol vs. placebo. Schizophrenia Research1993;9(2,3):245. [MEDLINE: 94350925] NCT00249132 . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. clinicaltrials.gov/show/NCT00249132(2005). SchoolerNR . Negative symptoms in schizophrenia: assessment of the effect of risperidone. Journal of Clinical Psychiatry1994;55(Suppl 5):22‐8. [MEDLINE: 94350925] SimpsonGM , LindenmayerJP . Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology1997;17(3):194‐201. [MEDLINE: 97313564; PsycINFO 1997‐06350‐009] ">Marder 1994a</a> and <a href="./references#CD006918-bbs2-0003" title="ChouinardG . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. [MEDLINE: 7537286] ChouinardG , AlbrightPS . Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology1997;17(4):298‐307. [MEDLINE: 9241010] ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. 1993:22. [MEDLINE: 94350925] ChouinardG , ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15(Suppl 1 Pt B):266. [MEDLINE: 94350925] ChouinardG , ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biological Psychiatry1992;31:158. [MEDLINE: 94350925] ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. [MEDLINE: 93253120] ChouinardG , VainerJL , BeauclairL . Dose regimens of neuroleptics in negative symptoms. 19th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1994 Jun 27‐Jul 1; Washington DC, USA1994;10(3 Suppl 1):S363. [MEDLINE: 94350925] ">Chouinard 1992</a> trials for efficacy measures in the meta‐analysis and the 4 mg arm data from <a href="./references#CD006918-bbs2-0011" title="PotkinSG , GutierrezR . Safety and efficacy of once‐daily risperidone in the treatment of schizophrenia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17‐22; San Diego, California, USA. 1997. ">Potkin 1997</a>. <a href="./references#CD006918-bbs2-0007" title="HeisterbergJ , BarbatoLM , YeungPP , ShapiraNA . Lipid profile among patients with schizophrenia randomized to bifeprunox, placebo, or risperidone: a comparison of results. Schizophrenia Bulletin2007;33(2):432‐3. YeungPP , BarbatoLM , HeisterbergJ , ShapiraNA . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Schizophrenia Bulletin2007;33(2):466‐7. YeungPP , ShapiraNA , HeisterbergJ . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28‐Apr 1, Colorado Springs, Colorado, USA. 2007. ">Heisterberg 2007</a> used bifeprunox as the other arm, <a href="./references#CD006918-bbs2-0012" title="PotkinSG , KujawaM , CarsonWH , SahaAR , AliM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2003;60(1):300. PotkinSG , SahaAR , KujawaMJ , CarsonWH , AliM , StockE , et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry2003;60(7):681‐90. SahaA , CarsonW , AliM , DunbarG , IngenitoG . Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001. YeungP , KujawaM , CarsonWH , SahaA , AlidM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2002;53(3 Suppl 1):185‐6. YeungP , McQuadeRD , CarsonWH , SahaA , AliMW , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia. European Psychiatry2002;17(Suppl 1):102s. YeungPP , CarsonWH , SahaA , McQuadeRD , AliM , StringfellowJC , et al. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: results of a placebo‐controlled trial with risperidone. European Neuropsychopharmacology2001;11(3):259. ">Potkin 2003</a> aripiprazole, <a href="./references#CD006918-bbs2-0013" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , McLemoreJ , GharabawiG . Atypical antipsychotics in patients with schizophrenia and comorbid substance abuse. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005:Nr279. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , et al. Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S503. NCT00061802 . A randomized, double blind study to evaluate the efficacy and safety of two atypical antipsychotics vs placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder. clinicaltrials.gov/show/NCT00061802(2003). PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. RupnowM , GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , GharabawiG , et al. Polypharmacy in schizophrenia: data from a randomized, double‐blind study. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005. StahlS , RupnowM , GreenspanA , Kosik‐GonzalezC , ZhuY , GharabawiG . Use and cost of polypharmacy in schizophrenia: data from a randomized, double‐blind study of risperidone and quetiapine. Neuropsychopharmacology2004;29(Suppl 1):S227. ">Potkin 2006</a> quetiapine, and <a href="./references#CD006918-bbs2-0014" title="PotkinS , FlemingK , BinnemanB , KellerDS , AlphsL , PanagidesJ . Asenapine improves cognitive function in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19‐24; San Diego, CA2007. PotkinS , FlemingK , BinnemanB , KellerS . Asenapine cognitive function effects in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Schizophrenia Bulletin2007;33(2):454. PotkinSG , CohenM , JinaAS , NettlerS , AlphsL , PanagidesJ . Asenapine efficacy during acute episodes of schizophrenia: a randomized placebo and risperidone controlled trial. Proceedings of the 44th American College of Neuropsychopharmacology; 2005 December 11‐15, Waikoloa, Hawaii2005. PotkinSG , CohenM , PanagidesJ . Efficacy and tolerability of asenapine in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Journal of Clinical Psychiatry2007;68(10):1492‐500. PotkinSG , CohenM , PanagidesJ , JinaA . Asenapine safety and tolerability in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. European Neuropsychopharmacology2006;16(Suppl 4):S401. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy in acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S275. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy, safety, and tolerability in the treatment of acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. Biological Psychiatry2006;59(8 Suppl):154S. ">Potkin 2007</a> asenapine. </p> </section> <section id="CD006918-sec-0090"> <h6 class="title">5.3 Augmentation</h6> <p>In three studies the risperidone and placebo arms were combined with clozapine (<a href="./references#CD006918-bbs2-0001" title="BachmannM , RamseyM , BuchananRW , ConleyRC , WeinerE . Clozapine treatment of schizophrenic patients. www.clinicaltrials.gov (accessed 9 October 2013). [NCT00056498] ">Bachmann 2003</a>; <a href="./references#CD006918-bbs2-0008" title="HonerW . International study of improving treatment for the most severely ill with schizophrenia. www.clinicaltrials.gov (accessed 9 October 2013). [NCT00272584] ">Honer 2006</a>; <a href="./references#CD006918-bbs2-0015" title="AkdedeBB , Anil YacioluAE , AlptekinK , TurgutTI , TumukluM , YaziciMK , et al. A double‐blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Journal of Clinical Psychiatry2006;67(12):1912‐9. YagciogluAE , Kivircik AkdedeBB , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry2005;66(1):63‐72. ">Yagcioglu 2005</a>). </p> </section> </section> <section id="CD006918-sec-0091"> <h5 class="title">6. Outcomes</h5> <p>Our primary outcome measures were mental state and service utilisation; no data were available for service utilisation. Other outcomes of interest were leaving the study early, global state, adverse effects, and quality of life. </p> <section id="CD006918-sec-0092"> <h6 class="title">6.1 Mental state</h6> <p>The trials used several different rating scales to report on mental state. <a href="./references#CD006918-bbs2-0007" title="HeisterbergJ , BarbatoLM , YeungPP , ShapiraNA . Lipid profile among patients with schizophrenia randomized to bifeprunox, placebo, or risperidone: a comparison of results. Schizophrenia Bulletin2007;33(2):432‐3. YeungPP , BarbatoLM , HeisterbergJ , ShapiraNA . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Schizophrenia Bulletin2007;33(2):466‐7. YeungPP , ShapiraNA , HeisterbergJ . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28‐Apr 1, Colorado Springs, Colorado, USA. 2007. ">Heisterberg 2007</a> did not report useable data on mental state, and we could not use the Positive and Negative Symptom Scale (PANSS) data from <a href="./references#CD006918-bbs2-0014" title="PotkinS , FlemingK , BinnemanB , KellerDS , AlphsL , PanagidesJ . Asenapine improves cognitive function in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19‐24; San Diego, CA2007. PotkinS , FlemingK , BinnemanB , KellerS . Asenapine cognitive function effects in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Schizophrenia Bulletin2007;33(2):454. PotkinSG , CohenM , JinaAS , NettlerS , AlphsL , PanagidesJ . Asenapine efficacy during acute episodes of schizophrenia: a randomized placebo and risperidone controlled trial. Proceedings of the 44th American College of Neuropsychopharmacology; 2005 December 11‐15, Waikoloa, Hawaii2005. PotkinSG , CohenM , PanagidesJ . Efficacy and tolerability of asenapine in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Journal of Clinical Psychiatry2007;68(10):1492‐500. PotkinSG , CohenM , PanagidesJ , JinaA . Asenapine safety and tolerability in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. European Neuropsychopharmacology2006;16(Suppl 4):S401. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy in acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S275. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy, safety, and tolerability in the treatment of acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. Biological Psychiatry2006;59(8 Suppl):154S. ">Potkin 2007</a> as this trial had more than 50% attrition. <a href="./references#CD006918-bbs2-0004" title="DowningA M , KinonB J , MillenB A , ZhangL , LiuL , MorozovaM A , et al. A double‐blind, placebo‐controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry2014;14:351. ">Downing 2014</a> only reported means of PANSS score in each group, therefore we are unable to use the data. All other trials used either the PANSS or the Brief Psychiatric Rating Scale to measure this outcome. Wherever possible, we used the binary data from these measures, but the validity of dichotomising these measures, although widely accepted, is, nevertheless, unclear. </p> </section> <section id="CD006918-sec-0093"> <h6 class="title">6.2 Leaving the study early</h6> <p>All included trials provided useable data on the number of participants leaving the study early. </p> </section> <section id="CD006918-sec-0094"> <h6 class="title">6.3 Global state</h6> <p>Five of the included studies reported global change using the Clinical Global Impression (CGI) scale (<a href="./references#CD006918-bbs2-0005" title="DurgamS , StaraceA , LiD , MiglioreR , RuthA , NemethG , et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res2014;152:450‐7. ">Durgam 2014</a>, <a href="./references#CD006918-bbs2-0008" title="HonerW . International study of improving treatment for the most severely ill with schizophrenia. www.clinicaltrials.gov (accessed 9 October 2013). [NCT00272584] ">Honer 2006</a>, <a href="./references#CD006918-bbs2-0009" title="EreshefskyL , AndersonC , TrueJ , SakladSR , ReisenmanC , ToneyG , et al. Plasma concentration of oral risperidone and active metabolite in schizophrenics. Pharmacotherapy1993;13(3):292. [LMD96402] LindenmayerJP , The Risperidone Study Group. Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia. 146th Annual Meeting of the American Psychiatric Association; 1993 May 22‐27; San Francisco, California, USA. 1993. [MEDLINE: 94350925] MarderS . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Clinical Research Report RIS‐INT‐31991. [MEDLINE: 1375802] MarderSR . Risperidone: clinical development: North American results. Clinical Neuropharmacology1992;15(Suppl 1 Pt A):92A‐3A. [MEDLINE: 92361850] MarderSR . Risperidone: efficacy. Journal of Clinical Psychiatry1994;12:49‐52. [MEDLINE: 94350925] MarderSR , DavisJM , ChouinardG . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychological Medicine [临床精神医学杂志]1997;58(12):538‐46. MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151(6):825‐35. [EMBASE 1994202181] McEvoyJP . Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry1994;55(5 Suppl):18‐21. [EMBASE 1994182002] MeibachR . Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. 1st International Risperidone Investigators' Meeting; 1992 Mar 9‐10; Paris, France. USA, 1992:28‐9. [LMD94893] MeibachRC , The Risperidone Study Group. A fixed dose, parallel group study of risperidone vs. haloperidol vs. placebo. Schizophrenia Research1993;9(2,3):245. [MEDLINE: 94350925] NCT00249132 . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. clinicaltrials.gov/show/NCT00249132(2005). SchoolerNR . Negative symptoms in schizophrenia: assessment of the effect of risperidone. Journal of Clinical Psychiatry1994;55(Suppl 5):22‐8. [MEDLINE: 94350925] SimpsonGM , LindenmayerJP . Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology1997;17(3):194‐201. [MEDLINE: 97313564; PsycINFO 1997‐06350‐009] ">Marder 1994a</a>, <a href="./references#CD006918-bbs2-0012" title="PotkinSG , KujawaM , CarsonWH , SahaAR , AliM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2003;60(1):300. PotkinSG , SahaAR , KujawaMJ , CarsonWH , AliM , StockE , et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry2003;60(7):681‐90. SahaA , CarsonW , AliM , DunbarG , IngenitoG . Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001. YeungP , KujawaM , CarsonWH , SahaA , AlidM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2002;53(3 Suppl 1):185‐6. YeungP , McQuadeRD , CarsonWH , SahaA , AliMW , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia. European Psychiatry2002;17(Suppl 1):102s. YeungPP , CarsonWH , SahaA , McQuadeRD , AliM , StringfellowJC , et al. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: results of a placebo‐controlled trial with risperidone. European Neuropsychopharmacology2001;11(3):259. ">Potkin 2003</a>, <a href="./references#CD006918-bbs2-0013" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , McLemoreJ , GharabawiG . Atypical antipsychotics in patients with schizophrenia and comorbid substance abuse. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005:Nr279. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , et al. Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S503. NCT00061802 . A randomized, double blind study to evaluate the efficacy and safety of two atypical antipsychotics vs placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder. clinicaltrials.gov/show/NCT00061802(2003). PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. RupnowM , GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , GharabawiG , et al. Polypharmacy in schizophrenia: data from a randomized, double‐blind study. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005. StahlS , RupnowM , GreenspanA , Kosik‐GonzalezC , ZhuY , GharabawiG . Use and cost of polypharmacy in schizophrenia: data from a randomized, double‐blind study of risperidone and quetiapine. Neuropsychopharmacology2004;29(Suppl 1):S227. ">Potkin 2006</a>). <a href="./references#CD006918-bbs2-0015" title="AkdedeBB , Anil YacioluAE , AlptekinK , TurgutTI , TumukluM , YaziciMK , et al. A double‐blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Journal of Clinical Psychiatry2006;67(12):1912‐9. YagciogluAE , Kivircik AkdedeBB , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry2005;66(1):63‐72. ">Yagcioglu 2005</a> used both the CGI and the Global Assessment of Functioning Scale. </p> </section> <section id="CD006918-sec-0095"> <h6 class="title">6.4 Adverse effects</h6> <p>Adverse effects are an important outcome measure from any trial. We were able to pool data on adverse effects from the majority of trials; some data was skewed and is presented in additional tables. </p> </section> <section id="CD006918-sec-0096"> <h6 class="title">6.5 Quality of life</h6> <p>were only presented by Only <a href="./references#CD006918-bbs2-0015" title="AkdedeBB , Anil YacioluAE , AlptekinK , TurgutTI , TumukluM , YaziciMK , et al. A double‐blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Journal of Clinical Psychiatry2006;67(12):1912‐9. YagciogluAE , Kivircik AkdedeBB , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry2005;66(1):63‐72. ">Yagcioglu 2005</a> presented quality of life data. </p> </section> <section id="CD006918-sec-0097"> <h6 class="title">6.6 Missing outcomes</h6> <p>No data were available for service utilisation or economic outcomes.</p> </section> <section id="CD006918-sec-0098"> <h6 class="title">6.7 Outcome scales</h6> <section id="CD006918-sec-0099"> <p><b>6.7.1 Global state scales</b></p> <p>6.7.1.1 Clinical Global Impression (<a href="./references#CD006918-bbs2-0146" title="GuyU . ECDEU assessment manual for psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976. ">Guy 1976</a>)<br/> The CGI scale was used to assess both severity of illness and clinical improvement by comparing the conditions of the person standardised against other people with the same diagnosis. It is a seven‐point scoring system with low scores showing decreased severity or overall improvement, or both. </p> <p>6.7.1.2 Global Assessment of Functioning Scale (<a href="./references#CD006918-bbs2-0140" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association, 1994. ">DSM‐IV‐TR</a>)<br/> The GAF scale is a numeric scale (0 through 100) used by mental‐health clinicians and doctors to rate the social, occupational, and psychological functioning of adults. The scale is presented and described in the <a href="./references#CD006918-bbs2-0140" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association, 1994. ">DSM‐IV‐TR</a> on page 32 (<a href="#CD006918-tbl-0004">Table 2</a>). </p> <div class="table" id="CD006918-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Global Assessment of Functioning scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Judgement</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91‐100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Superior functioning in a wide range of activities, life's problems never seem to get out of hand, is sought out by others because of his or her many qualities. No symptoms. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81‐90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absent or minimal symptoms, good functioning in all areas, interested and involved in a wide range of activities, socially effective, generally satisfied with life, no more than everyday problems or concerns. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71‐80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If symptoms are present they are transient and expectable reactions to psychosocial stresses; no more than slight impairment in social, occupational, or school functioning. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61‐70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some mild symptoms OR some difficulty in social, occupational, or school functioning, but generally functioning pretty well, has some meaningful interpersonal relationships. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51‐60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate symptoms OR any moderate difficulty in social, occupational, or school functioning.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41‐50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious symptoms OR any serious impairment in social, occupational, or school functioning.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31‐40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some impairment in reality testing or communication OR major impairment in several areas, such as work or school, family relations, judgement, thinking, or mood. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behavior is considerably influenced by delusions or hallucinations OR serious impairment in communications or judgment OR inability to function in all areas. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11‐20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some danger of hurting self or others OR occasionally fails to maintain minimal personal hygiene OR gross impairment in communication. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent danger of severely hurting self or others OR persistent inability to maintain minimum personal hygiene OR serious suicidal act with clear expectation of death. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not enough information available to provide GAF.</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD006918-sec-0100"> <p><b>6.7.2 Mental state scales</b></p> <p>6.7.2.1 Positive and Negative Syndrome Scale (<a href="./references#CD006918-bbs2-0159" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>)<br/> The PANSS is used for measuring symptom severity of people with schizophrenia. It is widely used in the study of antipsychotic therapy. The name refers to the two types of symptoms in schizophrenia, as defined by the American Psychiatric Association: positive symptoms, which refer to an excess or distortion of normal functions, and negative symptoms, which represent a diminution or loss of normal functions. </p> <p>6.7.2.2 Brief Psychiatric Rating Scale (<a href="./references#CD006918-bbs2-0177" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>)<br/> The BPRS consists of 18 items on a 7‐point severity scale. Initially published as a 16‐item scale in 1962, the standard 18‐item version has been used since 1967 to successfully demonstrate efficacy of antidepressants, anti‐anxiety drugs, and antipsychotics, including the newer 'atypical' antipsychotics. The BPRS has also been used in epidemiological studies, geropsychiatric research, and to compare diagnostic concepts between countries. It is most frequently used in schizophrenia. When using BPRS, rater training is a must and the use of a standardised interview is highly recommended in order to ascertain consistent results. </p> <p>6.7.2.3 Calgary Depression Scale for Schizophrenia (<a href="./references#CD006918-bbs2-0118" title="AddingtonD , AddingtonJ , Maticka‐TyndaleE . Assessing depression in schizophrenia: the Calgary Depression Scale. British Journal of Psychiatry1993;22:39‐44. ">Addington 1993</a>)<br/> Developed at the University of Calgary, the CDSS specifically assesses the level of depression in schizophrenia. It has been extensively evaluated in both relapsed and remitted patients and appears sensitive to change. </p> <p>6.7.2.4 Scale for the Assessment of Negative Symptoms (<a href="./references#CD006918-bbs2-0122" title="Andreasen , NC . Scale for the assessment of negative symptoms: SANS. Lowa: the University of Lowa.1981. ">Andreasen 1981</a>)<br/> The SANS assesses affective blunting, alogia, avolition/apathy, anhedonia/asociality, and disturbance of attention to measure negative symptoms in schizophrenia. </p> </section> <section id="CD006918-sec-0101"> <p><b>6.7.3 Adverse effects scales</b></p> <p>6.7.3.1 Barnes Akathisia Scale (<a href="./references#CD006918-bbs2-0125" title="BarnesTR . A rating scale for drug‐induced akathisia. British Journal of Psychiatry1989;154:672‐6. ">Barnes 1989</a>)<br/> The Barnes Akathisia Scale (commonly known as BAS or BARS) is a four‐item rating scale administered by physicians to assess the severity of drug‐induced akathisia. The most widely used scale for akathisia, it includes both objective items (e.g. observed restlessness) and subjective items (e.g. patient's awareness of restlessness and related distress), together with a global clinical assessment of akathisia. Global assessment is made on a scale of 0 to 5, with comprehensive definitions provided for each anchor point on the scale: 0 = absent; 1 = questionable; 2 = mild akathisia; 3 = moderate akathisia; 4 = marked akathisia; 5 = severe akathisia. </p> <p>6.7.3.2 Extrapyramidal Symptom Rating Scale (<a href="./references#CD006918-bbs2-0135" title="ChouinardG , ArnottW . Clinical review of risperidone. Canadian Journal of Psychiatry1993;38(Suppl 3):89‐95. ">Chouinard 1993</a>)<br/> The ESRS is a physician‐rated scale for measuring extrapyramidal adverse effects from antipsychotic medication. It takes approximately 10 minutes and involves 6 questions about the person’s subjective experience of extrapyramidal features (slowness, stiffness, and tremor); a standardised procedure for physical examination; and 7 rater‐assessed items that address parkinsonian features (rigidity and tremor). The instrument may not differentiate effectively between dyskinesia and dystonia. </p> <p>6.7.3.3 Simpson Angus Scale (<a href="./references#CD006918-bbs2-0180" title="SimpsonGM , AngusJWS . A rating scale for extrapyramidal side‐effects. Acta Psychiatrica Scandinavica Supplementum1970;212:11‐9. ">Simpson 1970</a>)<br/> The SAS is a 10‐item instrument used to evaluate the presence and severity of parkinsonian symptomatology specifically in patients who may be experiencing drug‐induced parkinsonism and other extrapyramidal effects. For the past 25 years it has been the most commonly used rating scale for parkinsonism in clinical trials. The 10 items focus on rigidity rather than bradykinesia, and do not assess subjective rigidity or slowness. Items are rated for severity on a 0 to 4 scale, with definitions given for each anchor point. </p> <p>6.7.3.4 Abnormal Involuntary Movement Scale (<a href="./references#CD006918-bbs2-0146" title="GuyU . ECDEU assessment manual for psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976. ">Guy 1976</a>)<br/> The AIMS is a 12‐item clinician‐rated scale to assess severity of dyskinesias including orofacial movements, extremity and truncal movements in patients taking neuroleptic medications. </p> <p>6.7.3.5 The UKU side effect rating scale (<a href="./references#CD006918-bbs2-0171" title="LingjaerdeO , AhlforsUG , BechP , DenckerSJ , ElgenK . The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a crosssectional study of side effects in neuroleptic‐treated patients. Acta Psychiatr Scand1987;76((suppl. 334)):1‐100. ">Lingjaerde 1987</a>) </p> <p>UKU is a 48 item clinician‐rated scale to assess the side effects of psychopharmacological medications. The interview takes anywhere from 10‐30 minutes depending on the number of symptoms reported, the complexity of the symptoms, and the patient’s ability to provide good report. </p> </section> <section id="CD006918-sec-0102"> <p><b>6.7.4 Quality of life scales</b></p> <p>6.7.4.1 Quality of Life Scale (<a href="./references#CD006918-bbs2-0132" title="CarpenterWTJr , BuchananRW . Schizophrenia. The New England Journal of Medicine1994;330(10):681‐90. ">Carpenter 1994</a>)<br/> The QLS is a 21‐item scale rated from a semistructured interview providing information on symptoms and functioning during the preceding 4 weeks. It is intended to be administered by a trained clinician and requires about 45 minutes to complete. Each item is rated on a 7‐point scale and, in all but 2 cases, requires a judgement by the clinician/interviewer. Each item is comprised of 3 parts: (1) a brief descriptive statement to focus the interviewer on the judgement to be made; (2) a set of suggested probes; and (3) the 7‐point scale with descriptive anchors for every other point. The specific descriptions vary among items, but the high end of the scales (scores 5 and 6) reflects normal or unimpaired functioning, and the low end of the scales (scores 0 and 1) reflects severe impairment of the function in question. The interviewer is instructed to probe around each item until he or she has an adequate basis for making the required judgement, and is encouraged to go beyond the suggested probes with questions tailored for the individual patient. Thus the experience of both the patient and interviewer is similar to a careful clinical interview. </p> </section> <section id="CD006918-sec-0103"> <p><b>6.7.5 Cognitive function scales</b></p> <p>6.7.5.1 Groton Maze Learning Test (<a href="./references#CD006918-bbs2-0178" title="PietrzakRH , MaruffbP , MayescLC , RomandSA , SosadJA , SnydePJ . An examination of the construct validity and factor structure of the Groton Maze Learning Test, a new measure of spatial working memory, learning efficiency, and error monitoring. Archives of Clinical Neuropsychology2008;23(4):433‐45. ">Pietrzak 2008</a>) (used in an ongoing study)<br/> The GMLT assesses processing speed, working memory, and aspects of executive function in healthy adults. Performance on GMLT outcome measures can be compared to performance on tests of psychomotor speed, working memory, and learning from the <a href="http://www.cogstate.com/" target="_blank">Cogstate computerized cognitive test battery</a>. Studies suggest that the GMLT measures of spatial learning efficiency and error monitoring correlate with Cogstate measures of attention, working memory, and learning. Exploratory factor analyses have yielded a two‐factor solution of error monitoring and learning efficiency, which have been stable across repeated assessments. </p> </section> </section> <section id="CD006918-sec-0104"> <h6 class="title">6.8 Of note</h6> <p><a href="./references#CD006918-bbs2-0002" title="BorisonR . Risperidone versus haloperidol versus placebo in the treatment of schizophrenia. Clinical report1991. ">Borison 1992</a>: In 1997 the first author and his colleague, Diamond, were convicted in the US courts (<a href="./references#CD006918-bbs2-0120" title="HassnerVS . Scientific fraud: Eric Poehlman / Richard Borison. Alliance for Human Research Protection (http://www.ahrp.org/cms/content/view/370/29/) 29 Oct 2006 (accessed 5 Nov 2009). ">AHRP 2006</a>; <a href="./references#CD006918-bbs2-0134" title="AugustaG . Drug money: Patients worsened; little oversight provided. CBS News (http://www.cbsnews.com/stories/2000/07/31/48hours/main220233.shtml) 31 Jul 2000 (accessed 5 November 2009). ">CBS News 2000CBS News 2000</a><a href="./references#CD006918-bbs2-0120" title="HassnerVS . Scientific fraud: Eric Poehlman / Richard Borison. Alliance for Human Research Protection (http://www.ahrp.org/cms/content/view/370/29/) 29 Oct 2006 (accessed 5 Nov 2009). ">AHRP 2006</a>). For example, one website states: “Diamond, a Ph.D. pharmacologist who had performed more than 300 trials over the course of his career on patients who assumed he was an M.D., was convicted in 1997 on 53 criminal counts, including practicing medicine without a license, theft, prescribing medications without a license, fraud, false statements, tax evasion and bribery. Although he admitted to a growing greed that led to some of his illegal practices, Diamond maintained that the pair had never fabricated research data.” We have continued to include data from this small study. </p> </section> </section> </section> <section id="CD006918-sec-0105"> <h4 class="title">Excluded studies</h4> <p>We excluded 86 studies, 7 of which were not randomised (<a href="./references#CD006918-bbs2-0045" title="DavidS , CrawfordAM , BreierA . Prolactin levels in olanzapine versus typical and atypical antipsychotics. European Neuropsychopharmacology1998;8(Suppl 2):s229. DavidSR , MeehanKM , SuttonVK , TaylorCC . Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents. European Neuropsychopharmacology1999;9:S292. DavidSR , TaylorCC , KinonBJ , BreierA . The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clinical Therapeutics2000;22(9):1085‐96. ">David 2000</a>; <a href="./references#CD006918-bbs2-0046" title="DavisJM , ChenN . Evidence of efficacy of risperidone in schizophrenia. Schizophrenia Research2001;49(1‐2):224‐5. DavisSM , KochGG , DavisCE , LaVangeLM . Statistical approaches to effectiveness measurement and outcome‐driven re‐randomizations in the clinical antipsychotic trials of intervention effectiveness (CATIE) studies. Schizophrenia Bulletin2003;29(1):73‐80. ">Davis 2001</a>; <a href="./references#CD006918-bbs2-0024" title="BakerRA , JinN , AliMW , ForbesRA , OffordSJ , CarsonWH , SanchezR , McQuadeRD , RahmanZ . Long‐term effects (up to 4 years) of aripiprazole on maintenance treatment for schizophrenia or schizoaffective disorder: A pooled open‐label extension of two clinical trials. Schizophrenia research2012;136:S154. ">Baker 2012</a>; <a href="./references#CD006918-bbs2-0034" title="CastleDJ , JensenJKS . Management of depressive symptoms in schizophrenia: A pooled, post hoc analysis from the asenapine development program. Clinical Schizophrenia and Related Psychoses2015;9:13‐20. ">Castle 2015</a>; <a href="./references#CD006918-bbs2-0059" title="KinonBJ , MillenBA , ZhangL , McKinzieDL . Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. Biological psychiatry2015;InPress:InPress. ">Kinon 2015</a>; <a href="./references#CD006918-bbs2-0068" title="MarderSR , ChouinardG , DavisJM . The clinical actions of risperidone. Proceedings of the 6th World Congress of Biological Psychiatry1997;Jun 22‐27:Nice, France. ">Marder 1991</a>; <a href="./references#CD006918-bbs2-0083" title="PikalovA , CucchiaroJ , OgasaM , SilvaR , HsuJ , XuJ , LoebelA . Effect of lurasidone on weight and metabolic parameters: A comprehensive database analysis. Schizophrenia research2012;136:S278. ">Pikalov 2012</a>). We excluded seven studies due to their populations not including people with schizophrenia (<a href="./references#CD006918-bbs2-0019" title="AnwunahIJ , MitropoulouV , BushnoeL , SieverLJ . Risperidone treatment for schizotypal personality disorder. Proceedings of the 51st Institute on Psychiatric Services; 1999 Oct 25‐Nov 2; New Orleans, Louisiana, USA. 1999. ">Anwunah 1999</a>; <a href="./references#CD006918-bbs2-0020" title="AydFJ . Risperidone treatment for schizotypal personality disorder. International Drug Therapy Newsletter2001;36(8):58. ">Ayd 2001</a>; <a href="./references#CD006918-bbs2-0074" title="NCT00088075 . A randomized, double‐blind, placebo‐controlled clinical study of the efficacy and safety of risperidone for the treatment of schizophrenia in adolescents. clinicaltrials.gov/ct2/show/NCT00088075 (2004) (accessed 9 October 2013). ">NCT00088075</a>; <a href="./references#CD006918-bbs2-0078" title="NCT00305474 . Identification and treatment of the liability to develop schizophrenia. clinicaltrials.gov/ct2/show/results/NCT00305474 (2006) (accessed 9 October 2013). ">NCT00305474</a>; <a href="./references#CD006918-bbs2-0089" title="SieverLJ , KoenigsbergHW , MitropoulouV , GoodmanM , BuchsbaumMS . Neurobiology and pharmacologic treatment of schizotypal personality: implications for pharmacology. Proceeding of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Siever 2002</a>; <a href="./references#CD006918-bbs2-0019" title="AnwunahIJ , MitropoulouV , BushnoeL , SieverLJ . Risperidone treatment for schizotypal personality disorder. Proceedings of the 51st Institute on Psychiatric Services; 1999 Oct 25‐Nov 2; New Orleans, Louisiana, USA. 1999. ">Anwunah 1999</a>; <a href="./references#CD006918-bbs2-0088" title="SchmechtigA , DourishC , CraigK , DawsonGR , WilliamsS , DeakinW , LeesJ , WilkinsonL , EttingerU . Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by high schizotypy. Pharmacopsychiatry2011;21:A99. ">Schmechtig 2010</a>). The remaining excluded studies did not directly compare oral risperidone with placebo. </p> <section id="CD006918-sec-0106"> <h5 class="title">Ongoing studies</h5> <p>We identified one ongoing study. <a href="./references#CD006918-bbs2-0116" title="NCT00174200 . A randomized, double‐blind, crossover add‐on study to assess the differential sensitivity of 2 spatial working memory tests (the groton maze learning test [gmlt] and the motor delayed response test [mdr]) in non‐agitated, antipsychotic drug‐naive first‐episode schizophrenic or schizophreniform patients treated with risperidone 2 mg daily or placebo. clinicaltrials.gov/show/NCT00174200 (2005). Date accessed: 9/10/2013. ">NCT00174200</a> is assessing the effects of risperidone (2 mg daily) on the differential sensitivity of two spatial working memory tests in non‐agitated, drug‐naive people suffering from first‐episode schizophrenia or schizophreniform disorder. They intend to enrol 20 patients for the trial. Pfizer is sponsoring the study. </p> </section> <section id="CD006918-sec-0107"> <h5 class="title">Awaiting assessment</h5> <p>Fourteen studies are awaiting assessment as sufficient information is not currently available (<a href="./references#CD006918-bbs2-0102" title="Anon . An assessment of the long‐term efficacy and safety of org 5222, risperidone and placebo in subjects with schizophrenia. http://www.clinicalstudyresults.org/(2010). ">Anon 2010</a>; <a href="./references#CD006918-bbs2-0107" title="LitmanR , SmithM , DohertyJ , CrossA , RainesS , ZukinS . AZD8529, a positive allosteric modulator at the MGGLUR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. European neuropsychopharmacology2014;24:S508‐S509. LitmanRE , SmithMA , DohertyJ , CrossA , RainesS , ZukinS . AZD8529, a positive allosteric modulator at the mGLuR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Schizophrenia research2014;153:S176. NCT00921804 . Study to assess the efficacy, safety, and tolerability of AZD8529 in adult schizophrenia patients. clinicaltrials.gov/show/NCT00921804(2009). ">Litman 2014</a>; <a href="./references#CD006918-bbs2-0108" title="DebelleM , Faradzs‐zadeS , SzatmariB , NagyK , NemethG , DurgamS , LaszlovszkyI . Cariprazine in negative symptoms of schizophrenia: Post hoc analyses of a fixed‐dose, placebo‐and active‐controlled trial. European neuropsychopharmacology2014;24:S534. ">NCT 00694707</a>; <a href="./references#CD006918-bbs2-0114" title="Nct02469155 . A Trial to Assess the Antipsychotic Efficacy of ITI‐007 Over 6 Weeks of Treatment. https://ClinicalTrials.gov/show/NCT024691552015. VanoverK , DavisRE , EreshefskyL , MatesS . Positive results with ITI‐007 for the treatment of schizophrenia: A randomized double‐blind placebo‐ and active‐controlled phase 2 study. Schizophrenia research2014;153:S278‐S279. VanoverKE , DavisRE , MatesS . ITI‐007 for the treatment of schizophrenia: A differentiating response profile. Biological psychiatry2014;1:325S. VanoverKE , DavisRE , MatesS . ITI‐007, a new approach to the treatment of schizophrenia. Schizophrenia research2014;153:S21. VanoverKE , MatesS , GreengardP , DavisRE . Phase 2 evaluation of ITI‐007, a novel approach to the treatment of schizophrenia. Neuropsychopharmacology2013;38:S386‐S387. ">Vanover 2014</a>; <a href="./references#CD006918-bbs2-0112" title="NisenbaumL , MillenB A , ZhaoF , DowningA , QuigleyA , KohlerJ , et al. LY 2140023 monohydrate in the treatment of patients with schizophrenia: Pharmacogenetic analysis within a clinical trial assessing efficacy in treating acutely ill patients. Schizophrenia Bulletin2013;39:S105. ">Nisenbaum 2013</a>; <a href="./references#CD006918-bbs2-0115" title="XuZ . LDXGW for schizophrenia. Stanley Foundation Research Programs2009. ">Xu 2009</a>; <a href="./references#CD006918-bbs2-0103" title="BoseA , LiD , MiglioreR , WernerP , NemethG , LaszlovskyI . The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia. European Psychiatry2011;26(1):1354. BoseA , LiD , MiglioreR , WernerP , NemethG , LaszlovszkyI . The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia. European Neuropsychopharmacology2010:493‐4. ">Bose 2010a</a>; <a href="./references#CD006918-bbs2-0104" title="CavazzoniP , BergP , MillikanM , CarlsonC , BeasleyC . An integrated analysis of treatment‐emergent extrapyramidal syndrome in schizophrenic patients during olanzapine clinical trials versus placebo, haloperidol, risperidone or clozapine. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S164. CavazzoniP , BergPH , MillikanM , CarlsonC , BeasleyCM . An integrated analysis of treatment‐emergent extrapyramidal syndrome in schizophrenic patients during olanzapine clinical trials versus placebo, haloperidol, risperidone or clozapine. Schizophrenia Research2002;53(3 Suppl 1):171. ">Cavazzoni 2002</a>; <a href="./references#CD006918-bbs2-0105" title="DeMartinisNA . Results of a phase 2a proof‐of‐concept trial with a pde10a inhibitor in the treatment of acute exacerbation of schizophrenia. Biological Psychiatry2012;8(Suppl 1):17S‐8S. ">DeMartinis 2012</a>; <a href="./references#CD006918-bbs2-0106" title="NCT00049946 . A multicenter, double‐blind, double‐dummy, placebo‐controlled, randomized, parallel group evaluation of the efficacy and safety of a fixed‐dose of talnetant versus placebo versus risperidone in subjects with schizophrenia. clinicaltrials.gov/show/NCT00049946(2002). NCT00103727 . A multicenter, double‐blind, double‐dummy, placebo‐controlled, randomized, parallel group evaluation of the efficacy and safety of a fixed‐dose of talnetant versus placebo versus risperidone in subjects with schizophrenia. clinicaltrials.gov/show/NCT00103727(2005). [NCT00103727] NCT00300963 . A multicenter, double‐blind, double‐dummy, placebo‐controlled, randomized, parallel group evaluation of the efficacy and safety of a fixed‐dose of talnetant versus placebo versus risperidone in subjects with schizophrenia. clinicaltrials.gov/show/NCT00300963(2006). [NCT00300963] ">GlaxoSmithKline 2006</a>; <a href="./references#CD006918-bbs2-0109" title="NCT01086748 . A study in schizophrenia patients. ClinicalTrials.gov/show/NCT01086748(2010). ">NCT01086748</a>; <a href="./references#CD006918-bbs2-0110" title="NCT01175135 . An inpatient study of the efficacy, safety, and tolerability of pf‐02545920 in the treatment of acute exacerbation of schizophrenia. ClinicalTrials.gov/show/NCT01175135(2010). ">NCT01175135</a>; <a href="./references#CD006918-bbs2-0111" title="NCT01363349 . Phase iib‐iii study of bl‐1020 small molecule for schizophrenia. ClinicalTrials.gov/show/NCT01363349(2011). ">NCT01363349</a>; <a href="./references#CD006918-bbs2-0113" title="RujescuD . Riluzole for schizophrenia. Stanley Foundation Research Programs2009. ">Rujescu 2009</a>). </p> </section> </section> </section> <section id="CD006918-sec-0108"> <h3 class="title">Risk of bias in included studies</h3> <p>Pharmaceutical companies funded 8 out of the 15 included trials. We did our best to collect as much information as possible from different sources about the types of biases that could have occurred during these trials, and have presented the results of our investigations in the following paragraphs. <a href="#CD006918-fig-0003">Figure 3</a> and <a href="#CD006918-fig-0004">Figure 4</a> presents the summary of risk of bias in included studies. </p> <div class="figure" id="CD006918-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006918-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD006918-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD006918-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD006918-sec-0109"> <h4 class="title">Allocation</h4> <p>All included studies were said to be randomised, but many did not explicitly describe the method by which this was undertaken. <a href="./references#CD006918-bbs2-0001" title="BachmannM , RamseyM , BuchananRW , ConleyRC , WeinerE . Clozapine treatment of schizophrenic patients. www.clinicaltrials.gov (accessed 9 October 2013). [NCT00056498] ">Bachmann 2003</a> utilised randomisation that was stratified by inpatient status; no further details were provided. <a href="./references#CD006918-bbs2-0008" title="HonerW . International study of improving treatment for the most severely ill with schizophrenia. www.clinicaltrials.gov (accessed 9 October 2013). [NCT00272584] ">Honer 2006</a> used a computer‐generated schedule with a permuted‐block design to generate sequences. <a href="./references#CD006918-bbs2-0009" title="EreshefskyL , AndersonC , TrueJ , SakladSR , ReisenmanC , ToneyG , et al. Plasma concentration of oral risperidone and active metabolite in schizophrenics. Pharmacotherapy1993;13(3):292. [LMD96402] LindenmayerJP , The Risperidone Study Group. Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia. 146th Annual Meeting of the American Psychiatric Association; 1993 May 22‐27; San Francisco, California, USA. 1993. [MEDLINE: 94350925] MarderS . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Clinical Research Report RIS‐INT‐31991. [MEDLINE: 1375802] MarderSR . Risperidone: clinical development: North American results. Clinical Neuropharmacology1992;15(Suppl 1 Pt A):92A‐3A. [MEDLINE: 92361850] MarderSR . Risperidone: efficacy. Journal of Clinical Psychiatry1994;12:49‐52. [MEDLINE: 94350925] MarderSR , DavisJM , ChouinardG . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychological Medicine [临床精神医学杂志]1997;58(12):538‐46. MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151(6):825‐35. [EMBASE 1994202181] McEvoyJP . Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry1994;55(5 Suppl):18‐21. [EMBASE 1994182002] MeibachR . Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. 1st International Risperidone Investigators' Meeting; 1992 Mar 9‐10; Paris, France. USA, 1992:28‐9. [LMD94893] MeibachRC , The Risperidone Study Group. A fixed dose, parallel group study of risperidone vs. haloperidol vs. placebo. Schizophrenia Research1993;9(2,3):245. [MEDLINE: 94350925] NCT00249132 . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. clinicaltrials.gov/show/NCT00249132(2005). SchoolerNR . Negative symptoms in schizophrenia: assessment of the effect of risperidone. Journal of Clinical Psychiatry1994;55(Suppl 5):22‐8. [MEDLINE: 94350925] SimpsonGM , LindenmayerJP . Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology1997;17(3):194‐201. [MEDLINE: 97313564; PsycINFO 1997‐06350‐009] ">Marder 1994a</a> and <a href="./references#CD006918-bbs2-0003" title="ChouinardG . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. [MEDLINE: 7537286] ChouinardG , AlbrightPS . Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology1997;17(4):298‐307. [MEDLINE: 9241010] ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. 1993:22. [MEDLINE: 94350925] ChouinardG , ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15(Suppl 1 Pt B):266. [MEDLINE: 94350925] ChouinardG , ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biological Psychiatry1992;31:158. [MEDLINE: 94350925] ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. [MEDLINE: 93253120] ChouinardG , VainerJL , BeauclairL . Dose regimens of neuroleptics in negative symptoms. 19th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1994 Jun 27‐Jul 1; Washington DC, USA1994;10(3 Suppl 1):S363. [MEDLINE: 94350925] ">Chouinard 1992</a> undertook randomisation in blocks of 12. <a href="./references#CD006918-bbs2-0006" title="GeffenY , AnandR , KeefeR , DavidsonM . Results of phase 2b eagle trial; a double blind placebo control study evaluating the efficacy and safety of bl‐1020, a gaba enhanced antipsychotic for the treatment of schizophrenia. Schizophrenia Research2010;117(2‐3):212. ">Geffen 2010</a> and <a href="./references#CD006918-bbs2-0013" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , McLemoreJ , GharabawiG . Atypical antipsychotics in patients with schizophrenia and comorbid substance abuse. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005:Nr279. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , et al. Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S503. NCT00061802 . A randomized, double blind study to evaluate the efficacy and safety of two atypical antipsychotics vs placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder. clinicaltrials.gov/show/NCT00061802(2003). PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. RupnowM , GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , GharabawiG , et al. Polypharmacy in schizophrenia: data from a randomized, double‐blind study. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005. StahlS , RupnowM , GreenspanA , Kosik‐GonzalezC , ZhuY , GharabawiG . Use and cost of polypharmacy in schizophrenia: data from a randomized, double‐blind study of risperidone and quetiapine. Neuropsychopharmacology2004;29(Suppl 1):S227. ">Potkin 2006</a> both used a centralised interactive voice response system for allocation concealment. Although <a href="./references#CD006918-bbs2-0015" title="AkdedeBB , Anil YacioluAE , AlptekinK , TurgutTI , TumukluM , YaziciMK , et al. A double‐blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Journal of Clinical Psychiatry2006;67(12):1912‐9. YagciogluAE , Kivircik AkdedeBB , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry2005;66(1):63‐72. ">Yagcioglu 2005</a> used a pre‐assigned random sequence for each of their study sites that was developed before the start of their study no further details were provided. The rest of the studies provided no information about the process of randomisation (<a href="./references#CD006918-bbs2-0002" title="BorisonR . Risperidone versus haloperidol versus placebo in the treatment of schizophrenia. Clinical report1991. ">Borison 1992</a>; <a href="./references#CD006918-bbs2-0004" title="DowningA M , KinonB J , MillenB A , ZhangL , LiuL , MorozovaM A , et al. A double‐blind, placebo‐controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry2014;14:351. ">Downing 2014</a>; <a href="./references#CD006918-bbs2-0005" title="DurgamS , StaraceA , LiD , MiglioreR , RuthA , NemethG , et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res2014;152:450‐7. ">Durgam 2014</a>; <a href="./references#CD006918-bbs2-0007" title="HeisterbergJ , BarbatoLM , YeungPP , ShapiraNA . Lipid profile among patients with schizophrenia randomized to bifeprunox, placebo, or risperidone: a comparison of results. Schizophrenia Bulletin2007;33(2):432‐3. YeungPP , BarbatoLM , HeisterbergJ , ShapiraNA . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Schizophrenia Bulletin2007;33(2):466‐7. YeungPP , ShapiraNA , HeisterbergJ . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28‐Apr 1, Colorado Springs, Colorado, USA. 2007. ">Heisterberg 2007</a>; <a href="./references#CD006918-bbs2-0010" title="BaiYM , YuSC , LinCC . Risperidone for severe tardive dyskinesia: a 12‐week randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64(11):1342‐8. PaiY‐M , YuS‐C , LinC‐C . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. PaiY‐M , YuS‐C , LinC‐C . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Pai 2002</a>; <a href="./references#CD006918-bbs2-0011" title="PotkinSG , GutierrezR . Safety and efficacy of once‐daily risperidone in the treatment of schizophrenia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17‐22; San Diego, California, USA. 1997. ">Potkin 1997</a>; <a href="./references#CD006918-bbs2-0012" title="PotkinSG , KujawaM , CarsonWH , SahaAR , AliM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2003;60(1):300. PotkinSG , SahaAR , KujawaMJ , CarsonWH , AliM , StockE , et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry2003;60(7):681‐90. SahaA , CarsonW , AliM , DunbarG , IngenitoG . Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001. YeungP , KujawaM , CarsonWH , SahaA , AlidM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2002;53(3 Suppl 1):185‐6. YeungP , McQuadeRD , CarsonWH , SahaA , AliMW , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia. European Psychiatry2002;17(Suppl 1):102s. YeungPP , CarsonWH , SahaA , McQuadeRD , AliM , StringfellowJC , et al. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: results of a placebo‐controlled trial with risperidone. European Neuropsychopharmacology2001;11(3):259. ">Potkin 2003</a>; <a href="./references#CD006918-bbs2-0014" title="PotkinS , FlemingK , BinnemanB , KellerDS , AlphsL , PanagidesJ . Asenapine improves cognitive function in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19‐24; San Diego, CA2007. PotkinS , FlemingK , BinnemanB , KellerS . Asenapine cognitive function effects in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Schizophrenia Bulletin2007;33(2):454. PotkinSG , CohenM , JinaAS , NettlerS , AlphsL , PanagidesJ . Asenapine efficacy during acute episodes of schizophrenia: a randomized placebo and risperidone controlled trial. Proceedings of the 44th American College of Neuropsychopharmacology; 2005 December 11‐15, Waikoloa, Hawaii2005. PotkinSG , CohenM , PanagidesJ . Efficacy and tolerability of asenapine in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Journal of Clinical Psychiatry2007;68(10):1492‐500. PotkinSG , CohenM , PanagidesJ , JinaA . Asenapine safety and tolerability in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. European Neuropsychopharmacology2006;16(Suppl 4):S401. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy in acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S275. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy, safety, and tolerability in the treatment of acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. Biological Psychiatry2006;59(8 Suppl):154S. ">Potkin 2007</a>; <a href="./references#CD006918-bbs2-0012" title="PotkinSG , KujawaM , CarsonWH , SahaAR , AliM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2003;60(1):300. PotkinSG , SahaAR , KujawaMJ , CarsonWH , AliM , StockE , et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry2003;60(7):681‐90. SahaA , CarsonW , AliM , DunbarG , IngenitoG . Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001. YeungP , KujawaM , CarsonWH , SahaA , AlidM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2002;53(3 Suppl 1):185‐6. YeungP , McQuadeRD , CarsonWH , SahaA , AliMW , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia. European Psychiatry2002;17(Suppl 1):102s. YeungPP , CarsonWH , SahaA , McQuadeRD , AliM , StringfellowJC , et al. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: results of a placebo‐controlled trial with risperidone. European Neuropsychopharmacology2001;11(3):259. ">Potkin 2003</a>; <a href="./references#CD006918-bbs2-0011" title="PotkinSG , GutierrezR . Safety and efficacy of once‐daily risperidone in the treatment of schizophrenia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17‐22; San Diego, California, USA. 1997. ">Potkin 1997</a>; <a href="./references#CD006918-bbs2-0010" title="BaiYM , YuSC , LinCC . Risperidone for severe tardive dyskinesia: a 12‐week randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64(11):1342‐8. PaiY‐M , YuS‐C , LinC‐C . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. PaiY‐M , YuS‐C , LinC‐C . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Pai 2002</a>; <a href="./references#CD006918-bbs2-0007" title="HeisterbergJ , BarbatoLM , YeungPP , ShapiraNA . Lipid profile among patients with schizophrenia randomized to bifeprunox, placebo, or risperidone: a comparison of results. Schizophrenia Bulletin2007;33(2):432‐3. YeungPP , BarbatoLM , HeisterbergJ , ShapiraNA . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Schizophrenia Bulletin2007;33(2):466‐7. YeungPP , ShapiraNA , HeisterbergJ . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28‐Apr 1, Colorado Springs, Colorado, USA. 2007. ">Heisterberg 2007</a>; <a href="./references#CD006918-bbs2-0002" title="BorisonR . Risperidone versus haloperidol versus placebo in the treatment of schizophrenia. Clinical report1991. ">Borison 1992</a>), despite this having been repeatedly shown to be of key importance in excluding selection biases (<a href="./references#CD006918-bbs2-0158" title="JuniP , AltmanDG , EggerM . Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ2001;323:42‐6. ">Juni 2001</a>). </p> </section> <section id="CD006918-sec-0110"> <h4 class="title">Blinding</h4> <p>All the included studies were described as double blind, with some describing how this was achieved. Blinding is important for minimising observation bias and, because many of the outcomes were subjective. </p> </section> <section id="CD006918-sec-0111"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD006918-bbs2-0001" title="BachmannM , RamseyM , BuchananRW , ConleyRC , WeinerE . Clozapine treatment of schizophrenic patients. www.clinicaltrials.gov (accessed 9 October 2013). [NCT00056498] ">Bachmann 2003</a>, <a href="./references#CD006918-bbs2-0004" title="DowningA M , KinonB J , MillenB A , ZhangL , LiuL , MorozovaM A , et al. A double‐blind, placebo‐controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry2014;14:351. ">Downing 2014</a>, <a href="./references#CD006918-bbs2-0005" title="DurgamS , StaraceA , LiD , MiglioreR , RuthA , NemethG , et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res2014;152:450‐7. ">Durgam 2014</a>, <a href="./references#CD006918-bbs2-0006" title="GeffenY , AnandR , KeefeR , DavidsonM . Results of phase 2b eagle trial; a double blind placebo control study evaluating the efficacy and safety of bl‐1020, a gaba enhanced antipsychotic for the treatment of schizophrenia. Schizophrenia Research2010;117(2‐3):212. ">Geffen 2010</a>, <a href="./references#CD006918-bbs2-0007" title="HeisterbergJ , BarbatoLM , YeungPP , ShapiraNA . Lipid profile among patients with schizophrenia randomized to bifeprunox, placebo, or risperidone: a comparison of results. Schizophrenia Bulletin2007;33(2):432‐3. YeungPP , BarbatoLM , HeisterbergJ , ShapiraNA . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Schizophrenia Bulletin2007;33(2):466‐7. YeungPP , ShapiraNA , HeisterbergJ . Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28‐Apr 1, Colorado Springs, Colorado, USA. 2007. ">Heisterberg 2007</a>, <a href="./references#CD006918-bbs2-0009" title="EreshefskyL , AndersonC , TrueJ , SakladSR , ReisenmanC , ToneyG , et al. Plasma concentration of oral risperidone and active metabolite in schizophrenics. Pharmacotherapy1993;13(3):292. [LMD96402] LindenmayerJP , The Risperidone Study Group. Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia. 146th Annual Meeting of the American Psychiatric Association; 1993 May 22‐27; San Francisco, California, USA. 1993. [MEDLINE: 94350925] MarderS . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Clinical Research Report RIS‐INT‐31991. [MEDLINE: 1375802] MarderSR . Risperidone: clinical development: North American results. Clinical Neuropharmacology1992;15(Suppl 1 Pt A):92A‐3A. [MEDLINE: 92361850] MarderSR . Risperidone: efficacy. Journal of Clinical Psychiatry1994;12:49‐52. [MEDLINE: 94350925] MarderSR , DavisJM , ChouinardG . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychological Medicine [临床精神医学杂志]1997;58(12):538‐46. MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151(6):825‐35. [EMBASE 1994202181] McEvoyJP . Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry1994;55(5 Suppl):18‐21. [EMBASE 1994182002] MeibachR . Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. 1st International Risperidone Investigators' Meeting; 1992 Mar 9‐10; Paris, France. USA, 1992:28‐9. [LMD94893] MeibachRC , The Risperidone Study Group. A fixed dose, parallel group study of risperidone vs. haloperidol vs. placebo. Schizophrenia Research1993;9(2,3):245. [MEDLINE: 94350925] NCT00249132 . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. clinicaltrials.gov/show/NCT00249132(2005). SchoolerNR . Negative symptoms in schizophrenia: assessment of the effect of risperidone. Journal of Clinical Psychiatry1994;55(Suppl 5):22‐8. [MEDLINE: 94350925] SimpsonGM , LindenmayerJP . Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology1997;17(3):194‐201. [MEDLINE: 97313564; PsycINFO 1997‐06350‐009] ">Marder 1994a</a>, <a href="./references#CD006918-bbs2-0003" title="ChouinardG . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. [MEDLINE: 7537286] ChouinardG , AlbrightPS . Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology1997;17(4):298‐307. [MEDLINE: 9241010] ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. 1993:22. [MEDLINE: 94350925] ChouinardG , ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15(Suppl 1 Pt B):266. [MEDLINE: 94350925] ChouinardG , ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biological Psychiatry1992;31:158. [MEDLINE: 94350925] ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. [MEDLINE: 93253120] ChouinardG , VainerJL , BeauclairL . Dose regimens of neuroleptics in negative symptoms. 19th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1994 Jun 27‐Jul 1; Washington DC, USA1994;10(3 Suppl 1):S363. [MEDLINE: 94350925] ">Chouinard 1992</a>, and <a href="./references#CD006918-bbs2-0013" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , McLemoreJ , GharabawiG . Atypical antipsychotics in patients with schizophrenia and comorbid substance abuse. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005:Nr279. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , et al. Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S503. NCT00061802 . A randomized, double blind study to evaluate the efficacy and safety of two atypical antipsychotics vs placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder. clinicaltrials.gov/show/NCT00061802(2003). PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. RupnowM , GreenspanA , Kosik‐GonzalezC , BossieC , ZhuY , GharabawiG , et al. Polypharmacy in schizophrenia: data from a randomized, double‐blind study. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta, Georgia, USA. 2005. StahlS , RupnowM , GreenspanA , Kosik‐GonzalezC , ZhuY , GharabawiG . Use and cost of polypharmacy in schizophrenia: data from a randomized, double‐blind study of risperidone and quetiapine. Neuropsychopharmacology2004;29(Suppl 1):S227. ">Potkin 2006</a> used an intention‐to‐treat (ITT) analysis. <a href="./references#CD006918-bbs2-0008" title="HonerW . International study of improving treatment for the most severely ill with schizophrenia. www.clinicaltrials.gov (accessed 9 October 2013). [NCT00272584] ">Honer 2006</a>, <a href="./references#CD006918-bbs2-0015" title="AkdedeBB , Anil YacioluAE , AlptekinK , TurgutTI , TumukluM , YaziciMK , et al. A double‐blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Journal of Clinical Psychiatry2006;67(12):1912‐9. YagciogluAE , Kivircik AkdedeBB , TurgutTI , TumukluM , YaziciMK , AlptekinK , et al. A double‐blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry2005;66(1):63‐72. ">Yagcioglu 2005</a> and <a href="./references#CD006918-bbs2-0005" title="DurgamS , StaraceA , LiD , MiglioreR , RuthA , NemethG , et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res2014;152:450‐7. ">Durgam 2014</a> used the ITT principle in a mixed‐model analysis. <a href="./references#CD006918-bbs2-0014" title="PotkinS , FlemingK , BinnemanB , KellerDS , AlphsL , PanagidesJ . Asenapine improves cognitive function in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19‐24; San Diego, CA2007. PotkinS , FlemingK , BinnemanB , KellerS . Asenapine cognitive function effects in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Schizophrenia Bulletin2007;33(2):454. PotkinSG , CohenM , JinaAS , NettlerS , AlphsL , PanagidesJ . Asenapine efficacy during acute episodes of schizophrenia: a randomized placebo and risperidone controlled trial. Proceedings of the 44th American College of Neuropsychopharmacology; 2005 December 11‐15, Waikoloa, Hawaii2005. PotkinSG , CohenM , PanagidesJ . Efficacy and tolerability of asenapine in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. Journal of Clinical Psychiatry2007;68(10):1492‐500. PotkinSG , CohenM , PanagidesJ , JinaA . Asenapine safety and tolerability in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. European Neuropsychopharmacology2006;16(Suppl 4):S401. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy in acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S275. PotkinSG , CohenM , PanagidesJ , JinaAS . Asenapine efficacy, safety, and tolerability in the treatment of acute schizophrenia: a randomized, placebo‐ and risperidone‐controlled trial. Biological Psychiatry2006;59(8 Suppl):154S. ">Potkin 2007</a> used ITT for the efficacy data and last observation carried forward (LOCF) for safety data. </p> <p>We judged <a href="./references#CD006918-bbs2-0010" title="BaiYM , YuSC , LinCC . Risperidone for severe tardive dyskinesia: a 12‐week randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64(11):1342‐8. PaiY‐M , YuS‐C , LinC‐C . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. PaiY‐M , YuS‐C , LinC‐C . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Pai 2002</a> and <a href="./references#CD006918-bbs2-0002" title="BorisonR . Risperidone versus haloperidol versus placebo in the treatment of schizophrenia. Clinical report1991. ">Borison 1992</a> to have a high risk of bias, as they did not consider in their analysis the data of participants who left early. We judged <a href="./references#CD006918-bbs2-0011" title="PotkinSG , GutierrezR . Safety and efficacy of once‐daily risperidone in the treatment of schizophrenia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17‐22; San Diego, California, USA. 1997. ">Potkin 1997</a> to be at unclear risk of bias, as no information about loss to follow‐up was provided. <a href="./references#CD006918-bbs2-0012" title="PotkinSG , KujawaM , CarsonWH , SahaAR , AliM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2003;60(1):300. PotkinSG , SahaAR , KujawaMJ , CarsonWH , AliM , StockE , et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry2003;60(7):681‐90. SahaA , CarsonW , AliM , DunbarG , IngenitoG . Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001. YeungP , KujawaM , CarsonWH , SahaA , AlidM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2002;53(3 Suppl 1):185‐6. YeungP , McQuadeRD , CarsonWH , SahaA , AliMW , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia. European Psychiatry2002;17(Suppl 1):102s. YeungPP , CarsonWH , SahaA , McQuadeRD , AliM , StringfellowJC , et al. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: results of a placebo‐controlled trial with risperidone. European Neuropsychopharmacology2001;11(3):259. ">Potkin 2003</a> used the LOCF method to manage their loss to follow‐up, but as they had over 40% loss, we downgraded this category because such a high attrition rate makes data prone to bias. None of the trials attempted to validate assumptions by following up participants who did leave early. </p> </section> <section id="CD006918-sec-0112"> <h4 class="title">Selective reporting</h4> <p>We were unable to obtain original study protocol, however, the included studies appear to have reported the results for all the outcomes listed in their methods sections. Based on the information available, we did not detect any obvious act of selective reporting. </p> </section> <section id="CD006918-sec-0113"> <h4 class="title">Other potential sources of bias</h4> <section id="CD006918-sec-0114"> <h5 class="title">1. Poor reporting</h5> <p>We could not use much data because of poor reporting. Findings that are presented as graphs, in percentiles, or simply reported as inexact P values were of little use to us as review authors. Many studies failed to provide standard deviations (SDs) when reporting mean changes. We are seeking further data from the first authors of relevant trials. </p> </section> <section id="CD006918-sec-0115"> <h5 class="title">2. Industry</h5> <p>Pharmaceutical companies funded 8 out of the 13 included trials, with the majority of these funded by a company that would profit from finding beneficial effects of risperidone. </p> </section> </section> </section> <section id="CD006918-sec-0116"> <h3 class="title" id="CD006918-sec-0116">Effects of interventions</h3> <p>See: <a href="./full#CD006918-tbl-0001"><b>Summary of findings for the main comparison</b> RISPERIDONE compared to PLACEBO for schizophrenia</a>; <a href="./full#CD006918-tbl-0002"><b>Summary of findings 2</b> RISPERIDONE + CLOZAPINE compared to PLACEBO + CLOZAPINE for schizophrenia</a> </p> <p>Studies relevant to this review fall into three comparisons. We identified 15 randomised trials from which it is possible to extract numerical data. </p> <section id="CD006918-sec-0117"> <h4 class="title">1. COMPARISON 1: RISPERIDONE versus PLACEBO</h4> <p>This comparison has 20 outcomes.</p> </section> <section id="CD006918-sec-0118"> <h4 class="title">1.1 Mental state: no clinically significant response in psychotic symptoms (defined by various scale total score change) ‐ short term (up to 12 weeks) </h4> <section id="CD006918-sec-0119"> <h5 class="title">1.1.1 defined by PANSS &lt; 30% decline</h5> <p>Three trials with a total of 707 participants provided data for this subset . We did find evidence that 'risperidone' was clearly different in its effects compared with 'placebo' (RR 0.74, 95% CI 0.67 to 0.83) (<a href="./references#CD006918-fig-0005" title="">Analysis 1.1</a>). </p> </section> <section id="CD006918-sec-0120"> <h5 class="title">1.1.2 defined by PANSS/BPRS &lt; 20% decline</h5> <p>Six trials with a total of 864 participants provided data for this subset. We did find evidence that 'risperidone' was clearly different in its effects compared with 'placebo' (RR 0.64, 95% CI 0.52 to 0.78). This subgroup had important levels of heterogeneity (Chi<sup>2</sup> = 12.27; df = 5.0; P = 0.03; I<sup>2</sup> = 59%) (<a href="./references#CD006918-fig-0005" title="">Analysis 1.1</a>). </p> </section> </section> <section id="CD006918-sec-0121"> <h4 class="title">1.2 Leaving the study early ‐ short term (up to 12 weeks)</h4> <section id="CD006918-sec-0122"> <h5 class="title">1.2.1 any reason</h5> <p>There were 12 relevant trials, with a total of 2261 participants providing data for numbers leaving the study early for any reason. We did find evidence that 'risperidone' was clearly different in its effects compared with 'placebo' (RR 0.69, 95% CI 0.62 to 0.78). There are moderate levels of heterogeneity (Chi<sup>2</sup> = 14.73; df = 11; P = 0.20; I<sup>2</sup> = 25%) (<a href="./references#CD006918-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD006918-sec-0123"> <h5 class="title">1.2.2 due to adverse events</h5> <p>There were 10 relevant trials, with a total of 2081 participants, providing data for this subset. There was not a clear difference between 'risperidone' and 'placebo' (RR 0.78, 95% CI 0.59 to 1.03) (<a href="./references#CD006918-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD006918-sec-0124"> <h5 class="title">1.2.3 due to lack of efficacy</h5> <p>Eleven trials, with a total of 2211 participants provided data for this subset We found evidence of a clear difference between 'risperidone' and 'placebo' (RR 0.39, 95% CI 0.29 to 0.51). There are moderate levels of heterogeneity (Chi<sup>2</sup> = 14.70; df = 10; P = 0.14; I<sup>2</sup> = 32%) (<a href="./references#CD006918-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD006918-sec-0125"> <h5 class="title">1.2.4 due to non‐compliance</h5> <p>We found 4 trials to be relevant to this subset, with a total of 534 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.15, 95% CI 0.33 to 4.05) (<a href="./references#CD006918-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD006918-sec-0126"> <h5 class="title">1.2.5 lost to follow‐up</h5> <p>We found 6 trials to be relevant to this subset, with a total of 1545 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 0.79, 95% CI 0.25 to 2.56). This subset had important levels of heterogeneity (Chi<sup>2</sup> = 11.97; df = 4.0; P = 0.02; I<sup>2</sup> = 67%) (<a href="./references#CD006918-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD006918-sec-0127"> <h5 class="title">1.2.6 protocol violation</h5> <p>We found 4 trials to be relevant to this subset, with a total of 1257 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 0.79, 95% CI 0.39 to 1.62) (<a href="./references#CD006918-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD006918-sec-0128"> <h5 class="title">1.2.7 reported death</h5> <p>There were 10 relevant trials in this subset, with a total of 1532 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 3.07, 95% CI 0.13 to 74.28) (<a href="./references#CD006918-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD006918-sec-0129"> <h5 class="title">1.2.8 withdrawal of consent</h5> <p>We found 7 trials to be relevant to this subset, with a total of 1589 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 1.12, 95% CI 0.80 to 1.56) (<a href="./references#CD006918-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD006918-sec-0130"> <h5 class="title">1.2.9 other</h5> <p>There were 3 relevant trials in this subset, with a total of 615 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.03, 95% CI 0.68 to 1.57) (<a href="./references#CD006918-fig-0006" title="">Analysis 1.2</a>). </p> </section> </section> <section id="CD006918-sec-0131"> <h4 class="title">1.3 Global state: 1. average endpoint scores of CGI severity scale (high = poor) ‐ short term (up to 12 weeks) </h4> <p>We identified 3 studies relevant to this outcome, with a total of 457 participants. This outcome had no subsets. We found evidence of a clear difference between 'risperidone' and 'placebo' (MD ‐0.81, 95% CI ‐0.89 to ‐0.73) (<a href="./references#CD006918-fig-0007" title="">Analysis 1.3</a>). </p> </section> <section id="CD006918-sec-0132"> <h4 class="title">1.4 Global state: 2. no significant clinical improvement ‐ short term (up to 12 weeks)</h4> <p>For this outcome we found 4 relevant studies involving 594 participants. There were no subsets in this outcome. We found evidence of a clear difference between 'risperidone' and 'placebo' (RR 0.69, 95% CI 0.57 to 0.83). For this outcome heterogeneity was moderately high (Chi<sup>2</sup> = 5.43; df = 3.0; P = 0.14; I<sup>2</sup> = 44%) (<a href="./references#CD006918-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD006918-sec-0133"> <h4 class="title">1.5 Global state: 3. needing additional medication ‐ short term (up to 12 weeks)</h4> <p>For this outcome we found six relevant studies, the data from which we divided into seven subsets. </p> <section id="CD006918-sec-0134"> <h5 class="title">1.5.1 benzodiazepine</h5> <p>There was a single trial in this subset, with a total of 42 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 0.96, 95% CI 0.77 to 1.2) (<a href="./references#CD006918-fig-0009" title="">Analysis 1.5</a>). </p> </section> <section id="CD006918-sec-0135"> <h5 class="title">1.5.2 benzodiazepine derivatives ‐ lorazepam</h5> <p>There were 2 relevant trials in this subset, with a total of 228 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 0.93, 95% CI 0.68 to 1.27) (<a href="./references#CD006918-fig-0009" title="">Analysis 1.5</a>). </p> </section> <section id="CD006918-sec-0136"> <h5 class="title">1.5.3 benzodiazepine derivatives ‐ Nitrazepam</h5> <p>There was a single trial in this subset, with a total of 184 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 0.51, 95% CI 0.10 to 2.72) (<a href="./references#CD006918-fig-0009" title="">Analysis 1.5</a>). </p> </section> <section id="CD006918-sec-0137"> <h5 class="title">1.5.4 benzodiazepine related drugs ‐ Zolpidem</h5> <p>We found 1 trial to be relevant to this subset, with a total of 184 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 0.81, 95% CI 0.53 to 1.23) (<a href="./references#CD006918-fig-0009" title="">Analysis 1.5</a>). </p> </section> <section id="CD006918-sec-0138"> <h5 class="title">1.5.5 sedative/hypnotic</h5> <p>We found 2 trials to be relevant to this subset, with a total of 230 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 0.86, 95% CI 0.69 to 1.06) (<a href="./references#CD006918-fig-0009" title="">Analysis 1.5</a>). </p> </section> <section id="CD006918-sec-0139"> <h5 class="title">1.5.6 antiparkinsonian</h5> <p>There were 2 relevant trials in this subset, with a total of 172 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 1.21, 95% CI 0.79 to 1.86) (<a href="./references#CD006918-fig-0009" title="">Analysis 1.5</a>). </p> </section> <section id="CD006918-sec-0140"> <h5 class="title">1.5.7 psychotropics</h5> <p>We found 1 trial to be relevant to this subset, with a total of 186 participants. We found evidence of a clear difference between 'risperidone' and 'placebo' within this subset (RR 0.62, 95% CI 0.45 to 0.85) (<a href="./references#CD006918-fig-0009" title="">Analysis 1.5</a>). </p> </section> </section> <section id="CD006918-sec-0141"> <h4 class="title">1.6 Mental state: 1. average endpoint scores on various scales on psychotic symptoms (high = poor) ‐ short term (up to 12 weeks) </h4> <p>We identified three studies relevant to this outcome, the data from which we divided into five subsets. </p> <section id="CD006918-sec-0142"> <h5 class="title">1.6.1 BPRS total</h5> <p>We found 2 trials to be relevant to this subset, with a total of 171 participants. We found evidence of a clear difference between 'risperidone' and 'placebo' within this subset (MD ‐12.69, 95% CI ‐17.06 to ‐8.32) (<a href="./references#CD006918-fig-0010" title="">Analysis 1.6</a>). </p> </section> <section id="CD006918-sec-0143"> <h5 class="title">1.6.2 PANSS total</h5> <p>We found 3 trials to be relevant to this subset, with a total of 457 participants. For this outcome, within this subset, we did find evidence that 'risperidone' was clearly different in its effects compared with 'placebo' (MD ‐17.81, 95% CI ‐18.17 to ‐17.45) (<a href="./references#CD006918-fig-0010" title="">Analysis 1.6</a>). </p> </section> <section id="CD006918-sec-0144"> <h5 class="title">1.6.3 PANSS general pathology</h5> <p>There was a single trial in this subset, with a total of 44 participants. For this outcome, within this subset, we did find evidence that 'risperidone' was clearly different in its effects compared with 'placebo' (MD ‐13.20, 95% CI ‐20.15 to ‐6.25) (<a href="./references#CD006918-fig-0010" title="">Analysis 1.6</a>). </p> </section> <section id="CD006918-sec-0145"> <h5 class="title">1.6.4 PANSS negative symptom</h5> <p>There were 3 relevant trials in this subset, with a total of 457 participants. We found evidence of a clear difference between 'risperidone' and 'placebo' within this subset (MD ‐3.10, 95% CI ‐3.19 to ‐3.01) (<a href="./references#CD006918-fig-0010" title="">Analysis 1.6</a>). </p> </section> <section id="CD006918-sec-0146"> <h5 class="title">1.6.5 PANSS positive symptom</h5> <p>We found 3 trials to be relevant to this subset, with a total of 457 participants. For this outcome, within this subset, we did find evidence that 'risperidone' was clearly different in its effects compared with 'placebo' (MD ‐5.49, 95% CI ‐6.18 to ‐4.80) (<a href="./references#CD006918-fig-0010" title="">Analysis 1.6</a>). </p> </section> </section> <section id="CD006918-sec-0147"> <h4 class="title">1.7 Mental state: 2. skewed data ‐ short term (up to 12 weeks)</h4> <p>These continuous data, from two trials were skewed. Therefore we have reported these data in a separate data table (<a href="./references#CD006918-fig-0011" title="">Analysis 1.7</a>) . </p> </section> <section id="CD006918-sec-0148"> <h4 class="title">1.8 Adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term (up to 12 weeks)</h4> <p>We identified 11 studies relevant to this outcome, the data from which we divided into 12 subsets. </p> <section id="CD006918-sec-0149"> <h5 class="title">1.8.1 general ‐ any significant extrapyramidal symptom</h5> <p>We found 7 trials to be relevant to this subset, with a total of 1511 participants. We found evidence of a clear difference between 'risperidone' and 'placebo' within this subset (RR 1.56, 95% CI 1.13 to 2.15) (<a href="./references#CD006918-fig-0012" title="">Analysis 1.8</a>). </p> </section> <section id="CD006918-sec-0150"> <h5 class="title">1.8.2 general ‐ no improvement on AIMS score</h5> <p>There was a single trial in this subset, with a total of 42 participants. We found evidence of a clear difference between 'risperidone' and 'placebo' within this subset (RR 0.30, 95% CI 0.15 to 0.61) (<a href="./references#CD006918-fig-0012" title="">Analysis 1.8</a>). </p> </section> <section id="CD006918-sec-0151"> <h5 class="title">1.8.3 general ‐ no improvement on BAS score</h5> <p>There was a single trial in this subset, with a total of 226 participants. For this outcome, within this subset, we did find evidence that 'risperidone' was clearly different in its effects compared with 'placebo' (RR 1.14, 95% CI 1.01 to 1.28) (<a href="./references#CD006918-fig-0012" title="">Analysis 1.8</a>). </p> </section> <section id="CD006918-sec-0152"> <h5 class="title">1.8.4 general ‐ needing medication for EPS</h5> <p>We found 2 trials to be relevant to this subset, with a total of 94 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.14, 95% CI 0.78 to 1.67) (<a href="./references#CD006918-fig-0012" title="">Analysis 1.8</a>). </p> </section> <section id="CD006918-sec-0153"> <h5 class="title">1.8.5 specific ‐ akathisia</h5> <p>We found 5 trials to be relevant to this subset, with a total of 1204 participants. We found evidence of a clear difference between 'risperidone' and 'placebo' within this subset (RR 2.58, 95% CI 1.41 to 4.72). For this subset heterogeneity was moderately high (Chi<sup>2</sup> = 5.63; df = 4.0; P = 0.23; I<sup>2</sup> = 29%). (<a href="./references#CD006918-fig-0012" title="">Analysis 1.8</a>). </p> </section> <section id="CD006918-sec-0154"> <h5 class="title">1.8.6 specific ‐ bradykinesia</h5> <p>We found 2 trials to be relevant to this subset, with a total of 485 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 0.87, 95% CI 0.6 to 1.24) (<a href="./references#CD006918-fig-0012" title="">Analysis 1.8</a>). </p> </section> <section id="CD006918-sec-0155"> <h5 class="title">1.8.7 specific ‐ dyskinesia</h5> <p>We found 1 trial to be relevant to this subset, with a total of 303 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 0.32, 95% CI 0.01 to 7.86) (<a href="./references#CD006918-fig-0012" title="">Analysis 1.8</a>). </p> </section> <section id="CD006918-sec-0156"> <h5 class="title">1.8.8 specific ‐ dystonia</h5> <p>There were 3 relevant trials in this subset, with a total of 687 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 3.40, 95% CI 0.26 to 44.46). This subset had important levels of heterogeneity (Chi<sup>2</sup> = 13.09; df = 2.0; P = 0.001; I<sup>2</sup> = 84%) (<a href="./references#CD006918-fig-0012" title="">Analysis 1.8</a>). </p> </section> <section id="CD006918-sec-0157"> <h5 class="title">1.8.9 specific ‐ hypertonia</h5> <p>There were 3 relevant trials in this subset, with a total of 505 participants. We found evidence of a clear difference between 'risperidone' and 'placebo' within this subset (RR 2.98, 95% CI 1.35 to 6.59). For this subset heterogeneity was moderately high (Chi<sup>2</sup> = 2.87; df = 2.0; P = 0.24; I<sup>2</sup> = 30%) (<a href="./references#CD006918-fig-0012" title="">Analysis 1.8</a>). </p> </section> <section id="CD006918-sec-0158"> <h5 class="title">1.8.10 specific ‐ parkinsonism</h5> <p>We found 2 trials to be relevant to this subset, with a total of 485 participants. We found evidence of a clear difference between 'risperidone' and 'placebo' within this subset (RR 7.64, 95% CI 1.4 to 41.59) (<a href="./references#CD006918-fig-0012" title="">Analysis 1.8</a>). </p> </section> <section id="CD006918-sec-0159"> <h5 class="title">1.8.11 specific ‐ tardive dyskinesia</h5> <p>There was a single trial in this subset, with a total of 303 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 6.77, 95% CI 0.35 to 130.03) (<a href="./references#CD006918-fig-0012" title="">Analysis 1.8</a>). </p> </section> <section id="CD006918-sec-0160"> <h5 class="title">1.8.12 specific ‐ tremor</h5> <p>We found 5 trials to be relevant to this subset, with a total of 1204 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 1.60, 95% CI 0.89 to 2.88). This subset had moderate levels of heterogeneity (Chi<sup>2</sup> = 5.86; df = 4.0; P = 0.21; I<sup>2</sup> = 32%) (<a href="./references#CD006918-fig-0012" title="">Analysis 1.8</a>). </p> </section> </section> <section id="CD006918-sec-0161"> <h4 class="title">1.9 Adverse effects: 1b. extrapyramidal ‐ AIMS average endpoint score ‐ short term (up to 12 weeks) </h4> <p>For this outcome we found a single study. A greater reduction in AIMS scores were seen for people in the risperidone arm compared to the placebo arm (1 RCT, N=42, MD ‐5.50 95% CI ‐8.60 to ‐2.40) (<a href="./references#CD006918-fig-0013" title="">Analysis 1.9</a>). </p> </section> <section id="CD006918-sec-0162"> <h4 class="title">1.10 Adverse effects: 1c. extrapyramidal ‐ skewed data (various scales) ‐ short term (up to 12 weeks) </h4> <p>These continuous data (four RCTs) had such large SDs as to suggest that analysis within RevMan would be inadvisable. Therefore, we have reported these data in a separate table (<a href="./references#CD006918-fig-0014" title="">Analysis 1.10</a>). </p> </section> <section id="CD006918-sec-0163"> <h4 class="title">1.11 Adverse effects: 2. any adverse event ‐ short term (up to 12 weeks)</h4> <p>For this outcome we found 9 relevant studies and categorised data into 16 subsets.</p> <section id="CD006918-sec-0164"> <h5 class="title">1.11.1 any adverse event</h5> <p>There were 7 relevant trials in this subset, with a total of 1610 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.05, 95% CI 0.96 to 1.15). This subset had important levels of heterogeneity (Chi<sup>2</sup> = 14.46; df = 6.0; P = 0.02; I<sup>2</sup> = 58%) (<a href="./references#CD006918-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD006918-sec-0165"> <h5 class="title">1.11.2 asthenia</h5> <p>There were 2 trials in this subset, with a total of 639 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.93, 95% CI 0.62 to 6.02) (<a href="./references#CD006918-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD006918-sec-0166"> <h5 class="title">1.11.3 back pain</h5> <p>There was a single trial in this subset, with a total of 202 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.04, 95% CI 0.38 to 2.86) (<a href="./references#CD006918-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD006918-sec-0167"> <h5 class="title">1.11.4 blurred vision</h5> <p>There was a single trial in this subset, with a total of 202 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 4.16, 95% CI 0.47 to 36.59) (<a href="./references#CD006918-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD006918-sec-0168"> <h5 class="title">1.11.5 cogwheel rigidity</h5> <p>We found 1 trial to be relevant to this subset, with a total of 226 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 5.25, 95% CI 0.69 to 39.88) (<a href="./references#CD006918-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD006918-sec-0169"> <h5 class="title">1.11.6 death</h5> <p>We found 1 trial to be relevant to this subset, with a total of 182 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 3.13, 95% CI 0.13 to 75.92) (<a href="./references#CD006918-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD006918-sec-0170"> <h5 class="title">1.11.7 dental disorder</h5> <p>There was a single trial in this subset, with a total of 202 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 3.64, 95% CI 0.78 to 17.11) (<a href="./references#CD006918-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD006918-sec-0171"> <h5 class="title">1.11.8 dysmenorrhoea</h5> <p>There were two trials in this subset, with a total of 495 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 1.10, 95% CI 0.04 to 30.00) (<a href="./references#CD006918-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD006918-sec-0172"> <h5 class="title">1.11.9 fatigue</h5> <p>There were two trial in this subset, with a total of 558 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 2.23, 95% CI 0.69 to 7.22) (<a href="./references#CD006918-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD006918-sec-0173"> <h5 class="title">1.11.10 fever</h5> <p>We found 1 trial to be relevant to this subset, with a total of 130 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 9.28, 95% CI 0.51 to 168.9) (<a href="./references#CD006918-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD006918-sec-0174"> <h5 class="title">1.11.11 infection</h5> <p>We found 1 trial to be relevant to this subset, with a total of 202 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 0.52, 95% CI 0.10 to 2.78) (<a href="./references#CD006918-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD006918-sec-0175"> <h5 class="title">1.11.12 salivation ‐ increased</h5> <p>There was a single trial in this subset, with a total of 202 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 7.28, 95% CI 0.38 to 139.15) (<a href="./references#CD006918-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD006918-sec-0176"> <h5 class="title">1.11.13 pyrexia</h5> <p>We found 1 trial to be relevant to this subset, with a total of 182 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.19, 95% CI 0.45 to 3.16) (<a href="./references#CD006918-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD006918-sec-0177"> <h5 class="title">1.11.14 pain</h5> <p>There was a single trial in this subset, with a total of 121 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 1.58, 95% CI 0.47 to 5.31) (<a href="./references#CD006918-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD006918-sec-0178"> <h5 class="title">1.11.15 rash (skin)</h5> <p>There was a single trial in this subset, with a total of 202 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 1.19, 95% CI 0.45 to 3.16) (<a href="./references#CD006918-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD006918-sec-0179"> <h5 class="title">1.11.16 vaginitis</h5> <p>There was a single trial in this subset, with a total of 58 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.07, 95% CI 0.07 to 16.32) (<a href="./references#CD006918-fig-0015" title="">Analysis 1.11</a>). </p> </section> </section> <section id="CD006918-sec-0180"> <h4 class="title">1.12 Adverse effects: 3. cardiovascular ‐ short term (up to 12 weeks)</h4> <p>For this outcome we found four relevant studies and categorised data into seven subsets.</p> <section id="CD006918-sec-0181"> <h5 class="title">1.12.1 dizziness ‐ orthostatic</h5> <p>There was a single trial in this subset, with a total of 44 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 3.0, 95% CI 0.13 to 69.87) (<a href="./references#CD006918-fig-0016" title="">Analysis 1.12</a>). </p> </section> <section id="CD006918-sec-0182"> <h5 class="title">1.12.2 ECG abnormal</h5> <p>We found 1 trial to be relevant to this subset, with a total of 182 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 9.40, 95% CI 0.51 to 172.11) (<a href="./references#CD006918-fig-0016" title="">Analysis 1.12</a>). </p> </section> <section id="CD006918-sec-0183"> <h5 class="title">1.12.3 heart rate decreased</h5> <p>We found 1 trial to be relevant to this subset, with a total of 182 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 0.52, 95% CI 0.05 to 5.66) (<a href="./references#CD006918-fig-0016" title="">Analysis 1.12</a>). </p> </section> <section id="CD006918-sec-0184"> <h5 class="title">1.12.4 heart rate increased</h5> <p>There was a single trial in this subset, with a total of 182 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 0.85, 95% CI 0.37 to 1.96) (<a href="./references#CD006918-fig-0016" title="">Analysis 1.12</a>). </p> </section> <section id="CD006918-sec-0185"> <h5 class="title">1.12.5 hypotension ‐ postural</h5> <p>There was a single trial in this subset, with a total of 44 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 3.00, 95% CI 0.13 to 69.87) (<a href="./references#CD006918-fig-0016" title="">Analysis 1.12</a>). </p> </section> <section id="CD006918-sec-0186"> <h5 class="title">1.12.6 corrected QT interval &gt; 450 milliseconds or &gt; 10% increase from baseline</h5> <p>We found 2 trials to be relevant to this subset, with a total of 380 participants. We found evidence of a clear difference between 'risperidone' and 'placebo' within this subset (RR 8.46, 95% CI 1.07 to 67.07) (<a href="./references#CD006918-fig-0016" title="">Analysis 1.12</a>). </p> </section> <section id="CD006918-sec-0187"> <h5 class="title">1.12.7 tachycardia</h5> <p>We found 2 trials to be relevant to this subset, with a total of 332 participants. We found evidence of a clear difference between 'risperidone' and 'placebo' within this subset (RR 12.22, 95% CI 2.33 to 64.1) (<a href="./references#CD006918-fig-0016" title="">Analysis 1.12</a>). </p> </section> </section> <section id="CD006918-sec-0188"> <h4 class="title">1.13 Adverse effects: 4. central nervous system ‐ short term (up to 12 weeks)</h4> <p>We identified ten studies relevant to this outcome, the data from which we divided into eight subsets. </p> <section id="CD006918-sec-0189"> <h5 class="title">1.13.1 agitation</h5> <p>There were 8 relevant trials in this subset, with a total of 1388 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 0.93, 95% CI 0.75 to 1.17) (<a href="./references#CD006918-fig-0017" title="">Analysis 1.13</a>). </p> </section> <section id="CD006918-sec-0190"> <h5 class="title">1.13.2 anxiety</h5> <p>We found 6 trials to be relevant to this subset, with a total of 1225 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 1.04, 95% CI 0.73 to 1.48) (<a href="./references#CD006918-fig-0017" title="">Analysis 1.13</a>). </p> </section> <section id="CD006918-sec-0191"> <h5 class="title">1.13.3 dizziness</h5> <p>There were 5 relevant trials in this subset, with a total of 970 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 1.41, 95% CI 0.65 to 3.05). This subset had moderate levels of heterogeneity (Chi<sup>2</sup> = 7.37; df = 4.0; P = 0.12; I<sup>2</sup> = 46%) (<a href="./references#CD006918-fig-0017" title="">Analysis 1.13</a>). </p> </section> <section id="CD006918-sec-0192"> <h5 class="title">1.13.4 headache</h5> <p>We found 10 trials to be relevant to this subset, with a total of 1905 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 0.99, 95% CI 0.81 to 1.21) (<a href="./references#CD006918-fig-0017" title="">Analysis 1.13</a>). </p> </section> <section id="CD006918-sec-0193"> <h5 class="title">1.13.5 insomnia</h5> <p>We found 10 trials to be relevant to this subset, with a total of 1905 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 1.16, 95% CI 0.97 to 1.39) (<a href="./references#CD006918-fig-0017" title="">Analysis 1.13</a>). </p> </section> <section id="CD006918-sec-0194"> <h5 class="title">1.13.6 sedation</h5> <p>There were two trials in this subset, with a total of 517 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.84, 95% CI 0.52 to 6.50) (<a href="./references#CD006918-fig-0017" title="">Analysis 1.13</a>). </p> </section> <section id="CD006918-sec-0195"> <h5 class="title">1.13.7 somnolence</h5> <p>We found 6 trials to be relevant to this subset, with a total of 951 participants. We found evidence of a clear difference between 'risperidone' and 'placebo' within this subset (RR 1.61, 95% CI 1.06 to 2.45) (<a href="./references#CD006918-fig-0017" title="">Analysis 1.13</a>). </p> </section> <section id="CD006918-sec-0196"> <h5 class="title">1.13.8 restlessness</h5> <p>There were two trials in this subset, with a total of 619 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.16, 95% CI 0.49 to 2.74) (<a href="./references#CD006918-fig-0017" title="">Analysis 1.13</a>). </p> </section> </section> <section id="CD006918-sec-0197"> <h4 class="title">1.14 Adverse effects: 5. endocrine ‐ serum prolactin increase above reference range (23 ng/ml) ‐ short term (up to 12 weeks) </h4> <p>For this outcome we found 2 relevant studies, with a total of 323 participants. There were no subsets in this outcome. We found evidence of a clear difference between 'risperidone' and 'placebo' (RR 12.14, 95% CI 4.38 to 33.68). For this outcome heterogeneity was high (Chi<sup>2</sup> = 2.14; df = 1.0; P = 0.14; I<sup>2</sup> = 53%). </p> </section> <section id="CD006918-sec-0198"> <h4 class="title">1.15 Adverse effects: 6. gastrointestinal system ‐ short term (up to 12 weeks)</h4> <p>For this outcome we found ten relevant studies and categorised data into six subsets.</p> <section id="CD006918-sec-0199"> <h5 class="title">1.15.1 constipation</h5> <p>We found 8 trials to be relevant to this subset, with a total of 1695 participants. We found evidence of a clear difference between 'risperidone' and 'placebo' within this subset (RR 1.88, 95% CI 1.19 to 2.96) (<a href="./references#CD006918-fig-0019" title="">Analysis 1.15</a>). </p> </section> <section id="CD006918-sec-0200"> <h5 class="title">1.15.2 diarrhoea</h5> <p>There was a single trial in this subset, with a total of 202 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 0.92, 95% CI 0.37 to 2.3) (<a href="./references#CD006918-fig-0019" title="">Analysis 1.15</a>). </p> </section> <section id="CD006918-sec-0201"> <h5 class="title">1.15.3 dry mouth</h5> <p>We found 1 trial to be relevant to this subset, with a total of 202 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 2.43, 95% CI 0.65 to 9.12) (<a href="./references#CD006918-fig-0019" title="">Analysis 1.15</a>). </p> </section> <section id="CD006918-sec-0202"> <h5 class="title">1.15.4 dyspepsia</h5> <p>There were 5 relevant trials in this subset, with a total of 1058 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 1.24, 95% CI 0.64 to 2.40) (<a href="./references#CD006918-fig-0019" title="">Analysis 1.15</a>). </p> </section> <section id="CD006918-sec-0203"> <h5 class="title">1.15.5 nausea</h5> <p>There were 6 relevant trials in this subset, with a total of 1225 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 1.18, 95% CI 0.75 to 1.86) (<a href="./references#CD006918-fig-0019" title="">Analysis 1.15</a>). </p> </section> <section id="CD006918-sec-0204"> <h5 class="title">1.15.6 vomiting</h5> <p>There were 5 relevant trials in this subset, with a total of 1181 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 1.16, 95% CI 0.65 to 2.07) (<a href="./references#CD006918-fig-0019" title="">Analysis 1.15</a>). </p> </section> </section> <section id="CD006918-sec-0205"> <h4 class="title">1.16 Adverse effects: 7a. metabolic ‐ weight gain ‐ short term (up to 12 weeks)</h4> <p>For this outcome we found six relevant studies, the data from which we divided into two subsets. </p> <section id="CD006918-sec-0206"> <h5 class="title">1.16.1 any gain</h5> <p>We found 3 trials to be relevant to this subset, with a total of 910 participants. For this outcome, within this subset, we did find evidence that 'risperidone' was clearly different in its effects compared with 'placebo' (RR 3.77, 95% CI 1.34 to 10.63) (<a href="./references#CD006918-fig-0020" title="">Analysis 1.16</a>). </p> </section> <section id="CD006918-sec-0207"> <h5 class="title">1.16.2 &gt; 7% increase from baseline</h5> <p>We found 3 trials to be relevant to this subset, with a total of 606 participants. For this outcome, within this subset, we did find evidence that 'risperidone' was clearly different in its effects compared with 'placebo' (RR 3.47, 95% CI 1.64 to 7.33) (<a href="./references#CD006918-fig-0020" title="">Analysis 1.16</a>). </p> </section> </section> <section id="CD006918-sec-0208"> <h4 class="title">1.17 Adverse effects: 7b. metabolic ‐ skewed data ‐ average change value on lipid profile ‐ short term (up to 12 weeks) </h4> <p>These continuous data (two RCTs) had such large SDs as to suggest that analysis within RevMan would be inadvisable. Therefore, we presented them in an separate table (<a href="./references#CD006918-fig-0021" title="">Analysis 1.17</a>). </p> </section> <section id="CD006918-sec-0209"> <h4 class="title">1.18 Adverse effects: 8. musculoskeletal system ‐ short term (up to 12 weeks)</h4> <p>We identified one study relevant to this outcome and categorised data into two subsets.</p> <section id="CD006918-sec-0210"> <h5 class="title">1.18.1 myalgia</h5> <p>We found 1 trial to be relevant to this subset, with a total of 202 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 0.69, 95% CI 0.12 to 4.06). (<a href="./references#CD006918-fig-0022" title="">Analysis 1.18</a>). </p> </section> <section id="CD006918-sec-0211"> <h5 class="title">1.18.2 joint disorder</h5> <p>We found 1 trial to be relevant to this subset, with a total of 202 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 2.6, 95% CI 0.52 to 13.1) (<a href="./references#CD006918-fig-0022" title="">Analysis 1.18</a>). </p> </section> </section> <section id="CD006918-sec-0212"> <h4 class="title">1.19 Adverse effects: 9. physiology ‐ short term (up to 12 weeks)</h4> <p>For this outcome we found two studies and categorised data into four subsets.</p> <section id="CD006918-sec-0213"> <h5 class="title">1.19.1 alanine aminotransferase increased</h5> <p>There was a single trial in this subset, with a total of 182 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.04, 95% CI 0.07 to 16.45) (<a href="./references#CD006918-fig-0023" title="">Analysis 1.19</a>). </p> </section> <section id="CD006918-sec-0214"> <h5 class="title">1.19.2 aspartate aminotransferase increased</h5> <p>There was a single trial in this subset, with a total of 182 participants. No increase occured in either group. (<a href="./references#CD006918-fig-0023" title="">Analysis 1.19</a>). </p> </section> <section id="CD006918-sec-0215"> <h5 class="title">1.19.3 blood creatine phosphokinase increased</h5> <p>We found 2 trials to be relevant to this subset, with a total of 619 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 0.67, 95% CI 0.23 to 1.95) (<a href="./references#CD006918-fig-0023" title="">Analysis 1.19</a>). </p> </section> <section id="CD006918-sec-0216"> <h5 class="title">1.19.4 blood pressure increased</h5> <p>There was a single trial in this subset, with a total of 182 participants. There was not a clear difference between 'risperidone' and 'placebo' within this subset (RR 1.04, 95% CI 0.15 to 7.26) (<a href="./references#CD006918-fig-0023" title="">Analysis 1.19</a>). </p> </section> </section> <section id="CD006918-sec-0217"> <h4 class="title">1.20 Adverse effects: 10. respiratory system ‐ short term (up to 12 weeks)</h4> <p>For this outcome we found four relevant studies and categorised data into three subsets.</p> <section id="CD006918-sec-0218"> <h5 class="title">1.20.1 upper respiratory infection</h5> <p>There were 2 relevant trials in this subset, with a total of 323 participants. We found evidence of a clear difference between 'risperidone' and 'placebo' within this subset (RR 2.83, 95% CI 1.03 to 7.74) (<a href="./references#CD006918-fig-0024" title="">Analysis 1.20</a>). </p> </section> <section id="CD006918-sec-0219"> <h5 class="title">1.20.2 pharyngitis</h5> <p>There was a single trial in this subset, with a total of 202 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 0.42, 95% CI 0.08 to 2.1) (<a href="./references#CD006918-fig-0024" title="">Analysis 1.20</a>). </p> </section> <section id="CD006918-sec-0220"> <h5 class="title">1.20.3 rhinitis</h5> <p>There were 2 relevant trials in this subset, with a total of 306 participants. For this outcome, within this subset, we found evidence that 'risperidone' was clearly different in its effects compared with 'placebo' (RR 10.81, 95% CI 2.58 to 45.29) (<a href="./references#CD006918-fig-0024" title="">Analysis 1.20</a>). </p> </section> <section id="CD006918-sec-0221"> <h5 class="title">1.20.4 Sinusitis</h5> <p>There were 1 relevant trial in this subset, with a total of 437 participants. For this outcome, we did not find evidence of a clear difference between the two treatments (RR 1.04, 95% CI 0.09 to 11.36) (<a href="./references#CD006918-fig-0024" title="">Analysis 1.20</a>). </p> </section> </section> <section id="CD006918-sec-0222"> <h4 class="title">2. COMPARISON 2: RISPERIDONE plus CLOZAPINE versus PLACEBO plus CLOZAPINE</h4> <p>This particular comparison had 23 outcomes.</p> </section> <section id="CD006918-sec-0223"> <h4 class="title">2.1 Mental state: no clinically significant response in psychotic symptoms (defined by PANSS/BPRS &lt; 20% decline) ‐ short term (up to 12 weeks) </h4> <p>For this outcome two relevant studies found no clear difference between treatments (2 RCTS, N = 98, RR 1.15, 95% CI 0.93 to 1.42 <a href="./references#CD006918-fig-0025" title="">Analysis 2.1</a> ) </p> </section> <section id="CD006918-sec-0224"> <h4 class="title">2.2 Leaving the study early ‐ short term (up to 12 weeks)</h4> <p>For this outcome we found three relevant studies and categorised data into nine subsets.</p> <section id="CD006918-sec-0225"> <h5 class="title">2.2.1 any reason</h5> <p>We found 3 trials to be relevant to this subset, with a total of 167 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.13, 95% CI 0.53 to 2.42) (<a href="./references#CD006918-fig-0026" title="">Analysis 2.2</a>). </p> </section> <section id="CD006918-sec-0226"> <h5 class="title">2.2.2 due to adverse events</h5> <p>There were 2 relevant trials in this subset, with a total of 137 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (RR 4.11, 95% CI 0.47 to 36.24) (<a href="./references#CD006918-fig-0026" title="">Analysis 2.2</a>). </p> </section> <section id="CD006918-sec-0227"> <h5 class="title">2.2.3 due to lack of efficacy</h5> <p>We found 1 trial to be relevant to this subset, with a total of 69 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (RR 0.55, 95% CI 0.11 to 2.78) (<a href="./references#CD006918-fig-0026" title="">Analysis 2.2</a>). </p> </section> <section id="CD006918-sec-0228"> <h5 class="title">2.2.4 due to noncompliance</h5> <p>We found 1 trial to be relevant to this subset, with a total of 69 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 0.36, 95% CI 0.02 to 8.61) (<a href="./references#CD006918-fig-0026" title="">Analysis 2.2</a>). </p> </section> <section id="CD006918-sec-0229"> <h5 class="title">2.2.5 lost to follow‐up</h5> <p>We found 1 trial to be relevant to this subset, with a total of 69 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 0.36, 95% CI 0.02 to 8.61) (<a href="./references#CD006918-fig-0026" title="">Analysis 2.2</a>). </p> </section> <section id="CD006918-sec-0230"> <h5 class="title">2.2.6 reported death</h5> <p>There was a single trial in this subset, with a total of 68 participants. No deaths were reported. (<a href="./references#CD006918-fig-0026" title="">Analysis 2.2</a>). </p> </section> <section id="CD006918-sec-0231"> <h5 class="title">2.2.7 withdrawal of consent</h5> <p>There were 3 relevant trials in this subset, with a total of 167 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.41, 95% CI 0.28 to 7.09) (<a href="./references#CD006918-fig-0026" title="">Analysis 2.2</a>). </p> </section> <section id="CD006918-sec-0232"> <h5 class="title">2.2.8 administrative reasons</h5> <p>We found 1 trial to be relevant to this subset, with a total of 69 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 5.44, 95% CI 0.27 to 109.34) (<a href="./references#CD006918-fig-0026" title="">Analysis 2.2</a>). </p> </section> <section id="CD006918-sec-0233"> <h5 class="title">2.2.9 abnormal lab results</h5> <p>We found 1 trial to be relevant to this subset, with a total of 69 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 0.36, 95% CI 0.02 to 8.61) (<a href="./references#CD006918-fig-0026" title="">Analysis 2.2</a>). </p> </section> </section> <section id="CD006918-sec-0234"> <h4 class="title">2.3 Global state: 1. average endpoint scores of CGI severity scale (high = poor) ‐ short term (up to 12 weeks) </h4> <p>We identified 1 study relevant to this outcome involving 65 participants. This outcome had no subsets. We did not find evidence of a clear difference between the two treatments in this comparison (MD 0.51, 95% CI 0.02 to 1.00). </p> </section> <section id="CD006918-sec-0235"> <h4 class="title">2.4 Global state: 2. no significant clinical improvement ‐ short term (up to 12 weeks)</h4> <p>We identified 1 study relevant to this outcome, with a total of 68 participants. There were no subsets in this outcome. We did not find evidence of a clear difference between the two treatments in this comparison (RR 1.12, 95% CI 0.87 to 1.44) (<a href="./references#CD006918-fig-0028" title="">Analysis 2.4</a>). </p> </section> <section id="CD006918-sec-0236"> <h4 class="title">2.5 Global state: 3. general functioning ‐ average endpoint GAF score (high = good) ‐ short term (up to 12 weeks) </h4> <p>We identified 1 study relevant to this outcome involving 30 participants. This outcome had no subsets. We found evidence of a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' (MD ‐4.50, 95% CI ‐8.38 to ‐0.62) (<a href="./references#CD006918-fig-0029" title="">Analysis 2.5</a>). </p> </section> <section id="CD006918-sec-0237"> <h4 class="title">2.6 Mental state: 1. average endpoint scores on various scales on psychotic symptoms (high = poor) ‐ short term (up to 12 weeks) </h4> <p>For this outcome we found two relevant studies and categorised data into five subsets.</p> <section id="CD006918-sec-0238"> <h5 class="title">2.6.1 PANSS total</h5> <p>We found 2 trials to be relevant to this subset, with a total of 95 participants. We found evidence of a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (MD 5.56, 95% CI 1.59 to 9.53) (<a href="./references#CD006918-fig-0030" title="">Analysis 2.6</a>). </p> </section> <section id="CD006918-sec-0239"> <h5 class="title">2.6.2 PANSS general pathology</h5> <p>There was a single trial in this subset, with a total of 30 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (MD 2.50, 95% CI 0.03 to 4.97) (<a href="./references#CD006918-fig-0030" title="">Analysis 2.6</a>). </p> </section> <section id="CD006918-sec-0240"> <h5 class="title">2.6.3 PANSS delusion</h5> <p>We found 1 trial to be relevant to this subset, with a total of 30 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (MD 0.70, 95% CI 0.09 to 1.31) (<a href="./references#CD006918-fig-0030" title="">Analysis 2.6</a>). </p> </section> <section id="CD006918-sec-0241"> <h5 class="title">2.6.4 PANSS negative symptom</h5> <p>We found 2 trials to be relevant to this subset, with a total of 95 participants. For this subset, we did not find evidence of a clear difference between the two treatments (MD 0.69, 95% CI ‐0.68 to 2.05) (<a href="./references#CD006918-fig-0030" title="">Analysis 2.6</a>). </p> </section> <section id="CD006918-sec-0242"> <h5 class="title">2.6.5 PANSS positive symptom</h5> <p>We found 2 trials to be relevant to this subset, with a total of 95 participants. For this subset, we did not find evidence of a clear difference between the two treatments (MD 2.30, 95% CI 0.98 to 3.62) (<a href="./references#CD006918-fig-0030" title="">Analysis 2.6</a>). </p> </section> </section> <section id="CD006918-sec-0243"> <h4 class="title">2.7 Mental state: 2. average endpoint scores on various scales on psychotic symptoms (high = poor) ‐ medium term (up to 26 weeks) </h4> <p>For this outcome we found a single study, the data from which we divided into four subsets. </p> <section id="CD006918-sec-0244"> <h5 class="title">2.7.1 BPRS total</h5> <p>We found 1 trial to be relevant to this subset, with a total of 53 participants. We found evidence of a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (MD ‐4.60, 95% CI ‐9.88 to 0.68) (<a href="./references#CD006918-fig-0031" title="">Analysis 2.7</a>). </p> </section> <section id="CD006918-sec-0245"> <h5 class="title">2.7.2 BPRS positive symptom</h5> <p>There was a single trial in this subset, with a total of 53 participants. For this subset, we did not find evidence of a clear difference between the two treatments (MD ‐0.90, 95% CI ‐2.81 to 1.01) (<a href="./references#CD006918-fig-0031" title="">Analysis 2.7</a>). </p> </section> <section id="CD006918-sec-0246"> <h5 class="title">2.7.3 BPRS anxiety/depression factor</h5> <p>There was a single trial in this subset, with a total of 53 participants. We found evidence of a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (MD ‐1.00, 95% CI ‐2.80 to 0.80) (<a href="./references#CD006918-fig-0031" title="">Analysis 2.7</a>). </p> </section> <section id="CD006918-sec-0247"> <h5 class="title">2.7.4 SANS total</h5> <p>We found 1 trial to be relevant to this subset, with a total of 53 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (MD ‐3.10, 95% CI ‐10.30 to 4.10) (<a href="./references#CD006918-fig-0031" title="">Analysis 2.7</a>). </p> </section> </section> <section id="CD006918-sec-0248"> <h4 class="title">2.8 Mental state: 3. skewed data ‐ short term (up to 12 weeks)</h4> <p>These continuous data (two RCTs) had such large SDs as to suggest that analysis within RevMan would be inadvisable. Therefore, we have presented them in a separate data table (<a href="./references#CD006918-fig-0032" title="">Analysis 2.8</a>). </p> </section> <section id="CD006918-sec-0249"> <h4 class="title">2.9 Adverse effects: 1a. extrapyramidal ‐ average endpoint SAS score ‐ short term (up to 12 weeks) </h4> <p>For this outcome we found a single study. People in the risperidone + clozapine arm were less likely to experience extrapyramidal adverse events as reported on the SAS than those in the placebo + clozapine arm (1 RCT, N=30, MD ‐0.90 95% CI ‐1.97 to 0.17) (<a href="./references#CD006918-fig-0033" title="">Analysis 2.9</a>). </p> </section> <section id="CD006918-sec-0250"> <h4 class="title">2.10 Adverse effects: 1b. extrapyramidal ‐ skewed data (various scales) ‐ short term (up to 12 weeks) </h4> <p>These continuous data (two RCTs) had such large SDs as to suggest that analysis within RevMan would be inadvisable. Therefore, we have presented them in a separate data table (<a href="./references#CD006918-fig-0034" title="">Analysis 2.10</a>). </p> </section> <section id="CD006918-sec-0251"> <h4 class="title">2.11 Adverse effects: 1c. extrapyramidal ‐ skewed data (various scales) ‐ medium term (up to 26 weeks) </h4> <p>These continuous data (one RCT) were too skewed to report in a graphic. Therefore, we have reported these data in a separate data table (<a href="./references#CD006918-fig-0035" title="">Analysis 2.11</a>). </p> </section> <section id="CD006918-sec-0252"> <h4 class="title">2.12 Adverse effects: 2. any adverse event ‐ short term (up to 12 weeks)</h4> <p>We identified one study relevant to this outcome and categorised data into nine subsets.</p> <section id="CD006918-sec-0253"> <h5 class="title">2.12.1 any adverse event</h5> <p>We found 1 trial to be relevant to this subset, with a total of 64 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.14, 95% CI 0.83 to 1.58) (<a href="./references#CD006918-fig-0036" title="">Analysis 2.12</a>). </p> </section> <section id="CD006918-sec-0254"> <h5 class="title">2.12.2 amenorrhoea</h5> <p>There was a single trial in this subset, with a total of 64 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 3.00, 95% CI 0.13 to 71.0) (<a href="./references#CD006918-fig-0036" title="">Analysis 2.12</a>). </p> </section> <section id="CD006918-sec-0255"> <h5 class="title">2.12.3 asthenia</h5> <p>There was a single trial in this subset, with a total of 64 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (RR 1.08, 95% CI 0.61 to 1.91) (<a href="./references#CD006918-fig-0036" title="">Analysis 2.12</a>). </p> </section> <section id="CD006918-sec-0256"> <h5 class="title">2.12.4 depression</h5> <p>We found 1 trial to be relevant to this subset, with a total of 64 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (RR 1.20, 95% CI 0.61 to 2.37) (<a href="./references#CD006918-fig-0036" title="">Analysis 2.12</a>). </p> </section> <section id="CD006918-sec-0257"> <h5 class="title">2.12.5 emotional indifference</h5> <p>We found 1 trial to be relevant to this subset, with a total of 64 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (RR 1.11, 95% CI 0.52 to 2.37) (<a href="./references#CD006918-fig-0036" title="">Analysis 2.12</a>). </p> </section> <section id="CD006918-sec-0258"> <h5 class="title">2.12.6 fatigue</h5> <p>We found 1 trial to be relevant to this subset, with a total of 64 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.08, 95% CI 0.61 to 1.91) (<a href="./references#CD006918-fig-0036" title="">Analysis 2.12</a>). </p> </section> <section id="CD006918-sec-0259"> <h5 class="title">2.12.7 failing memory</h5> <p>There was a single trial in this subset, with a total of 64 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (RR 0.67, 95% CI 0.32 to 1.41) (<a href="./references#CD006918-fig-0036" title="">Analysis 2.12</a>). </p> </section> <section id="CD006918-sec-0260"> <h5 class="title">2.12.8 increased duration of sleep</h5> <p>We found 1 trial to be relevant to this subset, with a total of 64 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (RR 1.00, 95% CI 0.51 to 1.97) (<a href="./references#CD006918-fig-0036" title="">Analysis 2.12</a>). </p> </section> <section id="CD006918-sec-0261"> <h5 class="title">2.12.9 salivation ‐ increased</h5> <p>We found 1 trial to be relevant to this subset, with a total of 64 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.25, 95% CI 0.81 to 1.94) (<a href="./references#CD006918-fig-0036" title="">Analysis 2.12</a>). </p> </section> </section> <section id="CD006918-sec-0262"> <h4 class="title">2.13 Adverse effects: 3a. cardiovascular ‐ short term (up to 12 weeks)</h4> <p>For this outcome we found a single study and categorised data into three subsets (in keeping with our protocol). </p> <section id="CD006918-sec-0263"> <h5 class="title">2.13.1 dizziness ‐ orthostatic</h5> <p>We found 1 trial to be relevant to this subset, with a total of 64 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (RR 1.00, 95% CI 0.43 to 2.34) (<a href="./references#CD006918-fig-0037" title="">Analysis 2.13</a>). </p> </section> <section id="CD006918-sec-0264"> <h5 class="title">2.13.2 palpitation</h5> <p>There was a single trial in this subset, with a total of 64 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.00, 95% CI 0.27 to 3.66) (<a href="./references#CD006918-fig-0037" title="">Analysis 2.13</a>). </p> </section> <section id="CD006918-sec-0265"> <h5 class="title">2.13.3 tachycardia</h5> <p>We found 1 trial to be relevant to this subset, with a total of 64 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (RR 1.00, 95% CI 0.27 to 3.66) (<a href="./references#CD006918-fig-0037" title="">Analysis 2.13</a>). </p> </section> </section> <section id="CD006918-sec-0266"> <h4 class="title">2.14 Adverse effects: 3b. cardiovascular ‐ corrected QT interval ‐ short term (up to 12 weeks) </h4> <p>For this outcome we found a single study, with a total of 30 participants. There were no subsets in this outcome. We did not find evidence of a clear difference between the two treatments in this comparison (MD ‐19.70, 95% CI ‐42.08 to 2.68). </p> </section> <section id="CD006918-sec-0267"> <h4 class="title">2.15 Adverse effects: 4. central nervous system ‐ short term (up to 12 weeks)</h4> <p>For this outcome we found a single study and categorised data into three subsets.</p> <section id="CD006918-sec-0268"> <h5 class="title">2.15.1 sedation</h5> <p>There was a single trial in this subset, with a total of 64 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (RR 1.46, 95% CI 0.88 to 2.43) (<a href="./references#CD006918-fig-0039" title="">Analysis 2.15</a>). </p> </section> <section id="CD006918-sec-0269"> <h5 class="title">2.15.2 somnolence</h5> <p>We found 1 trial to be relevant to this subset, with a total of 64 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.00, 95% CI 0.51 to 1.97) (<a href="./references#CD006918-fig-0039" title="">Analysis 2.15</a>). </p> </section> <section id="CD006918-sec-0270"> <h5 class="title">2.15.3 tension</h5> <p>We found 1 trial to be relevant to this subset, with a total of 64 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.23, 95% CI 0.71 to 2.12) (<a href="./references#CD006918-fig-0039" title="">Analysis 2.15</a>). </p> </section> </section> <section id="CD006918-sec-0271"> <h4 class="title">2.16 Adverse effects: 5. gastrointestinal system ‐ short term (up to 12 weeks)</h4> <p>For this outcome we found a single study and categorised data into one subset.</p> <section id="CD006918-sec-0272"> <h5 class="title">2.16.1 constipation</h5> <p>We found 1 trial to be relevant to this subset, with a total of 64 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 0.71, 95% CI 0.25 to 2.02) (<a href="./references#CD006918-fig-0040" title="">Analysis 2.16</a>). </p> </section> </section> <section id="CD006918-sec-0273"> <h4 class="title">2.17 Adverse effects: 6a. haematological ‐ short term (up to 12 weeks)</h4> <p>We identified two studies relevant to this outcome and categorised data into three subsets. </p> <section id="CD006918-sec-0274"> <h5 class="title">2.17.1 neutrophil count</h5> <p>There was a single trial in this subset, with a total of 57 participants. For this subset, we did not find evidence of a clear difference between the two treatments (MD 0.37, 95% CI ‐0.42 to 1.16) (<a href="./references#CD006918-fig-0041" title="">Analysis 2.17</a>). </p> </section> <section id="CD006918-sec-0275"> <h5 class="title">2.17.2 prolactin level, ng/mL</h5> <p>We found 1 trial to be relevant to this subset, with a total of 30 participants. For this outcome, within this subset, we did find evidence that 'risperidone plus clozapine' was clearly different in its effects compared with 'placebo plus clozapine' (MD 60.1, 95% CI 46.52 to 73.68) (<a href="./references#CD006918-fig-0041" title="">Analysis 2.17</a>). </p> </section> <section id="CD006918-sec-0276"> <h5 class="title">2.17.3 white cell count</h5> <p>There was a single trial in this subset, with a total of 61 participants. For this subset, we did not find evidence of a clear difference between the two treatments (MD 0.66, 95% CI ‐0.20 to 1.52) (<a href="./references#CD006918-fig-0041" title="">Analysis 2.17</a>). </p> </section> </section> <section id="CD006918-sec-0277"> <h4 class="title">2.18 Adverse effects: 6b. haematological ‐ medium term (up to 26 weeks)</h4> <p>For this outcome we found a single study, the data from which we divided into two subsets. </p> <section id="CD006918-sec-0278"> <h5 class="title">2.18.1 prolactin level ng/mL</h5> <p>There was a single trial in this subset, with a total of 44 participants. We found evidence of a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (MD 34.1, 95% CI 17.63 to 50.57) (<a href="./references#CD006918-fig-0042" title="">Analysis 2.18</a>). </p> </section> <section id="CD006918-sec-0279"> <h5 class="title">2.18.2 fasting glucose</h5> <p>There was a single trial in this subset, with a total of 40 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (MD ‐4.60, 95% CI ‐17.09 to 7.89) (<a href="./references#CD006918-fig-0042" title="">Analysis 2.18</a>). </p> </section> </section> <section id="CD006918-sec-0280"> <h4 class="title">2.19 Adverse effects: 7a. metabolic ‐ weight gain ‐ short term (up to 12 weeks)</h4> <p>There was a single trial in this subset, with a total of 64 participants. For this subset, we did not find evidence of a clear difference between the two treatments (RR 1.00, 95% CI 0.40 to 2.52) (<a href="./references#CD006918-fig-0043" title="">Analysis 2.19</a>). </p> </section> <section id="CD006918-sec-0281"> <h4 class="title">2.20 Adverse effects: 7a. metabolic ‐ weight gain ‐ medium term (up to 26 weeks)</h4> <p>We found 1 trial to be relevant to this subset, with a total of 48 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (RR 0.20, 95% CI 0.01 to 3.96) (<a href="./references#CD006918-fig-0044" title="">Analysis 2.20</a>). </p> </section> <section id="CD006918-sec-0282"> <h4 class="title">2.21 Adverse effects: 7b. metabolic ‐ average endpoint value on lipid profile ‐ short term (up to 12 weeks) </h4> <p>For this outcome we found a single study and categorised data into four subsets.</p> <section id="CD006918-sec-0283"> <h5 class="title">2.21.1 cholesterol ‐ total (mg/dl)</h5> <p>We found 1 trial to be relevant to this subset, with a total of 56 participants. For this subset, we did not find evidence of a clear difference between the two treatments (MD ‐6.60, 95% CI ‐29.05 to 15.85) (<a href="./references#CD006918-fig-0045" title="">Analysis 2.21</a>). </p> </section> <section id="CD006918-sec-0284"> <h5 class="title">2.21.2 high‐density lipoprotein cholesterol (mg/dl)</h5> <p>We found 1 trial to be relevant to this subset, with a total of 52 participants. For this subset, we did not find evidence of a clear difference between the two treatments (MD 0.00, 95% CI ‐8.44 to 8.44) (<a href="./references#CD006918-fig-0045" title="">Analysis 2.21</a>). </p> </section> <section id="CD006918-sec-0285"> <h5 class="title">2.21.3 low‐density lipoprotein cholesterol (mg/dl)</h5> <p>There was a single trial in this subset, with a total of 53 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (MD ‐6.90, 95% CI ‐26.02 to 12.22) (<a href="./references#CD006918-fig-0045" title="">Analysis 2.21</a>). </p> </section> <section id="CD006918-sec-0286"> <h5 class="title">2.21.4 triglycerides (mg/dl)</h5> <p>There was a single trial in this subset, with a total of 56 participants. For this subset, we did not find evidence of a clear difference between the two treatments (MD 6.20, 95% CI ‐57.57 to 69.97) (<a href="./references#CD006918-fig-0045" title="">Analysis 2.21</a>). </p> </section> </section> <section id="CD006918-sec-0287"> <h4 class="title">2.22 Adverse effects: 7c. metabolic ‐ average endpoint value ‐ short term (up to 12 weeks) </h4> <p>We identified two studies relevant to this outcome, the data from which we divided into four subsets. </p> <section id="CD006918-sec-0288"> <h5 class="title">2.22.1 body mass index</h5> <p>We found 1 trial to be relevant to this subset, with a total of 63 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (MD 1.70, 95% CI ‐0.99 to 4.39) (<a href="./references#CD006918-fig-0046" title="">Analysis 2.22</a>). </p> </section> <section id="CD006918-sec-0289"> <h5 class="title">2.22.2 fasting glucose (mg/dl)</h5> <p>We found 1 trial to be relevant to this subset, with a total of 51 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (MD 16.20 95% CI ‐3.12 to 35.52) (<a href="./references#CD006918-fig-0046" title="">Analysis 2.22</a>). </p> </section> <section id="CD006918-sec-0290"> <h5 class="title">2.22.3 waist circumference (cm)</h5> <p>There was a single trial in this subset, with a total of 61 participants. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' within this subset (MD 5.10, 95% CI ‐4.14 to 14.34) (<a href="./references#CD006918-fig-0046" title="">Analysis 2.22</a>). </p> </section> <section id="CD006918-sec-0291"> <h5 class="title">2.22.4 weight gain</h5> <p>We found 2 trials to be relevant to this subset, with a total of 94 participants. For this subset, we did not find evidence of a clear difference between the two treatments (MD 0.34, 95% CI ‐0.84 to 1.53) (<a href="./references#CD006918-fig-0046" title="">Analysis 2.22</a>). </p> </section> </section> <section id="CD006918-sec-0292"> <h4 class="title">2.23 Adverse effects: 8. sleep ‐ skewed data ‐ average change score (UKU) ‐ short term (up to 12 weeks) </h4> <p>These continuous data, from a single trial, had such large SDs as to suggest that analysis within RevMan would be inadvisable. Therefore, we have presented them in a separate data table (<a href="./references#CD006918-fig-0047" title="">Analysis 2.23</a>). </p> </section> <section id="CD006918-sec-0293"> <h4 class="title">2.24 Quality of life: average endpoint score (QLS, high = good) ‐ short term (up to 12 weeks) </h4> <p>We identified 1 study relevant to this outcome involving 30 participants. There were no subsets in this outcome. There was not a clear difference between 'risperidone plus clozapine' and 'placebo plus clozapine' (MD 0.80, 95% CI ‐5.44 to 7.04) (<a href="./references#CD006918-fig-0048" title="">Analysis 2.24</a>). </p> </section> <section id="CD006918-sec-0294"> <h4 class="title">3. COMPARISON 3: SENSITIVITY ANALYSIS: RISPERIDONE versus PLACEBO (based on attrition)</h4> <p>This particular comparison had only one outcome.</p> </section> <section id="CD006918-sec-0295"> <h4 class="title">3.1 Mental state: 1. no clinically significant response (defined by PANSS/BPRS) ‐ short term (up to 12 weeks) </h4> <p>We identified six studies relevant to this outcome and categorised data into two subsets (in keeping with our protocol). </p> <section id="CD006918-sec-0296"> <h5 class="title">3.1.1 defined by PANSS/BPRS &lt; 20% decline</h5> <p>We found 6 trials to be relevant to this subset, with a total of 864 participants. We found evidence of a clear difference between 'sensitivity analysis: risperidone' and 'placebo (based on attrition)' within this subset (RR 0.64, 95% CI 0.52 to 0.78). For this outcome heterogeneity was high (Chi<sup>2</sup> = 12.27; df = 5.0; P = 0.03; I<sup>2</sup> = 59%) (<a href="./references#CD006918-fig-0049" title="">Analysis 3.1</a>). </p> </section> <section id="CD006918-sec-0297"> <h5 class="title">3.1.2 defined by PANSS/BPRS &lt; 20% decline (without studies with &gt; 50% leaving the study early) </h5> <p>There were 3 relevant trials in this subset, with a total of 589 participants. We found evidence of a clear difference between 'sensitivity analysis: risperidone' and 'placebo (based on attrition)' within this subgroup (RR 0.77, CI 0.67 to 0.88) (<a href="./references#CD006918-fig-0049" title="">Analysis 3.1</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006918-sec-0298" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006918-sec-0298"></div> <section id="CD006918-sec-0299"> <h3 class="title" id="CD006918-sec-0299">Summary of main results</h3> <section id="CD006918-sec-0300"> <h4 class="title">1. COMPARISON 1: RISPERIDONE versus PLACEBO</h4> <p>All of the included studies contributed data towards the comparison of risperidone versus placebo. Despite there being data from 15 studies in total, more often than not only a few studies contributed useable data towards each outcome. Most of the findings were based on few data, which in the majority of cases was of poor quality. The ratings within the Summary of findings table 1 reflect this, as we have judged the overall quality of evidence to be low or very low for each of the four main clinically relevant outcomes. </p> <p>There is a clear difference in the treatment effect favouring risperidone group. Compared to placebo, people who received risperidone has a 36% risk reduction (very low quality of evidence) in not achieving clinically significant improvement in psychotic symptoms. The effect withstood, even when three studies with &gt;50% attrition rate were removed from the analysis (3 RCTs, N = 589, RR 0.77, CI 0.67 to 0.88). Risperidone group also achieved greater reduction on BPRS score (a reduction of 12.69 compared to placebo group) and PANSS score (a reduction of 17.81 compared to placebo group). However the quality of evidence is compromised due to risk of bias of included studies, the slight heterogeneity and the involvement of industry sponsorship. Similarly, risperidone group are more likely to achieve significant clinical improvement than placebo group (a risk reduction of 31% in risperidone group, very low quality of evidence). </p> <p>A variety of reasons have caused people to leave the study early, but most showed no clear difference between groups. However, placebo group had significantly more people left the study early due to lack of efficacy (a risk reduction of 61% if one receives risperidone, low quality evidence). Overall, risperidone group is 31% less likely to drop out early compared to placebo group (low quality evidence). The participants have also experienced a range of adverse events, but most had similar incidence rate between groups, but some clearly favoured placebo group including, EPS (1.56 times less likely compared to risperidone group), akathisia (2.58 times times less likely compared to risperidone group), hypertonia (2.98 times times less likely compared to risperidone group) and parkinsonism (7.64 times times less likely compared to risperidone group), somnolence (1.61 times times less likely compared to risperidone group), constipation (1.88 times less likely), weight gain (3.77 times less likely), upper respiratory infection (2.83 times less likely), rhinitis (10.81 times less likely). </p> </section> <section id="CD006918-sec-0301"> <h4 class="title">2. COMPARISON 2: RISPERIDONE plus CLOZAPINE versus PLACEBO plus CLOZAPINE</h4> <p>When combined with clozapine, there was no obvious difference between groups in achieving clinically significant response in psychotic symptoms (low quality evidence). However, placebo plus clozapine group achieved greater reduction in PANSS score (MD = 5.56, 95% CI 1.59 to 9.53), while risperidone plus clozapine group appeared to produce more improvement in general functioning as assessed by GAF (MD = ‐4.5, 95% CI ‐8.38 to ‐0.62). Participants left the study early for a variety of reasons, but none of which discriminated against any interventions (very low quality of evidence). Similarly, we did not find any clear difference in the adverse events experienced between groups. </p> </section> </section> <section id="CD006918-sec-0302"> <h3 class="title" id="CD006918-sec-0302">Overall completeness and applicability of evidence</h3> <p>The review included 15 studies (n = 2428) of relatively short duration, between 8 and 16 weeks, hence limiting the applicability of the results of this review to long term use of risperidone. All participants in included trials were adults diagnosed with schizophrenia or schizoaffective disorder. The studies took place in both primary and secondary care settings, however, most were conducted in high income countries, hence the evidence should be applied with care in developing countries. There was a lack of data in included studies on the following outcome, including service utilisation and quality of life. </p> <section id="CD006918-sec-0303"> <h4 class="title">Issue of placebo‐controlled trials</h4> <p>Placebo‐controlled trials have been used as a licensing requirement by the US Food and Drug Administration (FDA) and other regulatory authorities for some time. Since 1964, the Helsinki Ethical Principles for Medical Research Involving Human Subjects <a href="./references#CD006918-bbs2-0182" title="World Medical Association. Ethical principles for medical research involving human subjects. World Medical Association2008. ">WMA 2008</a> have been considered a benchmark for trialists around the world (<a href="./references#CD006918-bbs2-0182" title="World Medical Association. Ethical principles for medical research involving human subjects. World Medical Association2008. ">WMA 2008</a>). However, recently it has been argued that it is unethical to conduct trials involving placebo arms for conditions that have an established standard treatment. Also recently, the FDA has adopted the less rigorous Good Clinical Practice as an alternative to the Helsinki declaration, although this has invited numerous criticisms (<a href="./references#CD006918-bbs2-0172" title="LurieP , WolfeSM . Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. The New England Journal of Medicine1997;337:853‐6. ">Lurie 1997</a>; <a href="./references#CD006918-bbs2-0173" title="LurieP , GrecoDB . US exceptionalism comes to research ethics. The Lancet2005;365:1117‐9. ">Lurie 2005</a>). Nevertheless, placebo trials do still have an important place, and some ethical bodies around the world do approve of trial methodologies with placebo arms. We suggest that the findings of this review support the continued need for placebo‐controlled studies. risperidone is a widely used drug. That many of the effects of this compound are not that different from a placebo is important and would not have been highlighted but for the use of this type of study. </p> </section> </section> <section id="CD006918-sec-0304"> <h3 class="title" id="CD006918-sec-0304">Quality of the evidence</h3> <p>The quality of reporting in most studies could have been much better (<a href="#CD006918-fig-0004">Figure 4</a>). Well over half of the included studies have concerns in sequence generation and allocation concealment. There has also been some controversy over the trials conducted by Borison, with the author being accused of scientific fraud (see <a href="#CD006918-sec-0082">Included studies</a>). Although<i>,</i> the trialists have not been found to have fabricated research data, this cast a shadow to the findings of his trials (<a href="./references#CD006918-bbs2-0120" title="HassnerVS . Scientific fraud: Eric Poehlman / Richard Borison. Alliance for Human Research Protection (http://www.ahrp.org/cms/content/view/370/29/) 29 Oct 2006 (accessed 5 Nov 2009). ">AHRP 2006</a>; <a href="./references#CD006918-bbs2-0134" title="AugustaG . Drug money: Patients worsened; little oversight provided. CBS News (http://www.cbsnews.com/stories/2000/07/31/48hours/main220233.shtml) 31 Jul 2000 (accessed 5 November 2009). ">CBS News 2000CBS News 2000</a><a href="./references#CD006918-bbs2-0120" title="HassnerVS . Scientific fraud: Eric Poehlman / Richard Borison. Alliance for Human Research Protection (http://www.ahrp.org/cms/content/view/370/29/) 29 Oct 2006 (accessed 5 Nov 2009). ">AHRP 2006</a>). </p> <p>Now, years after the first Consolidated Standards of Reporting Trials (CONSORT) statement (<a href="./references#CD006918-bbs2-0126" title="BeggC , ChoM , EastwoodS , HortonR , MoherD , OlkinI , et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA1996;276(8):637‐9. ">Begg 1996</a>), it is expected that all relevant details of methodology that are likely to influence outcome, such as means of allocation and concealment of allocation, are documented and reported. Only 5 out of 13 studies provided information about sequence generation, and 3 out of 13 provided any details about allocation concealment. Good randomisation methodology is essential, and more so for smaller trials, as it ensures that confounding variables are as equally distributed as possible between the intervention and control groups. Poor quality or inadequate randomisation procedures would instead produce imbalance between groups in terms of participant selection and could potentially bias the result. </p> </section> <section id="CD006918-sec-0305"> <h3 class="title" id="CD006918-sec-0305">Potential biases in the review process</h3> <p>The authors of this review made every effort to minimise bias in the review process by strictly following the Cochrane Handbook and conduct expectations. The majority of data in this review were collected from published reports. Even though we identified substantial number of conference proceedings and unpublished reports, however, we were not able to extract much data from these reports due to either poor reporting or lack of collection at trial stage, therefore, could not be used in this review. For example, in some studies trialists reported mean without standard deviation. Our attempts to contact authors of trials for additional data were unsuccessful. This directly results in </p> <section id="CD006918-sec-0306"> <h4 class="title">2. Omission of relevant data or studies</h4> <p>As defined in our protocol, we had to omit efficacy measures from studies that had attrition rates of higher than 50% at study endpoint in a sensitivity analysis for our main outcomes. We are not sure if this is correct, but have identified no ready solution to the problem of missing data and when assumptions become too much and undermine credibility (<a href="./references#CD006918-bbs2-0183" title="XiaJ , AdamsC , BhagatN , BhagatV , BhoopathyP , El‐SayehH , et al. Losing participants before the trial ends erodes credibility of findings. Psychiatric Bulletin2009;33:254‐7. ">Xia 2009</a>). Certainly, high attrition rates, poor reporting, and poor methodology, combined with the rules we had set ourselves within our protocol, limited the information available for us to use. We feel that people can leave the trials for several reasons, most of which are not specified in the reports. Many studies carried the last observation of such people to the end of the trial period and used those data as if things stayed stable beyond leaving the study. This may or may not be correct but has gone untested. We have taken a conservative approach in presentation of the available data. </p> </section> </section> <section id="CD006918-sec-0307"> <h3 class="title" id="CD006918-sec-0307">Agreements and disagreements with other studies or reviews</h3> <p>This review substantially updates the previous work in the area of risperidone. It also completes the series of direct comparison of risperidone with other drugs (<a href="./references#CD006918-bbs2-0144" title="GilbodySM , BagnallAM , DugganL , TuunainenA . Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD002306] ">Gilbody 2000</a>; <a href="./references#CD006918-bbs2-0151" title="HosalliP , DaviesJM . Depot risperidone for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD004161] ">Hosalli 2003</a>; <a href="./references#CD006918-bbs2-0152" title="HunterRH , JoyCB , KennedyE , GilbodySM , SongF . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000440] ">Hunter 2003</a>; <a href="./references#CD006918-bbs2-0155" title="JayaramMB , HosalliP , StroupS . Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD005237] ">Jayaram 2006</a>; <a href="./references#CD006918-bbs2-0160" title="KennedyE , SongF , HunterR , ClarkeA , GilbodyS . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD002306] ">Kennedy 2000</a>; <a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a>; <a href="./references#CD006918-bbs2-0170" title="LiC , XiaJ , WangJ . Risperidone dose for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007474.pub2] ">Li 2009</a>). The findings of this review were similar to the findings of other reviews involving risperidone. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006918-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Risperidone" data-id="CD006918-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risperidone</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006918-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006918-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD006918-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE vs PLACEBO, Outcome 1 Mental state: no clinically significant response in psychotic symptoms (defined by various scale total score change) ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 1 Mental state: no clinically significant response in psychotic symptoms (defined by various scale total score change) ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE vs PLACEBO, Outcome 2 Leaving the study early ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 2 Leaving the study early ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE vs PLACEBO, Outcome 3 Global state: 1. average endpoint scores of CGI severity scale (high=poor) ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 3 Global state: 1. average endpoint scores of CGI severity scale (high=poor) ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE vs PLACEBO, Outcome 4 Global state: 2. no significant clinical improvement CGI ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 4 Global state: 2. no significant clinical improvement CGI ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE vs PLACEBO, Outcome 5 Global state: 3. needing additional medication ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 5 Global state: 3. needing additional medication ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE vs PLACEBO, Outcome 6 Mental state: 1. average endpoint scores on various scales on psychotic symptoms (high=poor) ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 6 Mental state: 1. average endpoint scores on various scales on psychotic symptoms (high=poor) ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0011"> <p> <div class="table" id="CD006918-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average endpoint score BPRS total (high=poor)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pai 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pai 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of CGI‐C (larger decline=good)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potkin 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potkin 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of CGI‐SI (larger decline=good)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potkin 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potkin 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of HAM‐D‐17 (larger decline=good)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potkin 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potkin 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of PANSS total (larger decline=good)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potkin 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐27.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potkin 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐20.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of PANSS negative symptom (larger decline=good)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potkin 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potkin 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of PANSS positive symptom (larger decline=good)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potkin 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potkin 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 7 Mental state: 2. skewed data ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0011">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006918-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE vs PLACEBO, Outcome 8 Adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 8 Adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE vs PLACEBO, Outcome 9 Adverse effects: 1b. extrapyramidal ‐ AIMS average endpoint score ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 9 Adverse effects: 1b. extrapyramidal ‐ AIMS average endpoint score ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0014"> <p> <div class="table" id="CD006918-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of AIMS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potkin 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potkin 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of CGI severity dyskinesia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chouinard 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chouinard 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of CGI severity parkinsonism</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chouinard 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chouinard 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of ESRS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marder 1994a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marder 1994a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of ESRS ‐ akathisia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marder 1994a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marder 1994a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of ESRS ‐ dystonia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chouinard 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chouinard 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marder 1994a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marder 1994a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pai 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pai 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of ESRS ‐ dyskinesia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chouinard 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chouinard 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marder 1994a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marder 1994a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of ESRS ‐ parkinsonism</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chouinard 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chouinard 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marder 1994a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marder 1994a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pai 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pai 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 10 Adverse effects: 1c. extrapyramidal ‐ skewed data (various scales) ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0014">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006918-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE vs PLACEBO, Outcome 11 Adverse effects: 2. any adverse event ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 11 Adverse effects: 2. any adverse event ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE vs PLACEBO, Outcome 12 Adverse effects: 3. cardiovascular ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 12 Adverse effects: 3. cardiovascular ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE vs PLACEBO, Outcome 13 Adverse effects: 4. central nervous system ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 13 Adverse effects: 4. central nervous system ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE vs PLACEBO, Outcome 14 Adverse effects: 5. endocrine ‐ serum prolactin increase above reference range (23 ng/ml) ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 14 Adverse effects: 5. endocrine ‐ serum prolactin increase above reference range (23 ng/ml) ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE vs PLACEBO, Outcome 15 Adverse effects: 6. gastrointestinal system ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 15 Adverse effects: 6. gastrointestinal system ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE vs PLACEBO, Outcome 16 Adverse effects: 7a. metabolic ‐ weight gain ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 16 Adverse effects: 7a. metabolic ‐ weight gain ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0021"> <p> <div class="table" id="CD006918-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>cholesterol ‐ total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Durgam 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Durgam 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heisterberg 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>154</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heisterberg 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐14.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>HDL</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Durgam 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Durgam 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heisterberg 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>154</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heisterberg 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>LDL</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Durgam 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Durgam 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heisterberg 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>154</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heisterberg 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>triglycerides</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Durgam 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Durgam 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heisterberg 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>154</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heisterberg 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐27.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>VLDL</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heisterberg 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>154</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heisterberg 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 17 Adverse effects: 7b. metabolic ‐ skewed data ‐ average change value on lipid profile ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0021">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006918-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE vs PLACEBO, Outcome 18 Adverse effects: 8. musculoskeletal system ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 18 Adverse effects: 8. musculoskeletal system ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE vs PLACEBO, Outcome 19 Adverse effects: 9. physiology ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 19 Adverse effects: 9. physiology ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE vs PLACEBO, Outcome 20 Adverse effects: 10. respiratory system ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE vs PLACEBO, Outcome 20 Adverse effects: 10. respiratory system ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 1 Mental state: no clinically significant response in psychotic symptoms (defined by PANSS/BPRS&lt;20% decline) ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 1 Mental state: no clinically significant response in psychotic symptoms (defined by PANSS/BPRS&lt;20% decline) ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 2 Leaving the study early ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 2 Leaving the study early ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 3 Global state: 1. average endpoint scores of CGI severity scale (high=poor) ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 3 Global state: 1. average endpoint scores of CGI severity scale (high=poor) ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 4 Global state: 2. no significant clinical improvement CGI ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0028" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 4 Global state: 2. no significant clinical improvement CGI ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 5 Global state: 3. general functioning ‐ average endpoint GAF score (high=good) ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0029" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 5 Global state: 3. general functioning ‐ average endpoint GAF score (high=good) ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 6 Mental state: 1. average endpoint scores on various scales on psychotic symptoms (high=poor) ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0030" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 6 Mental state: 1. average endpoint scores on various scales on psychotic symptoms (high=poor) ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 7 Mental state: 2. average endpoint scores on various scales on psychotic symptoms (high=poor) ‐ medium term (up to 26 weeks)." data-id="CD006918-fig-0031" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 7 Mental state: 2. average endpoint scores on various scales on psychotic symptoms (high=poor) ‐ medium term (up to 26 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0032"> <p> <div class="table" id="CD006918-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average endpoint score of CDS total (high=poor)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yagcioglu 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yagcioglu 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average endpoint score on verbal working memory (SD, high=good)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Honer 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Honer 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 8 Mental state: 3. skewed data ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0032">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006918-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 9 Adverse effects: 1a. extrapyramidal ‐ average endpoint SAS score ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0033" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 9 Adverse effects: 1a. extrapyramidal ‐ average endpoint SAS score ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0034"> <p> <div class="table" id="CD006918-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average endpoint score of AIMS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yagcioglu 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yagcioglu 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of Barnes akathisia rating scale</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Honer 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Honer 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yagcioglu 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yagcioglu 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of ESRS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Honer 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Honer 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of ESRS ‐ dystonia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Honer 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Honer 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of ESRS ‐ dyskinesia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Honer 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Honer 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average change score of ESRS ‐ parkinsonism</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Honer 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Honer 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 10 Adverse effects: 1b. extrapyramidal ‐ skewed data (various scales) ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0034">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006918-fig-0035"> <p> <div class="table" id="CD006918-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average endpoint score of AIMS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bachmann 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bachmann 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average endpoint score of SAS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bachmann 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bachmann 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 11 Adverse effects: 1c. extrapyramidal ‐ skewed data (various scales) ‐ medium term (up to 26 weeks). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0035">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006918-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 12 Adverse effects: 2. any adverse event ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0036" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 12 Adverse effects: 2. any adverse event ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 13 Adverse effects: 3a. cardiovascular ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0037" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 13 Adverse effects: 3a. cardiovascular ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 14 Adverse effects: 3b. cardiovascular ‐ QTc interval ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0038" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 14 Adverse effects: 3b. cardiovascular ‐ QTc interval ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 15 Adverse effects: 4. central nervous system ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0039" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 15 Adverse effects: 4. central nervous system ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 16 Adverse effects: 5. gastrointestinal system ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0040" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 16 Adverse effects: 5. gastrointestinal system ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 17 Adverse effects: 6a. haematological ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0041" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 17 Adverse effects: 6a. haematological ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 18 Adverse effects: 6b. haematological ‐ medium term (up to 26 weeks)." data-id="CD006918-fig-0042" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 18 Adverse effects: 6b. haematological ‐ medium term (up to 26 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 19 Adverse effects: 7a. metabolic ‐ weight gain ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0043" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 19 Adverse effects: 7a. metabolic ‐ weight gain ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 20 Adverse effects: 7a. metabolic ‐ weight gain ‐ medium term (up to 26 weeks)." data-id="CD006918-fig-0044" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 20 Adverse effects: 7a. metabolic ‐ weight gain ‐ medium term (up to 26 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 21 Adverse effects: 7b. metabolic ‐ average endpoint value on lipid profile ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0045" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 21 Adverse effects: 7b. metabolic ‐ average endpoint value on lipid profile ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 22 Adverse effects: 7c. metabolic ‐ average endpoint value ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0046" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 22 Adverse effects: 7c. metabolic ‐ average endpoint value ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0047"> <p> <div class="table" id="CD006918-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yagcioglu 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yagcioglu 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 23 Adverse effects: 8. sleep ‐ skewed data ‐ average change score (UKU) ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0047">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006918-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-002-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-002-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 24 Quality of life: average endpoint score (QLS, high=good) ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0048" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 24 Quality of life: average endpoint score (QLS, high=good) ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-002-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006918-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/urn:x-wiley:14651858:media:CD006918:CD006918-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_t/tCD006918-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 SENSITIVITY ANALYSIS: RISPERIDONE vs PLACEBO (based on attrition), Outcome 1 Mental state: 1. no clinically significant response (defined by PANSS/BPRS) ‐ short term (up to 12 weeks)." data-id="CD006918-fig-0049" src="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 SENSITIVITY ANALYSIS: RISPERIDONE vs PLACEBO (based on attrition), Outcome 1 Mental state: 1. no clinically significant response (defined by PANSS/BPRS) ‐ short term (up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/media/CDSR/CD006918/image_n/nCD006918-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD006918-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reviews suggested by excluded studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Broad category of comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Excluded study/studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Existing Cochrane reviews</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><b>Augmentation [of]</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>risperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>by</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>antioxidants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0100" title="ZhangCZ . A study of the therapeutic effectiveness of risperidone in combination with antioxidants in the treatment of schizophrenia. Herald of Medicine2002;21(10):629‐30. ">Zhang 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>buflomedil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0101" title="ZhongZ‐Y , TaoJ , WangX‐L , WuX‐L , ZhangJ‐B . Effect of antipsychotic plus buflomedil hydrochloride in ameliorating the negative symptoms of patients with schizophrenia. Chinese Journal of Clinical Rehabilitation [Zhongguo lin chuang kang fu]2006;10(2):30‐2. ">Zhong 2006</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>celecoxib</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0087" title="RiedelM , MöllerHJ , MüllerN . Rational and efficacy of cox‐2‐inhibitors as adjunctive therapy in schizophrenia. European Neuropsychopharmacology2003;13(4):S96. ">Riedel 2003</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D‐alanine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0093" title="TsaiGE , YangP , ChangY‐C , ChongM‐Y . D‐alanine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry2006;59(3):230‐4. ">Tsai 2006</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sarcosine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0092" title="TsaiG , LaneHY , YangP , ChongMY , LangeN . Glycine transporter I inhibitor, N‐Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry2004;55(5):452‐6. ">Tsai 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>valproate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0095" title="WangG . 60 week, randomized, double‐blind, placebo‐controlled trial of valproate added to risperidone in 200 treatment‐naive, first‐episode patients with schizophrenia. Stanley Foundation Research Programs2003. ">Wang 2003</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clozapine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>risperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0071" title="McKennaPJ . An international study of improving treatment for the most severely ill with schizophrenia. National Research Register2004. ">McKenna 2004</a>, <a href="./references#CD006918-bbs2-0082" title="PeuskensJ , MollerHJ . Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. European Neuropsychopharmacology2001;11(3):255. ">Peuskens 2001a</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Long‐acting preparation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>depot risperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>versus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>olanzapine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0036" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Comparative efficacy and safety of long‐acting risperidone and risperidone oral tablets. European Neuropsychopharmacology2005;15(1):111‐7. ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tables. Schizophrenia Research2002;53(3 Suppl 1):174. ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Proceedings of the 11th Biennial Winter Workshop on Schizophrenia; 2002 Feb 24‐Mar 1; Davos, Switzerland. 2002. ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Poster supplied by Company2002. ">Chue 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD006918-bbs2-0151" title="HosalliP , DaviesJM . Depot risperidone for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD004161] ">Hosalli 2003</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0031" title="CadaDJ , LevienT , BakerDE . Risperidone long‐acting injection. Hospital Pharmacy2004;39(4):353‐62. ">Cada 2004</a>, <a href="./references#CD006918-bbs2-0037" title="CilibertoN , BossieCA , UriosteR , LasserRA . Lack of impact of race on the efficacy and safety of long‐acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. International Clinical Psychopharmacology2005;20(4):207‐12. ">Ciliberto 2005</a>, <a href="./references#CD006918-bbs2-0060" title="LaurielloJ , McEvoyJP , RodriguezS , BossieCA , LasserRA . Long‐acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophrenia Research2005;72(2‐3):249‐58. ">Lauriello 2005</a>, <a href="./references#CD006918-bbs2-0072" title="NasrallahHA , DuchesneI , MehnertA , JanagapC , EerdekensM . Correction. Journal of Clinical Psychiatry [linchuang jingshen yixue zazhi] [临床精神医学杂志]2004;65(8):1150. NasrallahHA , DuchesneI , MehnertA , JanagapC , EerdekensM . Health‐related quality of life in patients with schizophrenia during treatment with long‐acting, injectable risperidone. Journal of Clinical Psychiatry2004;65(4):531‐6. ">Nasrallah 2004a</a>, <a href="./references#CD006918-bbs2-0094" title="UriosteR , BossieC , ZhuY , CilibertoN , TrinhB , LasserR . Clinical improvement with long‐acting risperidone: no impact of race. Proceedings of the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. ">Urioste 2004</a>, <a href="./references#CD006918-bbs2-0076" title="NCT00249119 . Risperidone in the treatment of chronic schizophrenic patients: an international multicentre double‐blind parallel‐group comparative study versus haloperidol. clinicaltrials.gov/ct2/show/NCT00249119 (2005) (accessed 9 October 2013). ">NCT00249119</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Experimental compound</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>risperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>versus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BL‐1020</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT01363349a</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LY2140023</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT01086748a</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PF‐02545920</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DeMartinis 2012a, NCT01175135a</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><b>Versus another antipsychotic</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p>risperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p>versus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>amisulpride</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0055" title="HwangTJ , LeeS‐M , SunHJ , LinH‐N , TsaiS‐J , LeeY‐C , et al. Amisulpride versus risperidone in the treatment of schizophrenic patients: a double‐blind pilot study in Taiwan. Journal of the Formosan Medical Association2003;102(1):30‐6. ">Hwang 2003</a>, <a href="./references#CD006918-bbs2-0085" title="ReinW , FleurotO . Efficacy of amisulpride vs risperidone in the long‐term treatment of chronic schizophrenia: Results from a 12 month double‐blind study. European Neuropsychopharmacology2002;12(Suppl 3):S302. ReinW , FleurotO . Safety of amisulpride vs risperidone in the long‐term treatment of chronic schizophrenia: Results from a 12 month double‐blind study. European Neuropsychopharmacology2002;12(Suppl 3):S309. ">Rein 2002</a>, <a href="./references#CD006918-bbs2-0081" title="PeuskensJ , KasperS . Amisulpride versus risperidone in schizophrenia: comparing clinical and functional outcome in a 6 months study. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001. ">Peuskens 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0164" title="KomossaK , Rummel‐KlugeC , HungerH , SchmidF , SchwarzS , Silveira da Mota NetoJI , et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006624.pub2; PUBMED: 20091599] ">Komossa 2010</a>; <a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aripiprazole</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0048" title="DubitskyGM , HarrisR , LaughrenT , HardemanS . Abilify (aripiprazole) tablets; medical review part 1. www.fda.gov/cder/foi/nda/2002/21‐436_Abilify.htm 2002 (accessed 9 October 2013):1‐50. DubitskyGM , HarrisR , LaughrenT , HardemanS . Abilify (aripiprazole) tablets; medical review part 2. www.fda.gov/cder/foi/nda/2002/21‐436_Abilify.htm. U.S. Food and Drug Administration CDER, 2002 (accessed 9 October 2013):50‐110. DubitskyGM , HarrisR , LaughrenT , HardemanS . Abilify (aripiprazole) tablets; medical review part 3. www.fda.gov/cder/foi/nda/2002/21‐436_Abilify.htm. U.S. Food and Drug Administration CDER, 2002 (accessed 9 October 2013):111‐75. DubitskyGM , HarrisR , LaughrenT , HardemanS . Abilify (aripiprazole) tablets; medical review part 4. www.fda.gov/cder/foi/nda/2002/21‐436_Abilify.htm. U.S. Food and Drug Administration CDER, 2002 (accessed 9 October 2013):176‐232. ">Dubitsky 2002</a>, <a href="./references#CD006918-bbs2-0035" title="ChanH‐Y , LinW‐W , LinS‐K , HwangT‐J , SuT‐P , ChiangS‐C , et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. Journal of Clinical Psychiatry2007;68(1):29‐36. ">Chan 2007</a>, <a href="./references#CD006918-bbs2-0056" title="HwangTJ , ChanHY , LinWW , LinSK , HwuHG , ChengMY , et al. Aripiprazole versus risperidone in the treatment of acutely relapsed patients with schizophrenia in Taiwan: a randomized controlled trial. European Neuropsychopharmacology2005;15(Suppl 3):S497. ">Hwang 2005</a>, <a href="./references#CD006918-bbs2-0075" title="NCT00202007 . A multi‐center, randomized, double‐blind study, comparing with risperidone, to evaluate the efficacy and safety of aripiprazole in the treatment of patients with schizophrenia. clinicaltrials.gov/ct2/show/NCT00202007 (2005) (accessed 9 October 2013). ">NCT00202007</a>, <a href="./references#CD006918-bbs2-0057" title="KaneJ , CarsonWh , KujawaM , StringfellowJ , MarcusR , SanchezR , et al. Aripiprazole in treatment‐resistant schizophrenia: a 6‐week double‐blind comparison study versus perphenazine. Schizophrenia Research2004;67(1):155‐6. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of Risperdal Consta, a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cilag UK Ltd2002. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Proceedings of the 11th Biennial Winter Workshop on Schizophrenia; 2002 Feb 24‐Mar 1; Davos, Switzerland. 2002. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal constatm, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S188. KaneJ , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Schizophrenia Research2000;41(1):39. KaneJM . Preventing morbidity in first‐episode schizophrenia. clinicaltrials.gov/ct2/show/NCT00000374 (accessed 16 Feb 2001). KaneJM . The latest advance in long‐acting antipsychotic therapy. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. KaneJM , CarsonWH , SahaAR , McQuadeRD , IngenitoGG , ZimbroffDL , et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry2002;63(9):763‐71. KaneJM , ConleyRR , KeithSJ , NasrallahHA , TurnerM . Guidelines for the use of long‐acting injectable atypical antipsychotics. Journal of Clinical Psychiatry2004;65(1):120‐31. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research2002;53(3 Suppl 1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology2002;12(Suppl 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160:1125‐32. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [NR345 Tuesday, May 16, 3:00 p.m.‐5:00 p.m] KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S124. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. KaneJM , PotkinS , BuckleyP , DanielDG . Safety and efficacy of sertindole and risperidone in treatment resistant patients with schizophrenia. Schizophrenia Bulletin2005;31:490. KaneJM , WilliamHCJ , KujawaMJ , StringfellowJ , MarcusRN , SanchezR , et al. Aripiprazole vs perphenazine in treatment‐resistant schizophrenia. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. ">Kane 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0161" title="KhannaP , SuoT , KomossaK , MaH , Rummel‐KlugeC , El‐SayehHG , et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD006569.pub5; PUBMED: 24385408] ">Khanna 2014</a>; <a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>asenapine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0050" title="FlemingK , PotkinSG , BinnemanB , KellerD , AlphsL , PanagidesJ . Effects of asenapine on cognitive function in acute schizophrenia: a placebo‐ and risperidone‐controlled trial. European Neuropsychopharmacology2007;17(Suppl 4):S466. ">Fleming 2007a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cariprazine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bose 2010b</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Protocol underway</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clozapine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0027" title="BondolfiG , BaumannP , DufourH . Treatment‐resistant schizophrenia ‐ clinical experience with new antipsychotics. European Neuropsychopharmacology1996;6(Suppl 2):S21‐5. BondolfiG , BaumannP , PatrisM , MayJ , BilleterU , DufourH , et al. A randomized double‐bind trial of risperidone versus clozapine for treatment‐resistant chronic schizophrenia. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30‐Oct 4; Venice, Italy. 1995. BondolfiG , BaumannP , PatrisM , MayJP , BilleterU , DufourH . A randomised double‐blind trial of risperidone versus clozapine for treatment‐resistant chronic schizophrenia. Proceedings of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20‐25; Miami, Florida, USA. 1995. BondolfiG , BaumannP , PatrisM , MayJP , BilleterU , DufourH . A randomized double‐blind trial of risperidone versus clozapine for treatment‐resistant chronic schizophrenia. Proceedings of the Workshop on Critical Issues in the Treatment of Schizophrenia; 1995 Mar 10‐12; Florence, Italy. 1995. BondolfiG , DufourH , PatrisM , MayJP , BilleterU , EapCB , et al. Risperidone versus clozapine in treatment‐resistant chronic schizophrenia: a randomized double‐blind study. The Risperidone Study Group. American Journal of Psychiatry1998;155(4):499‐504. ">Bondolfi 1998</a>, Cavazzoni 2002a </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clocapramine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0099" title="YamawakiS , HayashiT , YokotaN , TakahashiT , SatoG , TaharaY . Serotonin‐dopamine antagonists in elderly schizophrenics. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. ">Yamawaki 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>haloperidol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0039" title="ClausA , BollenJ , DeCuyperH , EnemanM , MalfroidM , PeuskensJ , et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double‐blind comparative study. Acta Psychiatrica Scandinavica1992;85(4):295‐305. ">Claus 1992</a>, <a href="./references#CD006918-bbs2-0051" title="FriedmanJ , AdlerD , TemporiniH , HarveyP , KemetherE , DavisK . Alpha2 agonists enhance cognition of schizophrenia patients in combination with atypical but not typical neuroleptics. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S155. FriedmanJI , AdlerD , TemporiniHD , HarveyPD , KemetherEM , DavisKL . Alpha‐2 agonists enhance cognition of schizophrenia patients in combination with atypical but not typical neuroleptics. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. FriedmanJI , AdlerDN , HowanitzE , HarveyPD , BrennerG , TemporiniH , et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biological Psychiatry2002;51:349‐57. FriedmanJI , AdlerDN , HowanitzE , HarveyPD , BrennerG , TemporiniH , et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Schizophrenia Research2002;53(3 Suppl 1):9. FriedmanJI , AdlerDN , HowanitzE , TemporiniH , HarveyPD , DavisKL . Effects of donepezil on cognition, symptoms, and movement disorders in patients with chronic schizophrenia. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. FriedmanJI , AdlerDN , TemporiniHD , HarveyPD , DavisKL . Alpha‐2 agonists enhance cognition of schizophrenic patients in combination with atypical but not typical neuroleptics. Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12‐16; Acapulco, Mexico. 1999. FriedmanJI , AdlerDN , TemporiniHD , KemetherE , HarveyPD , WhiteL , et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropyschopharmacology2001;25(3):402‐9. NCT00488163 . Pilot study of atomoxetine to enhance cognition in patients with schizophrenia. clinicaltrials.gov/show/NCT00488163(2007). ">Friedman 2000</a>, <a href="./references#CD006918-bbs2-0063" title="LindstromE , vonKnorringL . Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol. Pharmacopsychiatry1994;27(3):108‐13. ">Lindstrom 1994</a>, <a href="./references#CD006918-bbs2-0065" title="Lopez IborJJ , AyusoJL , GutierrezM , GuimonJ , HerraizML , ChinchillaA , et al. Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol [Risperidona en el tratamiento de la esquizofrenia cronica: estudio multicentrico comparativo versus haloperidol]. Actas Luso Espanolas de Neurologia Psiquiatria y Ciencias Afines1996;24(4):165‐72. ">Lopez 1996</a>, <a href="./references#CD006918-bbs2-0066" title="Lopez‐IborJJ . Safety profile of risperidone in the multicentre trials. Proceedings of the 1st International Risperidone Investigators' Meeting; 1992 Mar 9‐10; Paris, France. 1992. ">Lopez‐Ibor 1992</a>, <a href="./references#CD006918-bbs2-0077" title="NCT00253136 . Risperidone depot (microspheres) vs placebo in the treatment of subjects with schizophrenia. clinicaltrials.gov/ct2/show/NCT00253136 (2005) (accessed 9 October 2013). ">NCT00253136</a>, <a href="./references#CD006918-bbs2-0080" title="PeuskensJ , Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi‐national, multi‐centre, double‐blind, parallel‐group study versus haloperidol. British Journal of Psychiatry1995;166:712‐26. ">Peuskens 1995</a>, <a href="./references#CD006918-bbs2-0084" title="RabinowitzJ , DavidsonM . Risperidone versus haloperidol in long‐term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis. Schizophrenia Research2001;50(1‐2):89‐93. ">Rabinowitz 2001</a>, <a href="./references#CD006918-bbs2-0098" title="WirshingDA , MarshallBDJr , GreenMF , MintzJ , MarderSR , WirshingWC . Risperidone in treatment‐refractory schizophrenia. American Journal of Psychiatry1999;156(9):1374‐9. WirshingWC , AmesD , GreenM , MarshallBD , MarderSR . Risperidone versus haloperidol in treatment‐refractory schizophrenia: preliminary results. Psychopharmacology Bulletin1995;31(3):633. WirshingWC , AmesD , MarderSR , MarshallBD , GreenMF , McGurkS . Risperidone vs haloperidol in treatment resistant schizophrenia: preliminary results. Schizophrenia Research1996;18(2, 3):130. WirshingWC , AmesD , MarderSR , MarshallBD , GreenMF , McGurkSR . Risperidone in treatment resistant schizophrenia. Proceedings of the 34th Annual Meeting of the American College of Neuropsychopharmacology; 1995 Dec 11‐15; San Juan, Puerto Rico. 1995. WirshingWC , AmesD , MarshallBD , GreenMF , McGurkS . Risperidone in treatment resistant schizophrenia. Proceeding of the 8th Biennial Winter Workshop on Schizophrenia; 1996 Mar 16‐22; Crans Montana, Switzerland. 1996. WirshingWC , AmesD , Palmer BrayM , MarshallBD , GreenMF , MarderSR . Risperidone versus haloperidol in treatment refractory schizophrenia: preliminary results. Proceeding of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20‐25; Miami, Florida, USA. 1995. WirshingWC , GreenMF , AmesD , MarshallBD , McGurkSR , MintzJ , et al. Risperidone vs. haloperidol in treatment‐resistant schizophrenia. Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22‐27; Nice, France. 1997. ">Wirshing 1995</a>, <a href="./references#CD006918-bbs2-0028" title="BorisonR . Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. Proceedings of the 1st International Risperidone Investigators' Meeting; 1992 Mar 9‐10; Paris, France. 1992. BorisonR , PathirajaA , DiamondB , MeibachR . Risperidone and schizophrenia. Biological Psychiatry1991;29:417. BorisonRL , DiamondBI , AugustaGA . Serotonin modulation of dopaminergic‐medicated extrapyramidal side effects. Neurology1991;41(Suppl 1):396. BorisonRL , DiamondBI , PathirajaA , MeibachRC . Clinical profile of risperidone in chronic schizophrenia. Proceedings of the 17th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1990 Sep 10‐14; Kyoto, Japan. 1991. BorisonRL , PathirajaAP , DiamondBI , MeibachRC . Risperidone ‐ clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin1992;28(2):213‐8. BorisonRL , PathirajaAP , DiamondBI , MeibachRC . Risperidone in the treatment of acute exacerbation of chronic schizophrenia. Schizophrenia Research1991;4(3):314‐5. BorisonRl , PathirajaAP , DiamondBI , MeibachRC . Antidopaminergic and antiserotonergic actions of risperidone in schizophrenia. Biological Psychiatry1991;29(Suppl):114a. ">Borison 1992a</a>, <a href="./references#CD006918-bbs2-0044" title="CsernanskyJ . Do novel antipsychotics optimize long term outcomes in schizophrenia. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S1. CsernanskyJ , BrecherM , OkamotoA . Risperidone vs haloperidol: relapse prevention in schizophrenia and schizoaffective disorders: a long‐term double‐blind comparison. Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6‐11; Hamburg, Germany. 1999. CsernanskyJ , OkamotoA . A long term double blind comparison of risperidone and haloperidol in stable outpatients with schizophrenia or schizoaffective disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S155. CsernanskyJ , OkamotoA . Risperidone versus haloperidol for prevention of relapse in schizophrenia and schizoaffective disorders: long term double blind comparison. Proceedings of the 22nd Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2000 Jul 9‐13; Brussels, Belgium. 2000. CsernanskyJ , OkamotoA . Risperidone versus haloperidol for prevention of relapse in schizophrenia and schizoaffective disorders: long term double blind comparison. Schizophrenia Research2000;41(1):198. CsernanskyJG , MahmoudR , BrennerR , The Risperidone‐USA‐79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. The New England Journal of Medicine2002;346(1):16‐22. CsernanskyJG , OkamotoA . Risperidone versus haloperidol for prevention of relapse in patients with schizophrenia and schizoaffective disorder: a long‐term double blind comparison. Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12‐16; Acapulco, Mexico. 1999. CsernanskyJG , OkamotoA . Risperidone versus haloperidol for relapse prevention in schizophrenia and schizoaffective disorder: a long‐term double‐blind placebo controlled comparison. Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30‐Jun 2; Boca Raton, Florida, USA. 2000. CsernanskyJG , OkamotoA . Risperidone vs haloperidol for relapse prevention in schizophrenia and schizoaffective disorder: a long‐term double‐blind comparison. Biological Psychiatry2000;47:31‐2S. CsernanskyJG , OkamotoA , BrecherM . Risperidone vs haloperidol: prevention of relapse in schizophrenia. European Neuropsychopharmacology1999;9:S268. CsernanskyJG , OkamotoA , BrecherMB . Risperidone versus haloperidol for prevention of relapse in schizophrenia and schizoaffective disorder: a long‐term, double‐blind comparison. Proceedings of the 51st Institute on Psychiatric Services; 1999 Oct 25‐Nov 2; New Orleans, Louisiana, USA. 1999. ">Csernansky 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0152" title="HunterRH , JoyCB , KennedyE , GilbodySM , SongF . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000440] ">Hunter 2003</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>molindone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0069" title="McClellanJ . Risperidone for schizophrenia. Stanley Foundation Research Programs2009. ">McClellan 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0124" title="BagnallA , FentonM , KleijnenJ , LewisR . Molindone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD002083.pub2; PUBMED: 17253473] ">Bagnall 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>olanzapine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0090" title="TollefsonG , BeasleyC , TranP , DellvaMA , KruegerJ , TamuraR . Olanzapine versus haloperidol: acute results of the multicenter international trial. Psychopharmacology Bulletin1996;32(3):401. TollefsonG , BeasleyC , TranP , SangerT . Olanzapine: an exciting atypical antipsychotic; the clinical experience. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30‐Oct 4; Venice, Italy. 1995. TollefsonG , LuY . Comorbid mood disturbance in schizophrenia. Schizophrenia Research1997;24:192. TollefsonGD . Olanzapine: a novel antipsychotic with a broad spectrum profile. Neuropyschopharmacology1994;10(Suppl 3 Pt 1):805S. TollefsonGD . The value of atypical antipsychotic medications. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17‐22; San Diego, California, USA. 1997. TollefsonGD . Treatment consideration for comorbid mood disorders in schizophrenic patients. Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22‐27; Nice, France. 1997. TollefsonGD . Update on new atypical antipsychotics. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30‐Oct 4; Venice, Italy. 1995. TollefsonGD , AndersenSW . Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?. Journal of Clinical Psychiatry1999;60(Suppl 5):23‐9. TollefsonGD , AndersenSW , TranPV . The course of depressive symptoms in predicting relapse in schizophrenia: a double blind, randomized comparison of olanzapine and risperidone. Biological Psychiatry1999;46(3):365‐73. TollefsonGD , BeasleyCM , TamuraRN , TranPV , PotvinJH . Blind, controlled, long term study of the comparative incidence of treatment emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry1997;154(9):1248‐54. TollefsonGD , BeasleyCM , TranPV , StreetJS , KruegerJA , TamuraRN , et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry1997;154(4):457‐65. TollefsonGD , LuY . Comorbid mood disturbance in schizophrenia. Biological Psychiatry1997;41:101S. TollefsonGD , LuY . Comorbid mood disturbance in schizophrenia. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. TollefsonGD , LuY . Comorbid mood disturbance in schizophrenia. Proceedings of the 9th European College of Neuropsychopharmacology Congress; 1996 Sep 21‐25; Amsterdam, Netherlands. 1996. TollefsonGD , LuY , SangerTM , BeasleyCM , TranPV . Olanzapine in the treatment of schizoaffective disorder. Schizophrenia Research1997;24(1, 2):92‐3. TollefsonGD , SangerTD , LiebermanJA . Olanzapine versus haloperidol in the treatment of first episode psychosis. Biological Psychiatry1997;41:73S. TollefsonGD , SangerTM . A blinded trial on the course and relationship of depressive symptoms in schizophrenia. Schizophrenia Research1998;29(1, 2):205. TollefsonGD , SangerTM . Negative symptoms: a path analytic approach to a double‐blind, placebo‐ and haloperidol‐controlled clinical trial with olanzapine. American Journal of Psychiatry1997;154(4):466‐74. TollefsonGD , SangerTM , BeasleyCM . The course of primary and secondary negative symptoms in a controlled trial with olanzapine. 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. [MEDLINE: 97245664] TollefsonGD , SangerTM , BeasleyCM . The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4‐9, New York, New York, USA. 1996. TollefsonGD , SangerTM , BeasleyCM . The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Schizophrenia Research1997;24(1, 2):192. TollefsonGD , SangerTM , BeasleyCM . The course of primary and secondary negative symptoms in a placebo‐ and comparator‐controlled trial of the typical antipsychotic olanzapine. Proceedings of the 9th European College of Neuropsychopharmacology Congress; 1996 Sep 21‐25; Amsterdam, Netherlands. 1996. TollefsonGD , SangerTM , BeasleyCM , TranPV . A double blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biological Psychiatry1998;43(11):803‐10. TollefsonGD , SangerTM , LeibermanJA . Olanzapine versus haloperidol in the treatment of first episode psychosis. Schizophrenia Research1997;24(1, 2):193. TollefsonGD , TranPV , HamiltonS , KuntzA . Olanzapine versus risperidone in the treatment of psychosis. Preliminary report. Biological Psychiatry1997;41:20S. TollefsonGD , TranPV , HamiltonS , KuntzA . Olanzapine versus risperidone in the treatment of psychosis. Preliminary report. Schizophrenia Research1997;24(1, 2):191‐2. ">Tollefson 1996</a>, <a href="./references#CD006918-bbs2-0049" title="EdgellET , AndersenSW , GraingerD , WangJ . Resource use and quality of life of olanzapine compared with risperidone: results from an international randomized clinical trial. Proceedings of the 21st Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1998 Jul 12‐16; Glasgow, UK. 1998. EdgellET , AndersenSW , JohnstoneBM , DulisseB , RevickiD , BreierA . Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S92. EdgellET , AndersenSW , JohnstoneBM , DulisseB , RevickiD , BreierA . Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics2000;18(6):567‐79. EdgellET , AndersenSW , JohnstoneBM , DulisseB , RevickiD , BreierA , et al. Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. European Psychiatry2000;15(Suppl 2):408s. EdgellET , GraingerDL , AndersenSW , WangJ . Resource use and quality of life associated with olanzapine compared with risperidone. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐Jun 4; Toronto, Ontario, Canada. 1998. EdgellET , HamiltonSH , RevickiDA , GendusoLA , TollefsonGD . Costs of olanzapine treatment compared with haloperidol for schizophrenia: results from a randomized clinical trial. Proceedings of the 21st Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1998 Jul 12‐6; Glasgow, UK. 1998. ">Edgell 2000</a>, <a href="./references#CD006918-bbs2-0091" title='TranP , BeasleyC , StreetJ , TamuraR , DellvaMA , GraffeoK , et al. Olanzapine versus haloperidol: acute results of the multi‐center international trial. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. TranP , BeasleyC , TollefsonG , BeuzenJ , DellvaM , SangerT , et al. Acute and long‐term results of the North American double‐blind olanzapine trial. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30‐Oct 4; Venice, Italy. 1995. TranP , BeasleyC , TollefsonG , CrawfordA , DellvaM , GusmanS , et al. Acute and long‐term results of the dose ranging double‐blind olanzapine trial. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. TranP , LuY , SangerT , BeasleyC , TollefsonG . Olanzapine in the treatment of schizoaffective disorder. Proceedings of the 21st Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1998 Jul 12‐16; Glasgow, UK. 1998. TranP , SangerTM , SatterleeW , BeasleyCJr , TamuraRN , TollefsonGD . Olanzapine vs haloperidol ‐ results of a large multi‐centre international trial. Proceedings of the 4th International Conference on Schizophrenia ‐ 1996: Breaking down the Barriers; 1996 Oct 6‐9; Vancouver, Canada. 1996. TranPV , BassonBR , KennedyJS , Beasley JrCM , BymasterFP , TollefsonGD . The comparative anti‐muscarinic‐like side effect profiles of olanzapine and risperidone treatment in patients with schizophrenia spectrum psychosis. European Neuropsychopharmacology1999;9:S290. TranPV , BeasleyCM , TollefosnGD , SangerT , SatterleeWG . Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent. Neuropsychopharmacology1994;10(3S):267S. TranPV , BeasleyCM , TollefsonGD , BeuzenJN , HolmanSL , SangerTM , et al. Olanzapine: a promising "atypical" antipsychotic agent. Schizophrenia Research1995;15(1, 2):169. TranPV , DellvaMA , BeasleyCMJr , SatterleeWG , CousinsLM , TollefsonGD . Clinical experience with long‐term continuation treatment with olanzapine. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4‐9, New York, New York, USA. 1996. TranPV , DellvaMA , TollefsonGD , BeasleyCMJr , PotvinJH , KieslerGM . Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. Journal of Clinical Psychiatry1997;58(5):205‐11. TranPV , HamilitonSH , KuntzAJ , TollefsonGD . Olanzapine versus risperidone in the treatment of psychosis disorders: a preliminary report. Proceedings of the 35th Annual Meeting of the American College of Neuropsychopharmacology; 1996 Dec 9‐13; San Juan, Puerto Rico. 1996. TranPV , HamiltonSH , KuntzAJ , PotvinJH , AndersenSW , BeasleyC , et al. Double‐blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology1997;17(5):407‐18. TranPV , TollefsonGD , AndersenSW , KuntzAJ , HamiltonSH . Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17; Vienna, Austria. 1997. TranPV , TollefsonGD , AndersonSW , KuntzA , HamiltonSH . Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Schizophrenia Research1998;29(1, 2):205. TranPV , TollefsonGD , CrawfordAM , DossenbachM , FriedelP , FolnegovicV , et al. Olanzapine versus fluphenazine in schizophrenia. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐Jun 4; Toronto, Ontario, Canada. 1998. TranPV , TollefsonGD , HamiltonS . Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17‐22; San Diego, California, USA. 1997. TranPV , TollefsonGD , HamiltonS , KuntzA . Olanzapine vs. risperidone in the treatment of psychosis. Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22‐27; Nice, France. 1997. '>Tran 1997</a>, <a href="./references#CD006918-bbs2-0040" title="ConleyRR , BrecherM , The Risperidone/Olanzapine Study Group. Risperidone versus olanzapine in patients with schizophrenia or schizoaffective disorders. Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4; Paris, France. 1998. ConleyRR , BrecherMB , Olanzapine‐Risperidone Study Group. Risperidone versus olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. ConleyRR , MahmoudR . A randomized double‐blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. American Journal of Psychiatry2001; Vol. 158, issue 5:765‐74. ConleyRR , MahmoudR . Efficacy of risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder. European Neuropsychopharmacology2000;10(Suppl 3):S343. [13th Congress of the European College of Neuropsychopharmacology [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2000 P3021] ConleyRR , MahmoudR . Efficacy of risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S151. ConleyRR , MahmoudR . Risperidone and olanzapine in people with schizophrenia or schizoaffective disorder: a randomised double‐blind study. Poster supplied by Company2001. ConleyRR , MahmoudR . Risperidone vs olanzapine in patients with schizophrenia &amp; schizoaffective disorder. Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30‐Jun 2; Boca Raton, Florida, USA. 2000. ConleyRR , MahmoudR . Risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder: safety comparisons. European Neuropsychopharmacology2000;10(Suppl 3):S342. [13th Congress of the European College of Neuropsychopharmacology [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2000 P3020] ConleyRR , MahmoudR . Risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder: safety comparisons. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S151. ConleyRR , MahmoudR , Risperidone Study Group. Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder. Proceedings of the 10th Biennial Winter Workshop on Schizophrenia; 2000 Feb 5‐11; Davos, Switzerland. 2000. ConleyRR , MahmoudR , Risperidone Study Group. Risperidone versus olanzapine in patients with schizophrenia and schizoaffective psychosis [Risperidon versus olanzapin bei patienten mit schizophrenie und schizoaffektiven psychosen]. Nervenheilkunde2000;19(5):110‐2. ConleyRR , MahmoudR , Risperidone Study Group. Risperidone vs. olanzapine in patients with schizophrenia and schizoaffective disorder. Biological Psychiatry2000;47:32S. ConleyRR , MahmoudRA . Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [NR1 Monday, May 15, 9:00 a.m.‐10:30 a.m] ConleyRR , MahmoudRA . Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. ConleyRR , MahmoudRA . Risperidone vs olanzapine in patients with schizophrenia and schizo‐affective disorder. International Drug Therapy Newsletter2000;35(10):77‐8. ">Conley 1998</a>, <a href="./references#CD006918-bbs2-0054" title="HarveyK , BurnsT , SedgwickP , HiggittA , CreedF , FahyT . Relatives of patients with severe psychotic disorders: factors that influence contact frequency. Report from the UK700 trial. British Journal of Psychiatry2001;178:248‐54. HarveyP , MeltzerH , GreenM . Long term cognitive effects of risperidone treatment in schizophrenia. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S154. HarveyP , MeltzerH , GreenM . Risperidone cognitive effects in schizophrenia and schizoaffective patients. International Drug Therapy Newsletter2001;36(8):59. HarveyP , MeltzerHY , GreenMP . Cognitive effects of risperidone versus olanzapine in patients with schizophrenia or schizoaffective disorder. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001. HarveyP , MelzerH , GreenM . Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder. Biological Psychiatry2001;49(8):123S. HarveyPD . Cognitive effects of risperidone and olanzapine in patients with schizophrenia. Proceedings of the 52nd Institute on Psychiatric Services; 2000 Oct 25‐29; Philadelphia, Pennsylvania, USA. 2000. HarveyPD . Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. HarveyPD . Long‐term cognitive effects of risperidone treatment in schizophrenia. Proceedings of the 52nd Institute on Psychiatric Services; 2000 Oct 25‐29; Philadelphia, Pennsylvania, USA. 2000. HarveyPD , GharabawiG . Risperidone and cognition in schizophrenic elderly. Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. HarveyPD , GreenMF , McGurkSR , MeltzerHY . Changes in cognitive functioning with risperidone and olanzapine treatment: a large‐scale, double‐blind, randomized study. Psychopharmacology2003;169(3‐4):404‐11. HarveyPD , LyonsBE , MahmoudR . Long term cognitive effects of risperidone. Schizophrenia Research2000;41(1):200‐1. HarveyPD , MahmoudR , MeltzerHY , GreenMP . Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder. European Neuropsychopharmacology2001;11(3):257. HarveyPD , MeltzerHY , GreenM . Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. HarveyPD , MeltzerHY , GreenMF . Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder. Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30‐Jun 2; Boca Raton, Florida, USA. 2000. HarveyPD , MeltzerHY , GreenMF . Long‐term cognitive effects of risperidone treatment in schizophrenia. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. ">Harvey 2001</a>, <a href="./references#CD006918-bbs2-0030" title="BrecherM . Risperidone versus olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder. Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4; Paris, France. 1998. BrecherM , The Risperidone Olanzapine Study Group. Risperidone versus olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder. Proceedings of the 21st Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1998 Jul 12‐16; Glasgow, UK. 1998. BrecherM , The Risperidone‐Olanzapine Study Group. Risperidone versus olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder conference abstract. Schizophrenia Research1999;36(1‐3):271. ">Brecher 1998</a>, <a href="./references#CD006918-bbs2-0069" title="McClellanJ . Risperidone for schizophrenia. Stanley Foundation Research Programs2009. ">McClellan 2009</a>, Cavazzoni 2002a, <a href="./references#CD006918-bbs2-0041" title="CooperSJ , ButlerA , TweedJ , RaniwallaJ , WelchC . Zotepine in the prevention of relapse. Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22‐27; Nice, France. 1997. CooperSJ , ButlerA , TweedJA , WelchCP , WightonAJ , ApplebyP , et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4; Paris, France. 1998. CooperSJ , ButlerA , TweedJA , WelchCP , WightonAJ , ApplebyP , et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. Schizophrenia Research2000;41(1):207‐8. CooperTB , VolavkaJ , CzoborP . Plasma drug level and clinical response. Journal of Clinical Psychopharmacology1992;12(2):134‐6. ">Cooper 1997</a>, <a href="./references#CD006918-bbs2-0073" title="NCT00034892 . Efficacy and tolerability of olanzapine, quetiapine and risperidone in the treatment of first episode psychosis: a randomized double blind 52‐week comparison. clinicaltrials.gov/ct2/show/NCT00034892 (2002) (accessed 9 October 2013). ">NCT00034892</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a>; <a href="./references#CD006918-bbs2-0156" title="JayaramMB , HosalliPM , StroupTS . Risperidone versus olanzapine for treatment of schizophrenia. Schizophrenia Bulletin2007;33(6):1274‐6. [PUBMED: 17921477] ">Jayaram 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>quetiapine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0041" title="CooperSJ , ButlerA , TweedJ , RaniwallaJ , WelchC . Zotepine in the prevention of relapse. Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22‐27; Nice, France. 1997. CooperSJ , ButlerA , TweedJA , WelchCP , WightonAJ , ApplebyP , et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4; Paris, France. 1998. CooperSJ , ButlerA , TweedJA , WelchCP , WightonAJ , ApplebyP , et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. Schizophrenia Research2000;41(1):207‐8. CooperTB , VolavkaJ , CzoborP . Plasma drug level and clinical response. Journal of Clinical Psychopharmacology1992;12(2):134‐6. ">Cooper 1997</a>, <a href="./references#CD006918-bbs2-0073" title="NCT00034892 . Efficacy and tolerability of olanzapine, quetiapine and risperidone in the treatment of first episode psychosis: a randomized double blind 52‐week comparison. clinicaltrials.gov/ct2/show/NCT00034892 (2002) (accessed 9 October 2013). ">NCT00034892</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0123" title="AsmalL , FlegarSJ , WangJ , Rummel‐KlugeC , KomossaK , LeuchtS . Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD006625.pub3; PUBMED: 24249315] ">Asmal 2013</a>; <a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sertindole</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0057" title="KaneJ , CarsonWh , KujawaM , StringfellowJ , MarcusR , SanchezR , et al. Aripiprazole in treatment‐resistant schizophrenia: a 6‐week double‐blind comparison study versus perphenazine. Schizophrenia Research2004;67(1):155‐6. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of Risperdal Consta, a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cilag UK Ltd2002. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Proceedings of the 11th Biennial Winter Workshop on Schizophrenia; 2002 Feb 24‐Mar 1; Davos, Switzerland. 2002. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal constatm, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S188. KaneJ , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Schizophrenia Research2000;41(1):39. KaneJM . Preventing morbidity in first‐episode schizophrenia. clinicaltrials.gov/ct2/show/NCT00000374 (accessed 16 Feb 2001). KaneJM . The latest advance in long‐acting antipsychotic therapy. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. KaneJM , CarsonWH , SahaAR , McQuadeRD , IngenitoGG , ZimbroffDL , et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry2002;63(9):763‐71. KaneJM , ConleyRR , KeithSJ , NasrallahHA , TurnerM . Guidelines for the use of long‐acting injectable atypical antipsychotics. Journal of Clinical Psychiatry2004;65(1):120‐31. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research2002;53(3 Suppl 1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology2002;12(Suppl 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160:1125‐32. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [NR345 Tuesday, May 16, 3:00 p.m.‐5:00 p.m] KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S124. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. KaneJM , PotkinS , BuckleyP , DanielDG . Safety and efficacy of sertindole and risperidone in treatment resistant patients with schizophrenia. Schizophrenia Bulletin2005;31:490. KaneJM , WilliamHCJ , KujawaMJ , StringfellowJ , MarcusRN , SanchezR , et al. Aripiprazole vs perphenazine in treatment‐resistant schizophrenia. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. ">Kane 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0163" title="KomossaK , Rummel‐KlugeC , HungerH , SchwarzS , SchmidtF , LewisR , et al. Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD006752.pub2; PUBMED: 19370652] ">Komossa 2009</a>; <a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>zuclopenthixol dihydrochloride</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0061" title="LemmensP , deSmedtG , GheuensJ , TritsmansL . Efficacy of risperidone in the treatment of schizophrenia. Proceedings of the 7th Biennial Winter Workshop on Schizophrenia; 1994 Jan 23‐28; Les Diablerets, Switzerland1994; Vol. 11, issue 2:106. ">Lemmens 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0152" title="HunterRH , JoyCB , KennedyE , GilbodySM , SongF . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000440] ">Hunter 2003</a>; <a href="./references#CD006918-bbs2-0165" title="KumarA , StrechD . Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD005474; PUBMED: 16235403] ">Kumar 2005</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p><b>Not risperidone</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>amisulpride</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p>versus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0029" title="BoyerP , LecrubierY , PuechAJ . Treatment of positive and negative symptoms: pharmacologic approaches. In: AndreasenNC editor(s). Modern problems of pharmacopsychiatry. Vol. 24, Basel, Switzerland: S. Karger, 1990:152‐74. BoyerP , LecrubierY , PuechAJ , DewaillyJ , AubinF . Treatment of negative symptoms in schizophrenia with amisulpride. British Journal of Psychiatry1995;166(1):68‐72. BoyerP , PuechAJ . Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools [Modalities d'action clinique des neuroleptiques: substances, doses, instruments de mesure utilises]. Psychiatrie and Psychobiologie1987;2(4):296‐305. BoyerP , PuechAJ , LecrubierY . Double blind trial versus placebo of low dose amisulpride (Solian 50) in schizophrenia with exclusively negative symptoms. Preliminary analysis of results [Etude en double insu contre placebo de l'amisulpride (Solian (r) 50) a faible dose chez des schizophrenes purement deficitaires. Premiere analyse des resultats]. Annales de Psychiatrie1988;3(3):321‐5. ">Boyer 1995</a>, <a href="./references#CD006918-bbs2-0064" title="LooH , Poirier LittreMF , TheronM , ReinW , FleurotO . Amisulpride versus placebo in the medium‐term treatment of the negative symptoms of schizophrenia. British Journal of Psychiatry1997;170:18‐22. [MEDLINE: 9068769] ">Loo 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0175" title="MotaNE , LimaMS , SoaresBG . Amisulpride for schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD001357; PUBMED: 12076408] ">Mota 2002</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>aripiprazole</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>haloperidol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0032" title="CarsonW , CornblattB , SahaA , AliM , KernR , GreenM . Neurocognitive benefits of aripiprazole versus olanzapine in stable psychosis. European Neuropsychopharmacology2002;12(Suppl 3):S291. CarsonW , McQuadeR , SahaA , TorbeynsA , StockE . Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia. European Neuropsychopharmacology2002;12(Suppl 3):S288. CarsonW , PigottT , SahaA , AliM , McQuadeRD , TorbeynsAF , et al. Aripiprazole vs placebo in the treatment of stable, chronic schizophrenia. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. CarsonWH , AliM , DunbarG , IngenitoG , SahaAR . A double‐blind, placebo‐controlled trial of aripiprazole and haloperidol. Schizophrenia Research2001;49(1,2):221‐2. CarsonWH , AliM , SahaAR , DunbarGC , IngenitoG . A double‐blind, placebo‐controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. CarsonWH , IngenitoGG , McquadeRD , StockEG , IwamotoT . Schizophrenia: safety / tolerability of aripiprazole. Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. CarsonWH , KaneJM , AliM , DunbarGC , IngenitoG . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. European Neuropsychopharmacology2000;10(Suppl 3):S309. CarsonWH , PigottTA , SahaAR , AliMW , McQuadeRD , TorbeynsAF , et al. Aripiprazole vs placebo in the treatment of chronic schizophrenia. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S187. CarsonWH , SahaAR , AliM , DunbarGC , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. 2001. CarsonWHJ , SahaAR , AliM , DunbarGC , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Carson 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0129" title="BhattacharjeeJ , El‐SayehHG . Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD006617.pub3; PUBMED: 18646161] ">Bhattacharjee 2008</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>olanzapine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0042" title="CornblattB , KernRS , CarsonWH , AliMW , LuoX , GreenM . Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S185. CornblattB , KernRS , CarsonWH , StockE , AliM , IngenitoG , et al. Neurocognitive effects of aripiprazole versus olanzapine in patients with stabile psychosis. Journal of Psychopharmacology2002;16(Suppl 3):A15. CornblattB , KernRS , CarsonWH , StockE , AliM , IngenitoG , et al. Neurocognitive effects of aripiprazole versus olanzapine in patients with stable psychosis. Schizophrenia Research2002;53(3 Suppl 1):27. ">Cornblatt 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0161" title="KhannaP , SuoT , KomossaK , MaH , Rummel‐KlugeC , El‐SayehHG , et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD006569.pub5; PUBMED: 24385408] ">Khanna 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>perphenazine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0052" title="GismondiR , MeltzerH , KujawaM , CarsonW , StringfellowJ , IwamotoT , et al. Aripiprazole versus perphenazine in treatment‐resistant schizophrenia. Proceedings of the XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. ">Gismondi 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0129" title="BhattacharjeeJ , El‐SayehHG . Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD006617.pub3; PUBMED: 18646161] ">Bhattacharjee 2008</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0032" title="CarsonW , CornblattB , SahaA , AliM , KernR , GreenM . Neurocognitive benefits of aripiprazole versus olanzapine in stable psychosis. European Neuropsychopharmacology2002;12(Suppl 3):S291. CarsonW , McQuadeR , SahaA , TorbeynsA , StockE . Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia. European Neuropsychopharmacology2002;12(Suppl 3):S288. CarsonW , PigottT , SahaA , AliM , McQuadeRD , TorbeynsAF , et al. Aripiprazole vs placebo in the treatment of stable, chronic schizophrenia. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. CarsonWH , AliM , DunbarG , IngenitoG , SahaAR . A double‐blind, placebo‐controlled trial of aripiprazole and haloperidol. Schizophrenia Research2001;49(1,2):221‐2. CarsonWH , AliM , SahaAR , DunbarGC , IngenitoG . A double‐blind, placebo‐controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. CarsonWH , IngenitoGG , McquadeRD , StockEG , IwamotoT . Schizophrenia: safety / tolerability of aripiprazole. Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. CarsonWH , KaneJM , AliM , DunbarGC , IngenitoG . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. European Neuropsychopharmacology2000;10(Suppl 3):S309. CarsonWH , PigottTA , SahaAR , AliMW , McQuadeRD , TorbeynsAF , et al. Aripiprazole vs placebo in the treatment of chronic schizophrenia. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S187. CarsonWH , SahaAR , AliM , DunbarGC , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. 2001. CarsonWHJ , SahaAR , AliM , DunbarGC , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Carson 2002</a>, <a href="./references#CD006918-bbs2-0033" title="CaseyD , BarbatoLM , HeisterbergJ , YeungPP , ShapiraNA . Results of a bifeprunox dose‐finding study in patients with acutely exacerbated schizophrenia. Schizophrenia Bulletin2007;33(2):425. CaseyD , SahaA , MarcusR , CarsonWH , McQuadeRD , TorbeynsAF , et al. Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia. Schizophrenia Research2003;60(1):276. CaseyD , SahaAR , AliMW , JodyDN , KujawaMJ , StockEG , et al. Switching to aripiprazole monotherapy. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S187. CaseyDE , BarbatoLM , HeisterbergJ , YeungPP , ShapiraNA . Results of a bifeprunox dose‐finding study in patients with acutely exacerbated schizophrenia. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28‐Apr 1, Colorado Springs, Colorado, USA2007. CaseyDE , CarsonWH , SahaAR , LiebeskindA , AliMW , JodyD , et al. Switching patients to aripiprazole from other antipsychotic agents: A multicenter randomized study. Psychopharmacology2003;166(4):391‐9. CaseyDE , DanielDG , WassefAA , TracyKA , WozniakP , SommervilleKW . Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropyschopharmacology2003;28(1):182‐92. CaseyDE , SahaAR , AliMW , JodyD , KujawaMJ , StockEG , et al. Switching to aripiprazole monotherapy. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Casey 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0127" title="BelgamwarRB , El‐SayehHG . Aripiprazole versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 8. [DOI: 10.1002/14651858.CD006622.pub2; PUBMED: 21833956] ">Belgamwar 2011</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>haloperidol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0026" title="BeasleyCJr , TollefsonGD , BeuzenJN , DellvaMA , SangerTM , PaulS . Acute and long‐term results of the North American double‐blind olanzapine trial. Proceedings of the 4th International Conference on Schizophrenia: Breaking Down the Barriers; 1996 Oct 6‐9; Vancouver, Canada. 1996. BeasleyC , TranP , BeuzenJN , TamuraR , DellvaMA , BaileyJ , et al. Olanzapine versus haloperidol: long‐term results of the multi‐center international trial. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. BeasleyC , TranP , SatterleeW , TollefsonG , LuY , KuntzA , et al. Olanzapine versus placebo, results of the United States double‐blind olanzapine trial. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. BeasleyCM . Safety of olanzapine. Journal of Clinical Psychiatry1997;15(2):19‐21. BeasleyCMJr , SangerT , SatterleeW , TollefsonG , TranP , HamiltonS . Olanzapine versus placebo ‐ results of a double‐blind, fixed dose olanzapine trial. Psychopharmacology1996;124(1‐2):159‐67. BeasleyCM , BergPH , DananbergJ , KwongKC , TaylorCCM , BreierA . Treatment‐emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo. Biological Psychiatry2001;49(8):121S. BeasleyCM , DellvaMA , TamuraRN , MorgensternH , GlazerWM , FergusonK , et al. A randomised double‐blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long‐term treatment with olanzapine or haloperidol. British Journal of Psychiatry1999;174:23‐30. BeasleyCM , HamiltonSH , CrawfordAM , DellvaMA , TollefsonGD , TranPV , et al. Olanzapine versus haloperidol: acute phase results of the international double‐blind olanzapine trial. European Neuropsychopharmacology1997;7(2):125‐37. BeasleyCM , SaylerME , KeislerGM , PotvinJH , SangerTM , TollefsonGD . The influence of pharamacotherapy on self‐directed and externally‐directed aggression in schizophrenia. Schizophrenia Research1998;29(1‐2):28. BeasleyCM , SowellMO , CarlsonC , MukhopadhyayN , DananbergJ , HenryR , et al. Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone or placebo. Schizophrenia Research2003;60(1):309. BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double‐blind, randomized, placebo‐controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23(6):582‐94. BeasleyCM , TollefsonG , TranP , SatterleeW , SangerT , HamiltonS . Olanzapine versus placebo and haloperidol: acute phase results of the North American double‐blind olanzapine trial. Neuropyschopharmacology1996;14(2):111‐23. BeasleyCM , TollefsonGD , DellvaMA , TamuraR , GlazerWM , MorgensternH . The differential risk of tardive dyskinesia with olanzapine. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐Jun 4; Toronto, Ontario, Canada. 1998. ">Beasley 1996</a>, <a href="./references#CD006918-bbs2-0032" title="CarsonW , CornblattB , SahaA , AliM , KernR , GreenM . Neurocognitive benefits of aripiprazole versus olanzapine in stable psychosis. European Neuropsychopharmacology2002;12(Suppl 3):S291. CarsonW , McQuadeR , SahaA , TorbeynsA , StockE . Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia. European Neuropsychopharmacology2002;12(Suppl 3):S288. CarsonW , PigottT , SahaA , AliM , McQuadeRD , TorbeynsAF , et al. Aripiprazole vs placebo in the treatment of stable, chronic schizophrenia. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. CarsonWH , AliM , DunbarG , IngenitoG , SahaAR . A double‐blind, placebo‐controlled trial of aripiprazole and haloperidol. Schizophrenia Research2001;49(1,2):221‐2. CarsonWH , AliM , SahaAR , DunbarGC , IngenitoG . A double‐blind, placebo‐controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. CarsonWH , IngenitoGG , McquadeRD , StockEG , IwamotoT . Schizophrenia: safety / tolerability of aripiprazole. Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. CarsonWH , KaneJM , AliM , DunbarGC , IngenitoG . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. European Neuropsychopharmacology2000;10(Suppl 3):S309. CarsonWH , PigottTA , SahaAR , AliMW , McQuadeRD , TorbeynsAF , et al. Aripiprazole vs placebo in the treatment of chronic schizophrenia. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S187. CarsonWH , SahaAR , AliM , DunbarGC , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. 2001. CarsonWHJ , SahaAR , AliM , DunbarGC , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Carson 2002</a>, <a href="./references#CD006918-bbs2-0043" title="CrawfordAM , BeasleyCM , TollefsonGD . Olanzapine ‐ impact of an atypical antipsychotic candidate on prolactin release. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4‐9, New York, New York, USA. 1996. CrawfordAM , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. European Neuropsychopharmacology1997;7(Suppl 2):199. CrawfordAM , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research1997;26(1):41‐54. CrawfordAMK , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17; Vienna, Austria. 1997. CrawfordAMK , GomezJC , BeasleyCMJr , TollefsonGD . Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi‐center international trial. European Neuropsychopharmacology1997;7:2.015. ">Crawford 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0117" title="AdamsCE , BergmanH , IrvingCB , LawrieS . Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD003082.pub3; PUBMED: 24242360] ">Adams 2013</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>olanzapine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>fluphenazine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0047" title="DossenbachM , FriedelP , JakovljevicM , HotujacL , FolnegovicV , UglesicB , et al. Olanzapine versus fluphenazine ‐ six weeks' treatment of acute schizophrenia. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17; Vienna, Austria. 1997. DossenbachM , JakovljevicM , FolnegovicF , UglesicB , DodigG , FriedelP , et al. Olanzapine versus fluphenazine ‐ 6 weeks treatment of anxiety symptoms during acute schizophrenia. Schizophrenia Research1998;29(1,2):203. ">Dossenbach 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD006918-bbs2-0141" title="DugganL , FentonM , RathboneJ , DardennesR , El‐DosokyA , IndranS . Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2; PUBMED: 15846619] ">Duggan 2005</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>haloperidol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0026" title="BeasleyCJr , TollefsonGD , BeuzenJN , DellvaMA , SangerTM , PaulS . Acute and long‐term results of the North American double‐blind olanzapine trial. Proceedings of the 4th International Conference on Schizophrenia: Breaking Down the Barriers; 1996 Oct 6‐9; Vancouver, Canada. 1996. BeasleyC , TranP , BeuzenJN , TamuraR , DellvaMA , BaileyJ , et al. Olanzapine versus haloperidol: long‐term results of the multi‐center international trial. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. BeasleyC , TranP , SatterleeW , TollefsonG , LuY , KuntzA , et al. Olanzapine versus placebo, results of the United States double‐blind olanzapine trial. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. BeasleyCM . Safety of olanzapine. Journal of Clinical Psychiatry1997;15(2):19‐21. BeasleyCMJr , SangerT , SatterleeW , TollefsonG , TranP , HamiltonS . Olanzapine versus placebo ‐ results of a double‐blind, fixed dose olanzapine trial. Psychopharmacology1996;124(1‐2):159‐67. BeasleyCM , BergPH , DananbergJ , KwongKC , TaylorCCM , BreierA . Treatment‐emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo. Biological Psychiatry2001;49(8):121S. BeasleyCM , DellvaMA , TamuraRN , MorgensternH , GlazerWM , FergusonK , et al. A randomised double‐blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long‐term treatment with olanzapine or haloperidol. British Journal of Psychiatry1999;174:23‐30. BeasleyCM , HamiltonSH , CrawfordAM , DellvaMA , TollefsonGD , TranPV , et al. Olanzapine versus haloperidol: acute phase results of the international double‐blind olanzapine trial. European Neuropsychopharmacology1997;7(2):125‐37. BeasleyCM , SaylerME , KeislerGM , PotvinJH , SangerTM , TollefsonGD . The influence of pharamacotherapy on self‐directed and externally‐directed aggression in schizophrenia. Schizophrenia Research1998;29(1‐2):28. BeasleyCM , SowellMO , CarlsonC , MukhopadhyayN , DananbergJ , HenryR , et al. Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone or placebo. Schizophrenia Research2003;60(1):309. BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double‐blind, randomized, placebo‐controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23(6):582‐94. BeasleyCM , TollefsonG , TranP , SatterleeW , SangerT , HamiltonS . Olanzapine versus placebo and haloperidol: acute phase results of the North American double‐blind olanzapine trial. Neuropyschopharmacology1996;14(2):111‐23. BeasleyCM , TollefsonGD , DellvaMA , TamuraR , GlazerWM , MorgensternH . The differential risk of tardive dyskinesia with olanzapine. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐Jun 4; Toronto, Ontario, Canada. 1998. ">Beasley 1996</a>, <a href="./references#CD006918-bbs2-0043" title="CrawfordAM , BeasleyCM , TollefsonGD . Olanzapine ‐ impact of an atypical antipsychotic candidate on prolactin release. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4‐9, New York, New York, USA. 1996. CrawfordAM , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. European Neuropsychopharmacology1997;7(Suppl 2):199. CrawfordAM , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research1997;26(1):41‐54. CrawfordAMK , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17; Vienna, Austria. 1997. CrawfordAMK , GomezJC , BeasleyCMJr , TollefsonGD . Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi‐center international trial. European Neuropsychopharmacology1997;7:2.015. ">Crawford 1997</a>, <a href="./references#CD006918-bbs2-0053" title="GregorK , HamiltonS , EdgellE . Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol. Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6‐11; Hamburg, Germany. 1999. GregorKJ , AllicarMP , LilliuH , OlivierV , LePenC , GavartS . An economic comparison of olanzapine versus haloperidol in the treatment of schizophrenia in France. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S161. GregorKJ , HamiltonSH , EdgellET . Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol. European Neuropsychopharmacology1999;9(Suppl 1):S11. GregorKJ , HamiltonSH , EdgellET . Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol. European Neuropsychopharmacology1999;9:S289. GregorKJ , HamiltonSH , EdgellET . Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol. Schizophrenia Research2000;41(1):189. ">Gregor 2000</a>, <a href="./references#CD006918-bbs2-0058" title="KinonB , BassonB , MalcolmS , BreierA . Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. Proceedings of the 39th Annual Meeting of the New Clinical Drug Evaluation Unit; 1999 Jun 1‐4; Boca Raton, Florida, USA. 1999. KinonB , BassonB , TollefsonGD . Gender‐specific prolactin olanzapine versus haloperidol in schizophrenia. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐Jun 4; Toronto, Ontario, Canada. 1998. [151st Annual Meeting of the American Psychiatric Association [CD‐ROM]: MARATHON Multimedia, 1988 NR449; 151st Annual Meeting of the American Psychiatric Association [CD‐ROM]: MARATHON Multimedia, 1988 NR739] KinonB , BassonB , TollefsonGD . Gender‐specific prolactin olanzapine versus haloperidol in schizophrenia. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐Jun 4; Toronto, Ontario, Canada. 1998. KinonB , BassonBR , MalcolmSK , TollefsonG . Strategies for switching from conventional antipsychotic drugs to olanzapine. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington, DC, USA. 1999. KinonB , BreierA , MalcolmS , BassonB . Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6‐11; Hamburg, Germany. 1999. KinonBJ , BassonB , HillAL , BergPH . Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine. European Neuropsychopharmacology2000;10(Suppl 3):S305. KinonBJ , BassonB , SzymanskiK , TollefsonGD . Predictors of weight gain during olanzapine treatment. Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4; Paris, France. 1998. KinonBJ , BassonB , WangJ , MalcolmSK . Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. Schizophrenia Research2000;41(1):194‐5. KinonBJ , BassonB , WangJ , MalcolmSK , StaufferVL . Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. European Neuropsychopharmacology2000;10(Suppl 3):S306. KinonBJ , BassonB , WangJ , MalcolmSK , StaufferVL . Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S155. KinonBJ , BassonB , WangJ , MalcolmSK , StaufferVL . Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30‐Jun 2; Boca Raton, Florida, USA. 2000. KinonBJ , BassonBR , GilmoreJA , MalcolmS , StaufferVL . Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. Journal of Clinical Psychiatry2000;61(11):833‐40. KinonBJ , BassonBR , GilmoreJA , TollefsonGD . Long‐term olanzapine treatment: weight change and weight‐related health factors in schizophrenia. Journal of Clinical Psychiatry2001;62(2):92‐100. KinonBJ , BassonBR , MalcolmSK , TollefsonGD . Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine conference abstract. Schizophrenia Research1999;36(1‐3):285‐6. KinonBJ , BassonBR , WangJ . Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. Proceedings of the 52nd Institute on Psychiatric Services; 2000 Oct 25‐29; Philadelphia, Pennsylvania, USA. 2000. KinonBJ , BassonBR , WangJ , MalcolmSK , StaufferVL . Rapid reduction in hyperprolactinemia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. KinonBJ , BassonMS , TollefsonGD . Gender‐specific prolactin response to treatment with olanzapine versus haloperidol in schizophrenia. Proceedings of the 9th Biennial Winter Workshop on Schizophrenia; 1998 Feb 7‐13; Davos, Switzerland1998. KinonBJ , GilmoreJA , GottschalkLA . Continued improvement in quality of life despite weight change during olanzapine treatment. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. KinonBJ , Liu‐SeifertH , AhlJ , AhmedS , BakerRW . Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4‐month study. Annals of the New York Academy of Sciences2004;1032:295‐6. KinonBJ , MiltonDR , GilmoreJA . Continued improvement in quality of life despite weight change during olanzapine treatment. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S154. KinonBJ , MiltonDR , HillAL . Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S154. KinonBJ , MiltonDR , HillAL , WilliamsonDJ . Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine. Journal of Psychopharmacology2000;14(3 Suppl):A60. KinonBJ , RoychowdhurySM , MiltonDR , HillAL . Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. Journal of Clinical Psychiatry2001;62(Suppl 2):17‐21. ">Kinon 1998</a>, <a href="./references#CD006918-bbs2-0062" title="LiebermanJ , McEnvoyJ , StroupS . Protocol: comparative effectiveness of antipsychotic medications in patients with schizophrenia: revised in response to DSMB comments. National Institute of Mental Health. Chapel Hill, USA: University of North Carolina, 2000. LiebermanJ , McEvoyJ , StroupS . Trial design summary: Comparative effectiveness of antipsychotic medications in patients with schizophrenia: Draft. National Institute of Mental Health. Chapel Hill, USA: University of North Carolina, 2002. LiebermanJ , McEvoyJP , PerkinsD , HamerRH . Comparison of atypicals in first‐episode psychosis: a randomized, 52‐week comparison of olanzapine, quetiapine, and risperidone. European Neuropsychopharmacology2005;15(Suppl 3):S525. LiebermanJA . Comparative effectiveness of antipsychotic medications in patients with schizophrenia (CATIE schizophrenia trial). clinicaltrials.gov/ct2/show/NCT00014001 2001 (accessed 9 October 2013). LiebermanJA . Research gaps and current research initiatives to improve the treatment of schizophrenia. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. LiebermanJA , SchneiderLS , McEroyJ , PariotP , StroupS , AdiaoJ , et al. Effectiveness trials of antipsychotic drugs. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. [No. 103D] LiebermanJA , SchneiderLS , McEroyJ , PariotP , StroupS , AdiaoJ , et al. Effectiveness trials of antipsychotic drugs. Proceeding of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. LiebermanJA , StroupTS . Schizophrenia, VI: treatments. American Journal of Psychiatry2003;160(10):1748. LiebermanJA , StroupTS , McEvoyJP , SwartzMS , KeefeR , PerkinsDO , et al. CATIE trial results. European Neuropsychopharmacology2006;16(Suppl 4):S184. LiebermanJA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine2005;353(12):1209‐23. LiebermanJA , TollefsonG , TohenM , GreenAI , GurRE , KahnR , et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first‐episode psychosis: a randomized, double‐blind trial of olanzapine versus haloperidol. American Journal of Psychiatry2003;160(8):1396‐404. ">Lieberman 2005</a>, <a href="./references#CD006918-bbs2-0086" title="RevickiD , GendusoLA , HamiltonSL , MartinC , ReblandoJ , TranPV . Quality of life outcomes for olanzapine and haloperidol treatment for schizophrenia and related psychotic disorders. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4‐9, New York, New York, USA. 1996. ">Revicki 1996</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>paliperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0067" title="罗燕 . Palley risperidone sustained release tablets and olanzapine tablets in the treatment of exacerbations and readmission of patients with schizophrenia in a randomized double‐blind placebo‐controlled study. Chinese Journal of Mental Health [中国民康医学]2011;23(05):560‐3. ">Luo 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a>; <a href="./references#CD006918-bbs2-0176" title="NussbaumAM , StroupTS . Paliperidone palmitate for schizophrenia. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD008296.pub2; PUBMED: 22696377] ">Nussbaum 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0026" title="BeasleyCJr , TollefsonGD , BeuzenJN , DellvaMA , SangerTM , PaulS . Acute and long‐term results of the North American double‐blind olanzapine trial. Proceedings of the 4th International Conference on Schizophrenia: Breaking Down the Barriers; 1996 Oct 6‐9; Vancouver, Canada. 1996. BeasleyC , TranP , BeuzenJN , TamuraR , DellvaMA , BaileyJ , et al. Olanzapine versus haloperidol: long‐term results of the multi‐center international trial. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. BeasleyC , TranP , SatterleeW , TollefsonG , LuY , KuntzA , et al. Olanzapine versus placebo, results of the United States double‐blind olanzapine trial. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. BeasleyCM . Safety of olanzapine. Journal of Clinical Psychiatry1997;15(2):19‐21. BeasleyCMJr , SangerT , SatterleeW , TollefsonG , TranP , HamiltonS . Olanzapine versus placebo ‐ results of a double‐blind, fixed dose olanzapine trial. Psychopharmacology1996;124(1‐2):159‐67. BeasleyCM , BergPH , DananbergJ , KwongKC , TaylorCCM , BreierA . Treatment‐emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo. Biological Psychiatry2001;49(8):121S. BeasleyCM , DellvaMA , TamuraRN , MorgensternH , GlazerWM , FergusonK , et al. A randomised double‐blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long‐term treatment with olanzapine or haloperidol. British Journal of Psychiatry1999;174:23‐30. BeasleyCM , HamiltonSH , CrawfordAM , DellvaMA , TollefsonGD , TranPV , et al. Olanzapine versus haloperidol: acute phase results of the international double‐blind olanzapine trial. European Neuropsychopharmacology1997;7(2):125‐37. BeasleyCM , SaylerME , KeislerGM , PotvinJH , SangerTM , TollefsonGD . The influence of pharamacotherapy on self‐directed and externally‐directed aggression in schizophrenia. Schizophrenia Research1998;29(1‐2):28. BeasleyCM , SowellMO , CarlsonC , MukhopadhyayN , DananbergJ , HenryR , et al. Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone or placebo. Schizophrenia Research2003;60(1):309. BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double‐blind, randomized, placebo‐controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23(6):582‐94. BeasleyCM , TollefsonG , TranP , SatterleeW , SangerT , HamiltonS . Olanzapine versus placebo and haloperidol: acute phase results of the North American double‐blind olanzapine trial. Neuropyschopharmacology1996;14(2):111‐23. BeasleyCM , TollefsonGD , DellvaMA , TamuraR , GlazerWM , MorgensternH . The differential risk of tardive dyskinesia with olanzapine. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30‐Jun 4; Toronto, Ontario, Canada. 1998. ">Beasley 1996</a>, <a href="./references#CD006918-bbs2-0043" title="CrawfordAM , BeasleyCM , TollefsonGD . Olanzapine ‐ impact of an atypical antipsychotic candidate on prolactin release. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4‐9, New York, New York, USA. 1996. CrawfordAM , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. European Neuropsychopharmacology1997;7(Suppl 2):199. CrawfordAM , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research1997;26(1):41‐54. CrawfordAMK , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17; Vienna, Austria. 1997. CrawfordAMK , GomezJC , BeasleyCMJr , TollefsonGD . Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi‐center international trial. European Neuropsychopharmacology1997;7:2.015. ">Crawford 1997</a>, <a href="./references#CD006918-bbs2-0067" title="罗燕 . Palley risperidone sustained release tablets and olanzapine tablets in the treatment of exacerbations and readmission of patients with schizophrenia in a randomized double‐blind placebo‐controlled study. Chinese Journal of Mental Health [中国民康医学]2011;23(05):560‐3. ">Luo 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Protocol underway</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>paliperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0067" title="罗燕 . Palley risperidone sustained release tablets and olanzapine tablets in the treatment of exacerbations and readmission of patients with schizophrenia in a randomized double‐blind placebo‐controlled study. Chinese Journal of Mental Health [中国民康医学]2011;23(05):560‐3. ">Luo 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0176" title="NussbaumAM , StroupTS . Paliperidone palmitate for schizophrenia. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD008296.pub2; PUBMED: 22696377] ">Nussbaum 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Single vs polypharmacy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>risperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>versus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>amisulpride + haloperidol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0082" title="PeuskensJ , MollerHJ . Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. European Neuropsychopharmacology2001;11(3):255. ">Peuskens 2001a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Miscellaneous</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>antipsychotic drugs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>versus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>miscellaneous (risperidone, olanzapine, quetiapine)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0096" title="WeickertTW , GoldbergTE , MarencoS , BigelowLB , EganMF , WeinbergerDR . Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology2003;28(8):1491‐500. ">Weickert 2003</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>risperidone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>valproate + miscellaneous antipsychotic drugs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0038" title="CitromeL , CaseyDE , DanielDG , WozniakP , KochanLD , TracyKA . Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatric Services2004;55(3):290‐4. CitromeLL , DanielDG , WassefAA , TracyKA , WozniakP , CaseyDE . Antipsychotic monotherapy versus combination treatment with valporate in hospitalized patients with acute schizophrenia: a double‐blind, multi‐center study. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Citrome 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>riluzole (a drug used to treat amyotrophic lateral sclerosis)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rujescu 2009a</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>talnetant (a</p> <p>neurokinin 3 receptor antagonist)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GlaxoSmithKline 2006a</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reviews suggested by excluded studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006918-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Suggested design of study</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Methods</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allocation: randomised, clearly described and concealed.<br/> Blinding: double, tested.<br/> Duration: 1 year or more. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis: schizophrenia, schizotypal, schizoaffective, delusional disorder, acute psychosis, comorbid alcohol problems, and substance misuse.<br/> N = 300.<br/> Age: adults.<br/> Sex: men or women.<br/> History: perhaps once an early episode of moderate severity has subsided and after a period of stable washout of the medications used during the acute phase, living anywhere and not just in hospital. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Risperidone: dose 4 mg/day or above.<br/> 2. Placebo. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthy days.<br/> Mental state: improved to important degree.<br/> Global state: improved to important degree, relapse.<br/> Service use: in hospital.<br/> Social functioning: employment status, relationships.<br/> Quality of life: improved to important degree.<br/> Economic outcomes: cost. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Notes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Free of all industry influence.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Suggested design of study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006918-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">RISPERIDONE compared to PLACEBO for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE compared to PLACEBO for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> RISPERIDONE<br/> <b>Comparison:</b> PLACEBO </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PLACEBO</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mental state: no clinically significant response in psychotic symptoms (defined by various scale total score change) ‐ short term (up to 12 weeks) ‐ defined by PANSS/BPRS &lt;20% decline</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.64</b> <br/> (0.52 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>864<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very Low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>692 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>443 per 1000</b> <br/> (360 to 540) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>733 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>469 per 1000</b> <br/> (381 to 572) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early ‐ short term (up to 12 weeks) ‐ any reason</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.69</b> <br/> (0.62 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2261<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>495 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>342 per 1000</b> <br/> (307 to 386) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>486 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>335 per 1000</b> <br/> (301 to 379) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global state: 2. no significant clinical improvement ‐ CGI, short term (up to 12 weeks)</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.69</b> <br/> (0.57 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>594<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>744 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>513 per 1000</b> <br/> (424 to 618) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>732 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>505 per 1000</b> <br/> (417 to 608) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term (up to 12 weeks) ‐ general ‐ any significant EPS</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.56</b> <br/> (1.13 to 2.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1511<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>113 per 1000</b> <br/> (82 to 156) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>106 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>165 per 1000</b> <br/> (120 to 228) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to risk of bias: studies contributing data to this body of evidence have unclear or high risk of bias in one or more domains, some were also sponsored by pharmaceutical companies.<br/> <sup>2</sup> Downgraded one level due to inconsistency: some concerns of heterogeneity were identified.<br/> <sup>3</sup> Downgraded one level due to publication bias: 'strongly suspected' ‐ most studies were sponsored by pharmaceutical companies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">RISPERIDONE compared to PLACEBO for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006918-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">RISPERIDONE + CLOZAPINE compared to PLACEBO + CLOZAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE + CLOZAPINE compared to PLACEBO + CLOZAPINE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> RISPERIDONE + CLOZAPINE<br/> <b>Comparison:</b> PLACEBO + CLOZAPINE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PLACEBO + CLOZAPINE</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE + CLOZAPINE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mental state: no clinically significant response in psychotic symptoms ‐ short term</b> <br/> PANSS/BPRS &lt; 20% decline<br/> Follow‐up: 6‐8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.15</b> <br/> (0.93 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>98<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>725 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>834 per 1000</b> <br/> (674 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early due to any reason ‐ short term</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>119 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>135 per 1000</b> </p> <p>(63 to 288)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR1.13</b> </p> <p>(0.53 to 2.42)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: no significant clinical improvement ‐ CGI short term</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>735 per 1000</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>824 per 1000</b> <br/> (640 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/> (0.87 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: extrapyramidal ‐ short term</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to risk of bias: studies contributing data to this body of evidence have unclear risk of bias in one or more domains.<br/> <sup>2</sup> Downgraded one level due to imprecision: wide confidence interval including no effect and appreciable harm, and less than optimal information size. <br/> <sup>3</sup> Downgraded one level due to publication bias: 'strongly suspected' ‐ most studies were sponsored by pharmaceutical companies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">RISPERIDONE + CLOZAPINE compared to PLACEBO + CLOZAPINE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006918-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risperidone reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Oral risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>vs other atypical drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0144" title="GilbodySM , BagnallAM , DugganL , TuunainenA . Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD002306] ">Gilbody 2000</a>; <a href="./references#CD006918-bbs2-0162" title="KomossaK , RummelC , HungerH , SchmidtF , SchwarzS , LeuchtS . Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2] ">Komossa 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>vs olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0155" title="JayaramMB , HosalliP , StroupS . Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD005237] ">Jayaram 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>vs typical drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0160" title="KennedyE , SongF , HunterR , ClarkeA , GilbodyS . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD002306] ">Kennedy 2000</a>; <a href="./references#CD006918-bbs2-0152" title="HunterRH , JoyCB , KennedyE , GilbodySM , SongF . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000440] ">Hunter 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Depot risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0151" title="HosalliP , DaviesJM . Depot risperidone for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD004161] ">Hosalli 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Risperidone dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0170" title="LiC , XiaJ , WangJ . Risperidone dose for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007474.pub2] ">Li 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Risperidone for acute aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006918-bbs2-0119" title="AhmedU , RehmanF , JonesH , Adams CliveE . Risperidone for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.CD009412; CD009412] ">Ahmed 2011</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risperidone reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006918-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Global Assessment of Functioning scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Judgement</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91‐100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Superior functioning in a wide range of activities, life's problems never seem to get out of hand, is sought out by others because of his or her many qualities. No symptoms. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81‐90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absent or minimal symptoms, good functioning in all areas, interested and involved in a wide range of activities, socially effective, generally satisfied with life, no more than everyday problems or concerns. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71‐80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If symptoms are present they are transient and expectable reactions to psychosocial stresses; no more than slight impairment in social, occupational, or school functioning. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61‐70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some mild symptoms OR some difficulty in social, occupational, or school functioning, but generally functioning pretty well, has some meaningful interpersonal relationships. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51‐60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate symptoms OR any moderate difficulty in social, occupational, or school functioning.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41‐50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious symptoms OR any serious impairment in social, occupational, or school functioning.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31‐40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some impairment in reality testing or communication OR major impairment in several areas, such as work or school, family relations, judgement, thinking, or mood. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21‐30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behavior is considerably influenced by delusions or hallucinations OR serious impairment in communications or judgment OR inability to function in all areas. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11‐20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some danger of hurting self or others OR occasionally fails to maintain minimal personal hygiene OR gross impairment in communication. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent danger of severely hurting self or others OR persistent inability to maintain minimum personal hygiene OR serious suicidal act with clear expectation of death. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not enough information available to provide GAF.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Global Assessment of Functioning scale</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/full#CD006918-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006918-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">RISPERIDONE vs PLACEBO</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state: no clinically significant response in psychotic symptoms (defined by various scale total score change) ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 defined by PANSS&lt;30% decline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>707</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.67, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 defined by PANSS/BPRS &lt;20% decline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.52, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Leaving the study early ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.62, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 due to adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2081</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.59, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 due to lack of efficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.29, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 due to noncompliance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.33, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 lost to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.25, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 protocol violation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.39, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 reported death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [0.13, 74.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 withdrawal of consent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.80, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.68, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 1. average endpoint scores of CGI severity scale (high=poor) ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.81 [‐0.89, ‐0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: 2. no significant clinical improvement CGI ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.57, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Global state: 3. needing additional medication ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 benzodiazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.77, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 benzodiazepine derivatives ‐ Lorazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.68, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 benzodiazepine derivatives ‐ Nitrazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.10, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 benzodiazepine related drugs ‐ Zolpidem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.53, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 sedative/hypnotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.69, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 antiparkinsonian</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.79, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 psychotropics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.45, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 1. average endpoint scores on various scales on psychotic symptoms (high=poor) ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 BPRS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.69 [‐17.06, ‐8.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 PANSS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐17.81 [‐18.17, ‐17.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 PANSS general pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.20 [‐20.15, ‐6.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 PANSS negative symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.10 [‐3.19, ‐3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 PANSS positive symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.49 [‐6.18, ‐4.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: 2. skewed data ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 average endpoint score BPRS total (high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 average change score of CGI‐C (larger decline=good)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 average change score of CGI‐SI (larger decline=good)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 average change score of HAM‐D‐17 (larger decline=good)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 average change score of PANSS total (larger decline=good)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 average change score of PANSS negative symptom (larger decline=good)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7 average change score of PANSS positive symptom (larger decline=good)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 general ‐ any significant EPS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [1.13, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 general ‐ no improvement on AIMS score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.15, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 general ‐ no improvement on BAS score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.01, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 general ‐ needing medication for EPS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.78, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 specific ‐ akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [1.41, 4.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 specific ‐ bradykinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.60, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 specific ‐ dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 specific ‐ dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.40 [0.26, 44.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.9 specific ‐ hypertonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.98 [1.35, 6.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.10 specific ‐ parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.64 [1.40, 41.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.11 specific ‐ tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.77 [0.35, 130.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.12 specific ‐ tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.89, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 1b. extrapyramidal ‐ AIMS average endpoint score ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects: 1c. extrapyramidal ‐ skewed data (various scales) ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 average change score of AIMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 average change score of CGI severity dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 average change score of CGI severity parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 average change score of ESRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 average change score of ESRS ‐ akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 average change score of ESRS ‐ dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.7 average change score of ESRS ‐ dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.8 average change score of ESRS ‐ parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 2. any adverse event ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 any adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.96, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.62, 6.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.38, 2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.16 [0.47, 36.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 cogwheel rigidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.25 [0.69, 39.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6 death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [0.13, 75.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7 dental disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.64 [0.78, 17.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.8 dysmenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.04, 30.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.9 fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [0.69, 7.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.10 fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.28 [0.51, 168.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.11 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.10, 2.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.12 salivation ‐ increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.28 [0.38, 139.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.13 pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.45, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.14 pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.47, 5.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.15 rash (skin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.45, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.16 vaginitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.07, 16.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.17 hyperhidrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.35 [0.50, 214.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 3. cardiovascular ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 dizziness ‐ orthostatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 ECG abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.40 [0.51, 172.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 heart rate decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.05, 5.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 heart rate increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.37, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 hypotension ‐ postural</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6 QTc &gt; 450 milliseconds or &gt; 10% increase from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.46 [1.07, 67.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.7 tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.22 [2.33, 64.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 4. central nervous system ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.75, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.73, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.65, 3.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.81, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.97, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6 sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [0.52, 6.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.7 somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [1.06, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.8 restlessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.49, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 5. endocrine ‐ serum prolactin increase above reference range (23 ng/ml) ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.14 [4.38, 33.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 6. gastrointestinal system ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [1.19, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.37, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [0.65, 9.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 dyspepsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1058</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.64, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5 nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.75, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6 vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.65, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 7a. metabolic ‐ weight gain ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 any gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.77 [1.34, 10.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 &gt;7% increase from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.47 [1.64, 7.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 7b. metabolic ‐ skewed data ‐ average change value on lipid profile ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 cholesterol ‐ total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 HDL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 LDL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 triglycerides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.5 VLDL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: 8. musculoskeletal system ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 myalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.12, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Joint disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [0.52, 13.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse effects: 9. physiology ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 ALT increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.07, 16.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 AST increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 blood CPK increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.23, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4 blood pressure increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.15, 7.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse effects: 10. respiratory system ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 upper respiratory infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [1.03, 7.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 pharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.08, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.81 [2.58, 45.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.4 sinusitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.09, 11.36]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">RISPERIDONE vs PLACEBO</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006918-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state: no clinically significant response in psychotic symptoms (defined by PANSS/BPRS&lt;20% decline) ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.93, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Leaving the study early ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.53, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 due to adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.11 [0.47, 36.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 due to lack of efficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.11, 2.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 due to noncompliance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.02, 8.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 lost to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.02, 8.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 reported death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 withdrawal of consent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.28, 7.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 administrative reasons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.44 [0.27, 109.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 abnormal lab results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.02, 8.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 1. average endpoint scores of CGI severity scale (high=poor) ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.02, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: 2. no significant clinical improvement CGI ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.87, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Global state: 3. general functioning ‐ average endpoint GAF score (high=good) ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.5 [‐8.38, ‐0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 1. average endpoint scores on various scales on psychotic symptoms (high=poor) ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 PANSS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.56 [1.59, 9.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 PANSS general pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.5 [0.03, 4.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 PANSS delusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.09, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 PANSS negative symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [‐0.68, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 PANSS positive symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [0.98, 3.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: 2. average endpoint scores on various scales on psychotic symptoms (high=poor) ‐ medium term (up to 26 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 BPRS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.60 [‐9.88, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 BPRS positive symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐2.81, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 BPRS anxiety/depression factor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐2.80, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 SANS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.10 [‐10.30, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: 3. skewed data ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 average endpoint score of CDS total (high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 average endpoint score on verbal working memory (SD, high=good)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 1a. extrapyramidal ‐ average endpoint SAS score ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects: 1b. extrapyramidal ‐ skewed data (various scales) ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 average endpoint score of AIMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 average change score of Barnes akathisia rating scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 average change score of ESRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 average change score of ESRS ‐ dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 average change score of ESRS ‐ dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 average change score of ESRS ‐ parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 1c. extrapyramidal ‐ skewed data (various scales) ‐ medium term (up to 26 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 average endpoint score of AIMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 average endpoint score of SAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 2. any adverse event ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 any adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.83, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 amenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 71.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.61, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.2 [0.61, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 emotional indifference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.52, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6 fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.61, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.7 failing memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.32, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.8 increased duration of sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.51, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.9 salivation ‐ increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.81, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 3a. cardiovascular ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 dizziness ‐ orthostatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.43, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 palpitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.27, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.27, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 3b. cardiovascular ‐ QTc interval ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐19.70 [‐42.08, 2.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 4. central nervous system ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.88, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.51, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 tension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.71, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 5. gastrointestinal system ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.25, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 6a. haematological ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 neutrophil count</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [‐0.42, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 prolactin level, ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>60.10 [46.52, 73.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 white cell count</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [‐0.20, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: 6b. haematological ‐ medium term (up to 26 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 prolactin level ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>34.1 [17.63, 50.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 fasting glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.60 [‐17.09, 7.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse effects: 7a. metabolic ‐ weight gain ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.40, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse effects: 7a. metabolic ‐ weight gain ‐ medium term (up to 26 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.2 [0.01, 3.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse effects: 7b. metabolic ‐ average endpoint value on lipid profile ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 cholesterol ‐ total (mg/dl)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.60 [‐29.05, 15.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 HDL cholesterol (mg/dl)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐8.44, 8.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 LDL cholesterol (mg/dl)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.90 [‐26.02, 12.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.4 triglycerides (mg/dl)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.20 [‐57.57, 69.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse effects: 7c. metabolic ‐ average endpoint value ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 body mass index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [‐0.99, 4.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 fasting glucose (mg/dl)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.20 [‐3.12, 35.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 waist circumference (cm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.10 [‐4.14, 14.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.4 weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [‐0.84, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse effects: 8. sleep ‐ skewed data ‐ average change score (UKU) ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Quality of life: average endpoint score (QLS, high=good) ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐5.44, 7.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006918-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">SENSITIVITY ANALYSIS: RISPERIDONE vs PLACEBO (based on attrition)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state: 1. no clinically significant response (defined by PANSS/BPRS) ‐ short term (up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 defined by PANSS/BPRS &lt;20% decline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.52, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 defined by PANSS/BPRS &lt;20% decline (without studies with &gt;50% left the study early)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.67, 0.88]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">SENSITIVITY ANALYSIS: RISPERIDONE vs PLACEBO (based on attrition)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006918.pub3/references#CD006918-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006918.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006918-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006918-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD006918-note-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD006918-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD006918-note-0002">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD006918-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006918\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006918\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006918\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006918\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006918\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006918\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006918\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006918\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006918\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006918\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006918\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006918\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006918\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006918\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006918\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006918\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006918\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006918\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006918.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006918.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006918.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006918.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006918.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715076405"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006918.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715076409"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006918.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7e39da321bde',t:'MTc0MDcxNTA3Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 